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SUMMARY
1.. Ariti-Torpedo marmorata AChR antibody fragments ( Fab and F (ab')̂  )
have been prepared from sheep immunised with Torpedo AChR, and
exhibiting experimental autoimmune myasthenia gravis. The antibody
125fragments were labelled with I with the retention of antigen 
binding capacity. Labelled and unlabelled antibody fragments were
used to study the antigenicity of soluble and membrane-bound AChR,
Anti-receptor antibodies were found to reduce (X-toxin binding to the 
AChR This was demonstrated to be caused by steric hindrance rather
than by direct blockade of the toxin binding site, or by antigenic
modulation of the receptor. Removal of carbohydrate residues from 
the AChR resulted in no decrease in antibody binding, implying that 
carbohydrate made no direct contribution to the antigenicity of the 
receptor. Dénaturation of the AChR resulted in a decrease in anti­
receptor antibody binding of between 60 and 84%. Thus antibodies were 
directed mainly at conformation-dependent sites on the receptor. 
Substantial differences between the antigenic sites of soluble and 
membrane-bound receptors were found.
2. The contribution of antibody-mediated muscle cell lysis in the 
pathogenesis of myasthenia gravis has been studied, using a novel 
in vitro cytotoxicity assay based on ^H-carnitine uptake and release 
by muscle cells in culture. Cytolytic activity toward both chick and 
human embryonic muscle cell cultures was demonstrated in over 30% of 
myasthenic sera, suggesting that myolysis may be a major mechanism 
for AChR loss in myasthenia gravis. Heat-inactivation of the sera 
abolished their lytic activity, and it was not fully restored by the 
addition of guinea pig complement. Myolysis may be caused by 




The understanding that the function of nerves is to carry 
messages dates back to early Greek physicians. Erasistratus of Chios 
(circa 310-250B.C.) believed that "animal spirits" flowed from the 
ventricles of the brain down the hollow nerves to make the muscles 
swell, and thus to shorten. This concept occurred throughout the 
history of investigation of peripheral nerve function until as late 
as the 17th century, when Jan Swammerdam (1637-80) the Dutch 
embryologist and microscopist introduced the nerve-muscle preparation, 
cuid showed that crushing a nerve induced contraction of the muscle 
without a change in muscle volume.
Until the work of Ramon y Cajal (1852-1934) in 1888 the nervous 
system was regarded as a syncytium or nerve net, and thus a continu­
ous network. In 1839 Theodore Schwann had enunciated the Cell Theory, 
stating that the body was composed of individual units or cells, and 
Cajal, from studies of metal-stained preparations of the nervous 
system,demonstrated the presence of separate cells in this system 
also. In 1891 von Waldeyer summarized all the evidence, starting from 
Schwann's Cell Theory, and named the basic unit or cell of the central 
nervous system the "neuron". Among Cajal's discoveries was that of the 
"bouton terminaux" by which neurons communicated with other cells.
This anatomical finding was later developed by Sir Charles Scott 
Sherrington, who in 1906 published "The Integrative Action of the 
Nervous System", in which he introduced the terra "synapse" to des­
cribe Cajal's bouton terminaux.
Claude Bernard in 1856 showed that injection of curare 
produced paralysis in frog leg muscle and also that the curare-
2.
poisoned leg muscle could not be stimulated electrically via its 
nerve but was nevertheless fully sensitive to direct electrical 
stimulation. These classic experiments were clearly the forerunners 
for the investigation of synaptic transmission, neurotransmitters, 
and indeed the whole field of neuropharmacology. However, it was 
only following the realisation that the nervous system was 
electrically discontinuous that the presence of some additional form 
of communication across the synapse became of paramount importance.
The beginning of the 20th century saw the elucidation of the 
pharmacology of the autonomic nervous system, which had an important 
bearing upon the understanding of all synaptic events. In 1904 
Thomas Elliott discovered that adrenaline had an effect similar to 
stimulation of the sympathetic nervous system, and suggested that 
adrenaline was released by sympathetic nerve activity. In 1906 
W.E. Dixon similarly deduced that muscarine or a muscarine-like 
compound was stored in parasympathetic nerve endings. These two 
discoveries formed the basis of the idea of neurohumoral transmission, 
in which a chemical messenger is released at the synapse, and conveys 
the message to adjacent cells. In 1921 Otto Loewi identified a 
chemical, called by him "Vagustuff" which was released from the 
stimulated vagus nerve. In 1914 Sir Henry Dale had discovered 
acetylcholine in extracts of ergot, and later showed that Loewi's 
vagustuff was, in fact, acetylcholine. Eventually,in 1936 Dale and 
his colleagues Vogt and Feldberg demonstrated that acetylcholine 
appeared after direct nerve stimulation, and that it could activate 
striated muscle. Thus the chemical theory of synaptic transmission 
was finally born.
It is now recognised that several criteria must be satisfied
3.
before a chemical mediator can be established as a neurotransmitter 
(Werman, 1966). These include the following:
1. The mediator is synthesized and stored in the nerve 
terminal.
2. The mediator is released on nerve stimulation, and this 
release must be calcium-dependent.
3. The mediator exerts its effect at a post-synaptic site by 
inducing a change in polarisation of the post-synaptic 
cell.
4. There exists a method for removal of the mediator.
The neuromuscular junction and synaptic transmission
The best elucidated system of synaptic transmission is the 
neuromuscular junction. Its function is to transfer the propagated 
electrical impulse from the ct-motoneuron to the muscle, leading 
ultimately to muscle contraction. It is now well established that 
acetylcholine is the only neuroactive agent at the vertebrate motor- 
end plate, and it has been shown that it satisfies all the criteria 
for a neurotransmitter.
The anatomy and physiology of the vertebrate neuromuscular 
junction have been extensively studied, not only because of its 
influence on muscle action, but also because of its ready 
accessability as a peripheral synapse, and the significant infor­
mation that it contributes to an understanding of synaptic 
morphology and function. The basic features of the cholinergic 
terminal at the vertebrate neuromuscular junction are shown 
schematically in Figure 1.
As the motor axon approaches the muscle fibre it loses its
4.
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myelin sheath and divides into several small branches. These 
branches lie in shallow grooves on the surface of the muscle fibre 
and run short distances before terminating. The region of the 
muscle fibre under the branches is termed the motor-end plate; it 
includes the sarcolemma and also a mound of sarcoplasm, the 
sole-plate. Within the sole-plate are collected a number of muscle 
fibre nuclei as well as many mitochondria, ribosomes and pinocytic 
vesicles. Lying over the whole end-plate are membrane-covered 
cytoplasmic processes derived from the Schwann cells. With the 
electron microscope it can be seen that the membrane of the aucon 
terminal is separated from the sarcolemma by a distinct gap 
measuring about 50nm - the primary synaptic cleft. The primary 
cleft is interrupted by repeated invaginations of the sarcolemma 
into the sole-plate. Each fold forms one secondary synaptic cleft. 
The secondary clefts are approximately 0.5 to 1/am deep and are wider 
(70-90nm) at their terminations than at their necks (SOnm). The 
electron microscope also shows that the basement membrane on the 
outside of the sarcolemma runs through both primary and secondary 
clefts to emerge on the far side of the junction. Like the muscle 
fibre, the axon is also highly specialised at the neuromuscular 
junction. The axon terminations contain large numbers of small 
spheres with membranous linings. They measure some 30nm across and 
are typically clustered opposite the secondary synaptic clefts.
These spheres are the synaptic vesicles, and contain acetylcholine. 
It has been suggested that the vesicles are formed by the pinching 
off of neurotubules or endoplasmic reticulum within the axon 
terminal (Blumcke and Niedorf, 1965). The axoplasm also contains 
two other types of vesicle, though in much smaller numbers. The 
dense-cored vesicles (70-110nm) resemble those known to contain
6.
monoamine transmitters in the central nervous system, and it is 
conceivable that their contents are similar at the neuromuscular 
junction. An alternative suggestion is that they contain 
neurotrophic messenger molecules. The coated vesicles apparently 
form by in-pouching of the axolemma, and presumably enable the axon 
terminal to take up impermeant molecules from the synaptic cleft.
Also within the axon terminal are large numbers of mitochondria 
which probably provide most of the energy, in the form of ATP, 
required for the synthesis of acetylcholine. Finally the axon 
terminal contains large numbers of neurotubules and neurofilaments 
which enter from the axon fibre.
A relatively satisfying account of the synaptic events which 
enable excitation to spread from the motor axon to the muscle fibre 
is possible, not only because many details of the transmission 
process are understood, but also because many structural features of 
the synapse can be correlated with function. The process of synaptic 
transmission is shown schematically in Figure 2. The first step in 
transmission is the propagation of the action potential into the 
distal regions of the motor axon. The impulse travels all the way to 
the synapse itself, as shown by Katz and Miledi (1965) who were able 
to record a propagated potential with an extracellular microelectrode 
positioned close to the axon terminal. When the impulse invades the 
axon terminal it depolarises the axon membrane. During this 
depolarisation calcium ions enter the axon from the extracellular 
fluid. Calcium ions are essential for the release of acetylcholine.
It is possible that they activate sites on the inside of the axolemma, 
so allowing fusion to take place between this membrane and that of 
the synaptic vesicles. The vesicles then discharge their 
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between the excitation in the nerve, and subsequently in the muscle 
fibre can be accounted for by the calcium-mediated release of trans­
mitter. In mammalian junctions this delay is of the order of
0.2 milliseconds. Once the acetylcholine is discharged into the 
cleft it diffuses very quickly towards the muscle fibre membrane.
The fall in muscle fibre membrane potential following an impulse in 
the motor-axon is termed an end-plate potential (E.P.P.). The E.P.P. 
results from an increase in the permeability of the membrane to both 
sodium and potassium ions initiated by the interaction of acetyl­
choline with the membrane. Under normal circumstances the 
developing E.P.P. is overtaken by an action potential, which arises 
as soon as the critical membrane potential has been exceeded (Fatt 
and Katz, 1951). The impulse is set up in the membrane at, and 
immediately adjacent to, the synapse, and is then propagated in both 
directions along the fibre. The sequence of events in the transmiss­
ion process is concluded by the hydrolysis of acetylcholine, to 
choline and acetate, catalysed by the enzyme acetylcholinesterase.
The acetylcholine receptor (AChR)
The nature of the interaction of acetylcholine with the muscle 
membrane has only been elucidated fully comparatively recently. The 
first experimental evidence of the possible existence of a receptive 
substance for acetylcholine at the neuromuscular junction was, 
however, provided by Langley as early as 1907. Direct evidence that 
the cholinergic receptors were localised at the cell membrane, and 
that they were orientated toward the extracellular space was reported 
in 1955 with the introduction of the iontophoretic application of 
acetylcholine at the myoneural junction. The elegant experiments of 
del Castillo and Katz demonstrated that the receptor could be
9,
activated only when the transmitter was applied extracellularly and 
not when it was injected inside the cell. These findings thus 
localised the search for an AChR to chemosensitive sites on the post- 
synaptic membrane at the synaptic junction.
The first report of purification of an AChR was made by Chagas 
and Ehrenpreis (reviewed by Hasson-Voloch, 1968). The pharmacology 
of this preparation was, however, suspect. In 1967 De Robertis, 
Fiszer and Soto used a similar approach to isolate a receptor 
protein from rat brain which bound cholinergic ligands. The problem 
of such tissue, however, is that it contains a mixed population of 
different receptors. Thus, for the isolation and characterisation 
of the AChR to be feasible, a rich source of relatively pure 
receptor was necessary. A second problem was to find a specific 
receptor marker by which the progress of the AChR through any 
purification procedure could be monitored. The first of these prob­
lems found its solution in the electric organs of the electric 
fishes.
The electric organs of the electric fish
The electric organs of electric fish consist of arrays of 
large flat cells called electroplaques, each of which is capable of 
producing a change in potential on receiving a nerve impulse. The 
potential generated by each electroplaque is of the order of 0.14 
volts. As the cells are arranged in series, the discharge produced 
is the summation of the evoked potentials. The two most studied 
fish, Electrophorus electricus (the electric eel) and Torpedo 
marmorata (electric ray) can generate potentials of 600 and 40-60 
volts respectively.
10,
The electroplaque of both species is a giant syncytium con­
taining several thousand nuclei. It is a highly assymetric cell, 
receiving nerve terminals on only one of its faces - the caudal 
face in Electrophorus, the ventral in Torpedo. The plasma membrane 
on both surfaces shows a remarkable increase of surface area as a 
consequence of the proliferation of invaginations and villosities.
In Electrophorus ̂ nerve endings establish 10^ to 10^ specific 
contacts with one electroplaque, but cover only 1.4 to 2% of the 
surface of the membrane on the innervated face. In Torpedo 
innervation is much denser, and the innervated membrane less 
convoluted, so that the subsynaptic areas occupy up to 50% of the 
total surface of the innervated membrane. Thus electric organs 
from Torpedo can be expected to be much richer in receptor than 
those of Electrophorus (Changeux, 1975). Figure 3 shows a schematic 
representation of an isolated electroplaque.
In 1877 Du Bois-Reymond realised that the electric discharge 
produced in the electric organs was generated in the same way as 
that at the neuromuscular junction. Embryologically the electric 
organ develops from the same tissue as skeletal muscle. Although, 
the contractile elements are absent from the electroplaques they 
nevertheless respond to acetylcholine in a similar way to muscle 
cells. In tbie electric organs of Electrophorus the response to 
acetylcholine is the generation of an action potential analogous to 
that seen in a muscle cell. The electroplaque of Torpedo, on the 
other hand, is unable to generate an action potential and the dis­
charge of the cell derives from the summation of individual 
excitatory end-plate potentials. In both types of electroplaque 
the net influx of current passes through the non-innervated face of 
the cell to complete the circuit (Lester, 1977).
11.














The electric organs of the electric fish are an ideal model 
for the study of neurotransmission at the neuromuscular junction, 
as they possess similar excitability properties. The organisation 
of the myoneural elements is such that all the mediators involved 
in the transduction process are present in eibnormally high concen­
trations. This fact, together with the fact that the tissues are 
purely nicotinic cholinergic, rapidly made electric organs the 
tissue of choice for the isolation and purification of the AChR, 
and it is the extensive investigation of this receptor which has 
revealed most of the currently known characteristics of the AChR,
The pharmacological properties of the isolated electroplaque
Drugs which affect transmission are classified either as 
activators (agonists) if they cause depolarisation of the post- 
synaptic membrane, or as blockers (antagonists) if they block the 
depolarisation caused by acetylcholine or its agonists. A few 
drugs called "depolarising blockers" bridge the gap between the two 
main classes. Long before acetylcholine was recognised as a neuro­
transmitter, neuromuscular junctions were classified into muscarinic 
and nicotinic types. The first of these are present in smooth 
muscle, and are activated by muscarine and inhibited by atropine.
The second type is present in skeletal muscles, and is activated by 
nicotine, and inhibited by d-tubocurarine. Some examples of 
chemicals acting at the synapse are given in Figure 4.
The pharmacological properties of the electroplaque have been 
well characterised (Nachmanson, 1959) and shown to be similar to 
those seen by Dale et al. (1936) at the neuromuscular junction. 
Agonist activity was found to be subject to strict structural 
limitations, requiring the presence of a trimethylammonium group
13,
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and a carbonyl oxygen at 0.59nm radial distance from a quaternary 
ammonium moiety. Concentration-effeet curves for agonist response 
showed saturation, with a maximum response being observed in the 
presence of excess agonist. The shape of the curves was slightly 
sigmoidal, and determination of the gradient of Hill plots 
revealed cooperativity. The effect of an agonist was shown to 
reverse the blocking effect of an antagonist, and vice-versa, 
rather like the competitive interaction between substrate emd 
inhibitor at an enzyme catalytic site. On this basis Nachmanson 
(1959) proposed that the receptor was a protein.
Evidence for the proteinaceous nature of the AChR was actually 
suggested as early as 1955, and fully established from about 1966 
onwards. The work of De Robertis et al. (1967) and Silman and 
Karlin (1967) made it evident that the receptor protein was prob­
ably an intrinsic protein of the cell membrane, requiring quite 
drastic treatments for extraction from its lipid milieu. Changeux 
et al. (1969) isolated a membrane fragment from Electrophorus 
electricus that was rich in acetylcholine activity. In view of the 
suggestion that the AChR was an integral membrane protein Changeux 
et al. (1970) used the ionic detergent, sodium deoxycholate to 
solubilise a protein from the electric organ of Electrophorus.
They showed agreement between the dissociation constants (K̂ ) for 
the binding of agonists and antagonists to the acetylcholinesterase- 
rich membrane fragments, the isolated electroplaque and the 
detergent-solubilised receptor.
Once a cholinergic tissue is homogenised the usual means of 
AChR identification in situ (the effect of drugs on the depolar­
isation of membranes or on muscle contraction) is lost. A
16.
successful way to identify AChR in subcellular fractions is to
study its binding to cholinergic ligands. However, binding of
such ligands is not in itself sufficient for the identification of 
the receptor, because macromolecules other than AChR (e.g. acidic 
mucopolysaccharides or albumin) can act similarly. Thus a 
quantitative, reproducible assay for the detection of the isolated 
AChR must satisfy several strict criteria if the measurements 
obtained are to be a true representation of the ligand-receptor 
interaction in vivo. These criteria are outlined below.
1. The ligand used as a probe must be fully active 
biologically so that it can mimic the activity of the
parent compound at the receptor site.
2. The binding observed must exhibit absolute structural 
and steric specificity, which must relate to the known 
biological activity of the parent ligand, its 
structural agonists and antagonists.
3. The binding should demonstrate saturability within a 
concentration range that can be meaningfully related 
to that of agonists which elicit the known biological 
response in intact biological systems.
4. The binding interactions should reflect an affinity 
in keeping with the sensitivity of the tissue to the 
physiologically active concentration of the ligand.
5. The presence of binding should be restricted to tissue 
known to be physiologically sensitive to the ligand.
Initially -décaméthonium (Changeux et al., 1971) or
Ĥ -acetylcholine (Eldefrawi and Eldefrawi, 1973a) were used, with 
bound ligand being separated from free ligand by equilibrium
17.
dialysis. However, a more sensitive and irreversibly-bound marker 
for the isolated AChR was necessary to assess accurately the purifi­
cation procedure. The answer to this requirement came surprisingly 
through the serendipitous discovery of the mode of action of the 
elapid snake venoms.
The o(-neurotoxins as probes for the AChR
Snakes from the elapid and hydrophobid families kill their prey 
by paralysing the respiratory muscles. In the late 1950's, Lee was 
able to explain the action of the venom in terms of its blockage of 
neuromuscular transmission (for review see Lee and Chang, 1966). Lee 
showed that very low concentrations of venom were capable of producing 
an anti-depolarising block at the neuromuscular junction very similar 
in action to that of acetylcholine antagonists. It did not affect the 
action potential of either the nerve or the muscle, the release of 
acetylcholine or its hydrolysis by acetylcholinesterase. The inhibit­
ory action could be reversed by cholinergic effectors. Analysis of 
the crude venom showed that a single class of polypeptides, now called 
«-toxins, was responsible for the neuromuscular block by binding 
specifically to the AChR.
Two types of «-neurotoxin have been isolated. Type I produce a 
reversible neuromuscular blockade, whereas for type II toxins the 
blockade is essentially irreversible. Both types of «-toxins are 
compact, basic polypeptides. Type I toxins, (such as «-toxin from 
Naja naja siamensis) have 60-62 amino acid residues (Cooper and Reich, 
1972), while type II (for example o(-bungarotoxin from Bulgarus 
multicinctus) have 71-74 residues. o(.-Bungarotoxin («-BGT) has a 
molecular weight of 8000, comprising 74 amino acid residues with 5 
disulphide bridges, and an isoelectric point (pU of 9.0 (Dolly,1979).
18.
Type II toxins are ideal probes for the AChR, and for this
purpose it is possible to radiolabel the «-toxins with the retention
of their biological activity. Several methods have been employed,
including incorporation of ^^^lodine or ^^^lodine into tyrosine
residues (Miledi et al., 1971; Berg et al., 1972), partial méthylation 
/ 14 \ ̂ CHg) of amino groups (Biesecker, 1973) and tritiation by incorpor­
ation of an acetyl (Dolly and Barnard, 1974) or propionyl group 
(Barnard et al., 1979).
The radiolabelled «-toxins have proved invaluable as they can 
be used to identify the AChR both in solution, and in fragments of 
cell membrane, where electrophysiological measurements of receptor 
function are not possible. Radiolabelled «-BGT has now become almost 
universally used for the detection of AChR because of its great 
sensitivity, made possible by labelling to high specific activities, 
and because of the virtually irreversible nature of its binding 
(Dolly, 1979; Vincent and Newsom-Davis, 1979).
Isolation of electric fish AChR
Conventional procedures for the purification of the AChR, such 
as ammonium sulphate precipitation, DEAE - cellulose chromatography 
or hydroxylapatite chromatography, have generally not resulted in 
complete purification of the active AChR.
«-Neurotoxins of type I have proved to be ideal ligands for 
use in affinity chromatography of the AChR, and this technique has 
given a dramatic one-step purification of the receptor.«-Neurotoxins 
commonly used as immobilised ligands include those from N.naja 
(Karlsson et al., 1972; Lindstrom and Patrick, 1974) and Naja naja 
siamensis (Klett et al., 1973; Eldefrawi and Eldefrawi, 1973b).
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Desorption of AChR from the affinity ligand is achieved by the use of
cholinergic agents such as carbamylcholine, hexaméthonium, or
gallamine triethiodide.
Other ligands, such as synthetic quaternary ammonium 
derivatives, have also been successfully applied in the purification 
of AChR by affinity chromatography (for review see Fulpius, 1976).
The eluting ligand is easily removed by dialysis (Karlsson 
et al., 1972; Olsen et al., 1972), or by gel filtration (Shorr et al.,
1978). Additional steps have been taken to purify the AChR to
homogeneity. These include (1) ultracentrifugation in a sucrose 
density gradient (Lindstrom and Patrick, 1974), (2) chromatography 
on DEAE -cellulose (Klett et al., 1973) or DEAE -Sephadex (Dolly and 
Barnard, 1977), (3) preparative electrophoresis (Eldefrawi and 
Eldefrawi, 1973b) or (4) chromatography on lentil lectin-Sepharose 
resin (Shorr et al., 1978).
The receptor protein from electric fish has been purified to 
specific activities in the range of 2-12/imoles of «-BGT binding sites 
per gram protein (for review see Changeux, 1981) using the techniques 
o u t l i n e d  above. P r o t e c t i v e  m e a s u r e s  to i n h i b i t  e n d o g e n o u s  p r o t e a s e s  
m u s t  be ta ke n in the i s o l a t i o n  p r o c e d u r e  in o r d e r  f o r  the n a t i v e  
s u b u n i t  s t r u c t u r e  o f  the A C h R  to be m a i n t a i n e d  ( L i n d s t r o m  et a l .,
1980; see p . 22 be lo w).
Isolation of skeletal muscle AChR
Progress in the purification of the AChR from skeletal muscle 
has been much slower than that of electric fish because of the very 
low content of receptor in muscle sarcolemma (Wallis et al., 1980) and 
the susceptibility of the receptor to proteolysis during purification
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(Lindstrom et al., 1980 ; Shorr et al., 1981; Einarson et al., 1982). 
Nevertheless, AChR purification has been reported from a number of 
vertebrate skeletal muscle sources (Table 1).
Properties of the isolated AChR
Molecular weight and molecular shape; Determination of the 
molecular weight of the purified receptor in solution can only give 
approximate values because of the presence of bound detergent.
Meunier et al., (1972b) showed that Triton XlOO can contribute up to 
21% (160-170 molecules) of the total mass of the receptor-toxin 
complex in solution. Similarly Karlin et al., (1979) reported that 
the AChR binds 0.5g of Triton XlOO per gram protein. Values for the 
molecular weight of all species range from 230000-370000 (for review 
see Changeux, 1981). Sedimentation of receptor or receptor-toxin 
complex in a sucrose density gradient showed that the protein 
sedimented with a sedimentation coefficient of ^9S (Sobel et al., 
1978; Biesecker, 1973; Dolly and Barnard, 1977; Froehner et al.,
1977a). A second species in both electric organ of Torpedo 
californica (McNamee et al., 1975) and Torpedo marmorata (Barnard 
et al., 1978) has been found with sedimentation coefficient S^^ ^13S, 
and has been shown to be a dimeric form of the receptor which is 
stabilised in the presence of N-ethyl maleimide (Barnard et al., 1978) 
Dimérisation is favoured at higher Triton XlOO concentrations 
(Reinhard et al., 1981). The ratio of the Stokes radius to the 
minimum possible radius for the protein-detergent complex falls out­
side the range for globular proteins (Meunier et al., 1972b) and, 
indeed, neutron scattering measurements of the monomer and dimer in 
detergent solution are consistent with the molecule's being an 







































Subunit composition; The receptor has been shown to have an 
oligomeric structure; in the presence of SDS it splits into subunits 
of lower molecular weight (Karlin et al., 1971; Meunier et al., 1971, 
1972a; Raftery et al., 1971). Analysis of the subunits by SDS poly­
acrylamide gel electrophoresis under denaturing conditions has shown 
that AChR from Torpedo marmorata and Torpedo californica has four 
subunits with molecular weights of 38-40000 (a) , 50000 (y0) , 57000 
(̂ ) and 64000 (5) present in the ratio 2:1:1:1 (Barnard et al., 1979; 
Lindstrom et al., 1979a; Raftery et al., 1979).
In mammalian muscle the number of subunits has been variously 
reported at between one and five (Table 1). It now appears, however, 
that reports of less than four subunits are attributable to selective 
proteolysis of the higher molecular weight subunits (Lindstrom et al., 
1980; Einarson et al., 1982).
The subunits of Torpedo AChR are acidic glycoproteins which can 
be distinguished by peptide mapping (Lindstrom et al., 1979b;
Vandlen et al., 1979; Nathanson and Hall, 1979). Specific affinity 
ligcinds can also be used to label individual subunits (Karlin, 1974; 
Lyddiat et al., 1979; Karlin, 1980; Saitoh et al., 1980). The arrange­
ment of subunits in the monomeric receptor is not known, but the 
subunits are known to be strongly noncovalently associated. Even 
after extensive proteolysis the proteolytic fragments remain 
associated, and both the ligand binding site and ion-channel of the 
receptor remain functional (Lindstrom et al., 1980; Conti-Tronconi 
et al., 1982).
Purified receptor is consistently associated with two 
additional protein components of 43000 cind 90-150000. The higher 
molecular weight compound is generally considered to be a component
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of the Na^,K^-ATPase. Most recent evidence suggests that the 43000 
protein is a peripheral protein associated with the cytoplasmic face 
of the membrane in situ, and possibly has a structural role (Barrantes 
et al., 1980; Lo et al., 1980; Wennogle and Changeux, 1980; Gordon et 
, 1983).
Reconstitution of AChR in model membranes
Re-assembly of the detergent-solubilised, purified receptor into 
a membrane environment constitutes proof that the purified protein 
contains all the essential elements of the functional AChR. The AChR 
has now been reconstituted into lipid bilayer vesicles and planar 
lipid films with complete recovery of ligand binding and ion 
permeability properties (Anholt, 1981; McNamee and Ochoa, 1982).
Biochemical properties of the isolated AChR
In 1955 Nachmanson suggested that the AChR was a protein on the 
assumption that only proteins had the ability to "recognise” specific 
molecules. Amino acid analysis of the purified receptor confirms the 
protein nature of the AChR. The amino acid composition of the AChR 
is very similar to that of acetylcholinesterase, a finding which led 
to early suggestions that the two were identical (O'Brien et al.,
1972). Devillers-Thiery et al. (1979) reported the amino terminal 
sequence (20 amino acids) of the o(-subunit of Torpedo marmorata.
More recently the identification of the messenger RNA for the AChR 
has allowed the cloning of complementary DNA(cDNA) and subsequent 
nucleotide sequencing of the o -̂chain in Torpedo marmorata (Sumikawa 
et al., 1982; Devillers-Thiery et al., 1983) and of all four chains in 
Torpedo californica (Ballivet et al., 1982; Noda et al., 1982,
1983a,b). In addition Noda et al. (1983c) have cloned cDNA for the
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drsubunit precursor of calf skeletal muscle AChR. Nucleotide 
sequencing of the mammalian DNA has revealed marked sequence homology 
with their Torpedo counterparts.
The receptor contains carbohydrate as shown by the interaction 
with plant lectins (Meunier et al., 1974) and this property has been 
utilised in the purification of mammalian muscle AChR (Shorr et al., 
1978; Brockes and Hall, 1975). Polyacrylamide electrophoresis gels 
of purified AChR stain with reagents specific for carbohydrate (Shorr 
et al., 1978; Lindstrom et al., 1979) and the carbohydrate composition 
of Torpedo californica AChR has been analysed by gas-liquid chroma­
tography (Lindstrom,1979a; Mattson and Heilbronn, 1975; Raftery 
et al., 1976). The carbohydrate content of Torpedo receptor 
represents 4-7% of the total receptor weight, with all of the 
individual subunits possessing glyco-moieties (Vandlen et al., 1979; 
Turnbull et al., 1984). There is general agreement on the presence 
of mannose, galactose and N-acetylgalactosamine (Heilbronn et al.,
1974; Lindstrom et al., 1979a; Vandlen et al., 1979). Neuraminidase 
treatment of the receptor, affecting exclusively the ^ and S subunits, 
has suggested the presence of sialic acid residues in these subunits 
(Criado and Barrantes, 1982) and a recent direct determination has 
confirmed the presence of about one mole of sialic acid per mole of 
receptor (Bersinger et al., 1983).
The possible functional involvement of a phospholipid component 
is suggested by the effect of phospholipase A treatment on the binding 
of acetylcholine and carbamylcholine by the receptor (Eldefrawi et al., 
1972; Hanley, 1978; Andreason et al., 1979). The lipid environment 
of the receptor has been reported to modulate its functional 
properties (Chang and Bock, 1979; Andreason et al., 1979) and a
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fraction of immobilised lipid has been reported to occur in the 
vicinity of the AChR (Marsh et al., 1981; Ellena et al., 1983).
More detailed studies of the influence of the lipid environment on 
the AChR have been allowed by reconstitution of the receptor into 
artificial lipid membranes (Epstein and Packer, 1978; Anholt et al.,
1982). Ion flux in such systems depends on the presence of neutral 
lipids (Dalziel et al., 1980) and charged natural phospholipids 
(Ochoa et al., 1983) . The transition of the receptor between low 
and high affinity states is also dependent on the lipid constitution 
of the reconstituted membrane (Heidmann et al., 1980; Criado et al., 
1984).
The structural characteristics of membrane-bound AChR
The AChR is an integral membrane protein, spanning the post- 
synaptic membrane, and extending out approximately l.Snm from the 
intracellular surface and almost S.Snm from the extracellular surface 
(Ross et al., 1977; Huang, 1979; Tarrab-Hazdai et al., 1978). The 
use of electron microscopy, combined with single-particle image 
averaging,indicates that the two ©(.-subunits are diametrically opposed 
with about Snm separating them (Zingsheim et al., 1982). Cross- 
linking studies demonstrate that predominantly the eC and S chains 
are cross-linked to oC-toxin (Karlin, 1980; Hucho, 1981). Scanning 
electron microscopy of diamide-induced trimers of AChR in receptor- 
rich membranes has given an indication of the spatial arrangement of 
the and 5 subunits (Wise et al., 1981). From such data a schematic 
representation of the subunit arrangement and topography of the 
membrane-bound AChR can be made (Figure 5). The orientation of 
specific subunits with respect to the membrane has been investigated 
by a variety of techniques, indicating that parts of all four
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FIGURE 5. A schematic representation of the subunit topography 





subunits are exposed on both the extracellular and cytoplasmic 
surfaces. The 43000 dalton protein is, however, exposed on only the 
cytoplasmic face (Cohen et al., 1980; Karlin, 1980; Wennogle et al., 
1981; Sargent et al., 1984).
Pharmacology of AChR in it's purified and membrane-bound forms
Although AChR's are classified into muscarinic and nicotinic 
types, the fact that acetylcholine binds to both types of receptor, 
as well as to acetylcholinesterase, choline acetyltransferase and 
certain storage proteins, indicates that there are similarities in the 
active sites of these proteins. Because the action of many neuro­
active drugs is attributable to their structural similarities to the 
neurotransmitter it is not unusual to find a cholinergic drug with 
more than one site of action; the primary target usually being the 
receptor for which it has the highest affinity. Thus, classification 
of drugs into muscarinic and nicotinic groups is dependent on their 
affinities for the two types of AChR, and hence a "drug profile" for 
the nicotinic AChR can be built up. From this it follows that in 
order to determine if the AChR protein has been altered by solubili­
sation and purification it is necessary to measure its affinity for 
cholinergic agonists and antagonists before and after such treatments. 
The binding characteristics of cholinergic ligands can be measured in 
a number of ways (Colquhoun, 1979; Conti-Tronconi and Raftery, 1982). 
On the basis of all of the available methods for determination of the 
detailed binding characteristics of both electric fish and skeletal 
muscle receptors, there is generally good agreement between the 
characteristics of soluble and membrane-bound receptors (for reviews 
see Dolly, 1979; Colquhoun, 1979), although the interconversion of 
agonist affinity states induced by desensitization is lost on
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dissolution of the membrane by neutral detergents or in sodium cholate 
(for review see Conti-Tronconi and Raftery, 1982).
The action of antagonists is generally considered to result from 
simple competitive binding to the acetylcholine binding site. 
Physiologically, therefore, the oc-neurotoxins act as antagonists, 
although the half-time of the blockade reversal is up to several 
days (Lee, 1972). Radiolabelled 0(-BGT binds to the AChR with regular 
second-order kinetic behaviour, and has a similar for both 
partially purified and membrane-bound rat muscle receptor (Dolly,
1979). A competitive relationship is observed between the binding 
of c h o l i n e r g i c  e f f e c t o r s  and the a - t o x i n s  to the A C h R ,  w i th each 
A C h R  m a c r o m o l e c u l e  p o s s e s s i n g  two l i g a n d / t o x i n  b i n d i n g  sites.
(for reviews see Fulpius, 1976; Heidmann and Changeux, 1978).
A number of substances are known which block the physiological 
response to acetylcholine. Local anaesthetics are thought to work 
by binding to the ion-channels. Histrionicotoxin, an alkaloid 
isolated from the Colombian arrow-poison frog, Dendrobates 
histrionicus (Daly et al., 1971) can also reversibly block the 
acetylcholine-mediated ion conductance at the neuromuscular junction, 
possibly via a direct block on the AChR ion channel (for review see 
Conti-Tronconi and Raftery, 1982).
Junctional and extrajunctional AChR
The distribution of AChR in the muscle cell membrane has been 
investigated by both the iontophoretic mapping of acetylcholine, and 
by autoradiography of bound o(-BGT (for review see FeQnbrough, 1979) .
In the embryonic myotube, prior to the onset of innervation, 
the receptor protein is widely distributed over the cell surface
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(extrajunctional receptor). As development of the neuromuscular 
junction progresses the receptor becomes progressively restricted to 
the junctional region (junctional receptor).
In adult innervated muscle the receptor is present only in the 
end-plate region (Dolly, 1979). If a mature, innervated muscle is 
denervated, however, the extrajunctional regions acquire receptors, 
producing a density which is less than the junctional area, but 
greater than embryonic muscle receptors (for review see Fambrough, 
1981).
Extrajunctional and junctional receptors in situ differ in a 
number of ways.
1. Embryonic extrajunctional receptor on cultured cells has 
been shown to exhibit significant lateral mobility, with 
a diffusion coefficient of 1 - 3 x 10 ^cm^/s at 37°C (for 
review see Fambrough, 1979) , whereas the junctional 
receptor is immobile.
2. The rate of turnover of extrajunctional receptor from 
both embryonic and denervated adult muscle is considerably 
higher than that of junctional receptor in adult muscle 
(average receptor lifetimes of 5 - 35h and >120h 
respectively; for review see Fambrough, 1979).
3. The ion channel of the receptor from adult rat and chick 
muscle possesses a mean channel open time 3 - 5  fold 
longer than that of the extrajunctional receptor from 
denervated adult muscle (Katz and Miledi, 1972; Neher 
and Sakmann, 1976).
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Purification of AChR from innervated and denervated adult rat 
muscle has demonstrated that junctional and extrajunctional receptors 
are remarkably similar in subunit composition, and are indistinguish­
able by gel filtration and sucrose density centrifugation (Brockes cind 
Hall, 1975; Froehner et al., 1977b; Nathanson and Hall, 1979). 
Nevertheless purified junctional and extrajunctional receptors from 
rat muscle have been reported to display three significant differences,
1. They have slightly different isoelectric pHs (Brockes and 
Hall, 1975) .
2. They exhibit different cholinergic drug sensitivities 
(Beranek and Vyskocil, 1967; Brockes and Hall, 1975).
3. Extrajunctional receptor may display more antigenic 
determinants than junctional receptor (see below).
The available evidence to date suggests that the biochemical 
and physiological differences between junctional and extrajunctional 
receptors result from post-translational modifications, such as 
phosphorylation and glycosylation (for review see Barnsta,ple et al.,
1983). It is possible that the receptor undergoes such modification 
before being assembled in the membrane (Changeux and Danchin, 1976).
The receptor will also be affected by its local environment, and in 
particular the lipid composition of this environment (Hall, 1981).
The AChR of muscle cells in culture
Tissue culture has been used to study smooth, striated and 
cardiac muscle, but has been most fruitful in the case of striated, 
skeletal muscle.
Multinucleated myotubes can be formed in culture from myoblasts 
obtained from embryonic muscle, or from satellite cells from adult
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muscle biopsies, or from established myoblast cell lines. Associated
with the appearance of fused fibres in the culture are increases in
the specific activity of a number of enzymes, and the accumulation of
contractile proteins (for review see Schubert et al., 1973). At the
time of myoblast fusion, AChR, detected either by electrophysiological
125response to acetylcholine or by I binding, begins to appear
in the culture (Fambrough and Rash, 1971; Patrick et al., 1972; Vogel 
et al., 1972). The AChR may be elaborated from a pool pre-existing 
in the myoblast (Teng and Fiszman, 1976), or by de novo synthesis 
after fusion has occurred (Merlie et al., 1975). Once the fusion 
process is complete the number of receptors on the surface of a 
muscle fibre represents a steady state determined by the relative rates 
of synthesis and degradation (Fambrough, 1979) .
In cultured chick myotubes synthesis of AChR occurs in less than 
30 minutes, but the receptors undergo a 3 hour transit time before 
being inserted into the membrane (Devreotes and Fambrough, 1976). A 
substantial fraction of newly synthesised receptor is located in the 
Golgi apparatus, where it resides for about 2 hours (Fambrough and 
Devreotes, 1978; Merlie and Sebbane, 1981; Bursztajn and Fischbach,
1984). Each subunit is translated from a separate mRNA (Anderson and 
Blobel, 1981) with co-translational insertion of each subunit into 
the rough endoplasmic reticulum (RER) membrane. Concomitant with this 
the subunits are also glycosylated. The subunits are also trans­
lated with signal peptides that govern their subsequent orientation 
in the membrane (for review see Anderson and Blobel, 1983). The AChR 
subunits are not assembled with one another into a functional complex 
immediately upon incorporation into the RER membrane. Assembly 
rather appears to be a fairly lengthy post-translational process. 
Post-translational modification of the o(-subunit to form the high-
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affinity <X-BGT binding site occurs over a period of about 30 minutes
after transport of the subunit out of the RER into the Golgi apparatus
(Merlie and Sebbane, 1981). Quaternary assembly of the subunits may
take at least as long as acquisition of the toxin-binding site (Merlie
et al., 1983). The incorporation of new receptors into the plasma
membrane is blocked by inhibitors such as 2,4 - dinitrophenol which
interfere with ATP synthesis. Incorporation is also dependent on
temperature in homeotherms, and does not occur at a significant rate
below 25°C in cultured chick skeletal muscle (Fambrough, 1979).
Treatment of cultured chick muscle with a specific inhibitor of
N-glycosylation, tunicamycin, has been reported to result in a ten-
125fold reduction in the number of surface I -a-BGT binding sites.
Bound toxin was also released at a more rapid rate than in control 
cultures (Prives and Olden, 1980). Tunicamycin also blocks maturation 
of the oC-BGT binding site on the o<-subunit (Merlie et al., 1981) .
The degradation rate of AChR can be approximated by measuring
125the rate of degradation of I -0(-BGT after it has bound to the 
receptor. From these data the average receptor lifetimes for extra­
junctional AChR on cultured muscle has been calculated at about 17 - 19 
hours (for review see Pumplin and Fambrough, 1982). The degradation 
process in chick muscle cultures is sensitive to protein content and 
pH of the culture medium, and is exquisitely sensitive to temperature 
(Devreotes and Fambrough, 1975). Metabolic inhibitors which interfere 
with ATP synthesis rapidly block or slow the degradation process, with 
a slower retardation being given by inhibitors of protein synthesis 
(Fambrough, 1979). Degradation of the AChR-toxin complex occurs via 
a process of internalisation followed by proteolytic degradation in 
secondary lysosomes (Devreotes and Fambrough, 1975; Axelrod et al., 
1976). Many different types of experiments have shown that the
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processes of AChR synthesis and degradation are not directly coupled 
(for review see Pumplin and Fambrough, 1982).
Newly synthesised and incorporated AChR in cultured muscle 
membranes may remain in diffuse distribution, or partition into dis­
crete clusters (Vogel et al., 1972; Sytkowski et al., 1973; Fischbach 
and Cohen, 1973; Prives et al., 1976; Bloch, 1979). AChR clusters are 
typically round or ovoid patches 5 - 10pm across, consisting of 
laterally immobile AChR with a density 2 - 3  fold lower than those at 
mature synapses (Sytkowski, 1974), and 10 fold higher than diffusely 
distributed receptors (Axelrod et al., 1976). Clusters may be found 
either juxtaposed to the substrate or on the free surface of the cell. 
In rat myotubes the localisation is primarily on the ventral surface, 
and is within broad regions of close cell to substrate contact (Bloch 
and Geiger, 1980). It is associated with a number of other cell 
membrane associated components (for review see Fambrough, 1984). 
Clusters of receptors have a half-time in the membrane similar to that 
of non-clustered receptors (Schuetze et al., 1978). Diffuse and 
clustered AChRs do not readily interconvert in short times, but can be 
induced to do so by treating cultures with sodium azide, or with 
medium depleted of calcium (Bloch, 1979). Autoradiographic studies of 
receptor distribution in embryonic rat and chick skeletal muscle 
in vivo suggest that AChR clusters do not occur on myotubes prior to 
innervation and occur only at neuromuscular connections thereafter 
(Burden, 1977; Bevan and Steinbach, 1977). The formation of clusters 
in vitro may, therefore, be a manifestation of synaptogenic mechanisms 
operating in the prolonged absence of innervation (Fambrough, 1979).
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The AChR and Myasthenia Gravis
Myasthenia gravis is a neuromuscular disorder which pursues a 
remitting and relapsing chronic course and is principally character­
ised by muscle weakness (Simpson, 1978a,b). The disease has a 
prevalence which is within the range of 1:10000 to 1:50000 of the 
population. The age of presentation ranges from early childhood to 
extreme old age. The incidence of myasthenia is higher in females 
than males, with a ratio of 6:4. In those presenting under 40 years, 
females predominate, while in those presenting cÜDOve this age, males 
predominate, with modal values for the two sexes being in the third 
and seventh decades respectively (Osserman and Genkins, 1971). The 
initial symptoms may present insidiously or may arise suddenly if 
precipitated by such factors as emotional disturbance, infection of 
the upper respiratory tract or anaesthesia. At first the weakness 
may affect any muscle, but certain ones are likely to be more affected 
than others. For example, weakness of the extraocular muscles is 
common, causing diplopia. Involvement of the elevators of the upper 
eyelids gives rise to ptosis. Other facial muscles may also be 
affected, and there is often weakness of bulbar muscles causing 
difficulty in swallowing and speaking.
The disease may undergo spontaneous remission although this is 
unconmon, and it is more usual for the weakness to spread to muscles 
other than those originally affected. A characteristic feature of 
myasthenia is the fact that the weakness is aggravated by exertion 
and improved by rest.
Other clinical disorders may be associated with myasthenia.
Of these, by far the most important is a thymoma which is present in 
about 10% of cases. A third of these tumours are malignant, but
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métastasés are uncommon. Disorders of the thyroid gland are also 
associated with myasthenia, being found in about 9% of males and 18% 
of females (Simpson, 1958; Downes et al., 1966). The most common of 
these disorders is thyrotoxicosis, but myxoedema, non-toxic goitre 
and Hashimoto’s thyroiditis may also occur. A variety of other 
diseases have been reported in conjunction with myasthenia, and 
include rheumatoid arthritis, Sjogren's disease, pernicious anaemia, 
epilepsy and psychotic illness (Simpson, 1974).
The first clear description of myasthenia gravis was given by 
Dr Thomas Willis in 1672 in his book "De Anima Brutorum". In the 
English version (published in 1683) he describes persons who:
'are distempered with Members very much loosened frcan their 
due vigour and strength, and with a languishing of their Limbs ; so 
that though they are well in their stomach, and have a good and 
laudable pulse and wine, yet they are as if they were enervated, 
and cannot stand upright, and dare scarce enter upon local motions, 
or if they do, cannot perform them long: yea some without any notable 
sickness, are for a long time fixed in their Bed, as if they were 
every day about to dye; whilst they lie undisturbed, talk with their 
Friends, and are chearful, but they will not, nor dare not move or 
walk; yea they shun all motion as a most horrid thing ....... where­
fore the sick are scarce brought by any perswasion to try whether 
they can go or not. Nevertheless, those labouring with a want of 
spirits, who will exercise local motions as well as they can, in the 
morning are able to walk firmly, to fling about their Arms hither 
and thither, or to take up any heavy thing, before noon the stock of 
spirits being spent, which had flowed into the Muscles, they are 
scarce able to move Hand or Foot'.
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A further two centuries passed before one finds another 
description suggestive of myasthenia. This was in a paper published 
in 1877 by Sir Samuel Wilks. Two years later a fuller description 
was given by a German physician, Erb, and over the next 15 years more 
isolated reports followed. The understanding of the disease was 
significantly advanced by Jolly (1895) who was able to show that 
muscle strength was normal initially, but then declined rapidly in 
patients (other workers subsequently demonstrated that electrical 
stimulation of the muscle fibres directly was effective in restoring 
contractions), and was the first to use the name myasthenia gravis 
(in fact myasthenia gravis pseudoparalytica) to describe the disease. 
Jolly also noted its similarity to curare poisoning.
The observations of Jolly, together with the findings much later 
of the beneficial effects of anticholinesterase drugs in the disease 
(Walker, 1934), and the demonstration of normal nerve action 
potentials (Alajouanine et al., 1959) all suggested that the neuro­
muscular junction was the site of the abnormality in myasthenia gravis. 
A number of defects in neuromuscular transmission are theoretically 
possible in myasthenia, which may be classified as follows :
1. Presynaptic
a. Failure of impulse propagation in axon terminal.
b. Impaired synthesis of acetylcholine.
c. Faulty packaging mechanism in vesicles.
d. Impaired release of acetylcholine.
e. Release of a "false" transmitter.
2. Intrasynaptic





a. Combination of a circulating blocking agent with AChR.
b. Depletion of AChR.
c. Desensitisation of AChR.
d. Increased acetylcholinesterase activity.
Many different, and widely differing, techniques have been used 
to determine the nature of the specific lesion in myasthenia gravis. 
The evidence of morphological, pharmacological and neurophysiological 
studies is summarised below.
Morphological studies
Using light microscopy, in combination with methylene blue 
"vital" staining, or cholinesterase staining, Coers and Woolf (1959) 
found two types of abnormality of the motor nerve endings which they 
termed "dystrophic" and "dysplastic".
Dystrophic junctions were characterised by branching of a single 
motor axon so as to form multiple end-plates on the same muscle fibre. 
Dysplastic junctions were those in which the end-plates were abnor­
mally lengthened on the surface of the fibre. Similar findings to 
those of Coers and Woolf were obtained by MacDermott (1950) and Reske- 
Nielsen et al. (1965) . A further important observation was that both 
types of neuromuscular abnormality could be found on muscle fibres 
without any microscopic evidence of degeneration, suggesting that the 
neuromuscular lesion was a primary event.
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A more detailed examination of the myasthenic neuromuscular 
junction by electron microscopy has shown a generalised simplification 
of structure. A widening of both primary and secondary clefts was 
observed, with a reduction in the number of synaptic clefts also being 
noted (Zacks et al., 1961; Santa et al., 1972). In contrast to these 
findings, the fine structure of the axon terminal appeared well 
preserved in myasthenia, with normal numbers and sizes of synaptic 
vesicles being noted by Johnson and Woolf (1965) and Santa et al.
(1972). One pre-synaptic change which was clearly evident in some 
junctions studied by both Zacks et al., and Johnson and Woolf was a 
reduction in the size of the terminal axonal expansion. As the axon 
retracted, its place was taken by an extension of Schwann cell cyto­
plasm. A pictorial summary of the morphological features of the 
myasthenic neuromuscular junction is shown in Figure 6.
Early investigations performed at post mortem on the muscle 
fibres of myasthenic patients revealed three categories of changes 
(Russell, 1953).
Type I: An acute change in which the fibres underwent coagulative
necrosis and became swollen, subsequently losing their nuclei and 
myofibrils. There was a pronounced infiltration of inflammatory cells 
in and around the fibres, in which polymorphonuclear leukocytes and 
macrophages predominated.
Type II: This change was concerned with the formation of lymphorrhages
(collections of small lymphocytes around single muscle fibres under­
going atrophy).
Type III: A simple atrophy affecting single muscle fibres or groups of
fibres. The characteristic eosinophilia of the sarcoplasm was
FIGURE 6. (After Lindstrom, 1979)
A Diagrammatic representation of a normal neuromuscular junction.
(1) Acetylcholine containing vesicles in the nerve ending.
(2) The presynaptic membrane of the nerve.
(3) The intersynaptic space across which acetylcholine must 
diffuse after release through specific regions in the 
presynaptic membrane.
(4) Folds in the postsynaptic membrane of the muscle;the 
acetylcholine receptors are concentrated at the tips and 
are close to the sites of acetylcholine release.
B Diagrammatic representation of a neuromuscular junction in
chronic EAMG and human myasthenia gravis.
(1) The folded structure of the postsynaptic membrane is highly 
simplified and contains a greatly reduced number of 
acetylcholine receptors.
(2) Many of the acetylcholine receptors that remain have 
antibody bound to them.
(3) Complement-mediated focal destruction of the postsynaptic 
membrane causes loss of acetylcholine receptors through 
shedding of complexes of antibody,acetycholine receptors 
and complement into the intersynaptic space.
(4) Antigenic modulation of the acetylcholine receptor causes 
loss of receptors independent of complement.This may proceed 
through endocytosis of the receptors aggregated by antibodies
(5) Enhanced synthesis of the acetylcholine receptors may 







retained, and the nuclei remained at the periphery of the fibres.
No loss of cross-striations was noted and there was no infiltration 
by inflammatory cells.
More recently Werneck (1982) found that fresh-frozen sections 
from 15 of 17 muscle biopsies of myasthenic patients were abnormal.
Of these, 7 had type III atrophy, 4 showed lymphocyte infiltration and 
one had fibre necrosis with phagocytosis. Eleven of the biopsies 
showed evidence of denervation. There was a direct correlation 
between disease duration and the severity of histological abnormality.
Pharmacological studies
Pharmacological tests of myasthenic patients have shown that 
they are unusually susceptible to the effects of curare and 
d-tubocurarine. They are resistant to the prompt depressant action of 
acetylcholine when injected intra-arterially, and are also resistant 
to the administration of décaméthonium. Finally their symptoms are 
alleviated by anti-acetylcholinesterases (for review see Simpson,
1974).
Neurophysiological studies
Neurophysiological studies of myasthenic patients have shown 
that the action potential generated by the nerve is normal. Intra­
cellular recordings of the electrical activity of the muscle fibre, 
however, have shown that the miniature end-plate potentials (MEPPs) 
are reduced in size (Elmquist et al., 1964) and that myasthenic motor 
end-plates in vitro are much less sensitive to iontophoretically 
applied acetylcholine than normal end-plates (Rash et al., 1976). 
Multi-electrode recordings from two or more muscle fibres from the 
same motor unit during a voluntary contraction showed a greater time
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delay between the two impulses in myasthenic muscle fibres than in 
normal fibres (Ekstedt and Stalberg, 1967). This is attributed to the 
delay in onset of end-plate potentials resulting from the diminished 
size of the MEPPs. Measurements of whole muscle subjected to 
repetitive supramaximal stimuli of the nerve show that a significant 
decrement is observed in myasthenia (Desmedt, 1966). The décrémentai 
response is consistent with the observed physical fatiguability of 
myasthenic patients, and the experimental finding of reduced MEPPs.
A pre-synaptic origin for the physiological abnormalities is dis­
counted by the finding that the acetylcholine content of myasthenic 
muscle is actually higher than in control muscle (Ito et al., 1976) 
and that 2 - 5  times as many quanta of acetylcholine are released at 
myasthenic motor nerve terminals than at normal terminals (Cull- 
Candy et al., 1980). The abnormalities may, however, be adequately 
accounted for by the reduction in the number of AChRs in the post- 
synaptic membrane of the myasthenic junction which has been reported 
(Ito et al.,1978).
The immunology of myasthenia gravis
It has been found that one in seven children born to myasthenic 
mothers shows transient symptoms of myasthenia which disappear after 
a few weeks of life. This observation suggests that a blocking agent 
crosses the placenta from the mother to the child in these cases, eind 
is effective in blocking neurotransmission. The observations on 
neonatal myasthenia, and the superficial resemblance of myasthenic 
weakness to that of curare intoxication prompted numerous attempts to 
demonstrate the existence of a humoral blocking agent in myasthenia.
In 1934 Mary Walker, best known for her introduction of anticholin­
esterase therapy in myasthenia, reported that ptosis could occur
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following release of a tourniquet that had prevented return of venous 
blood from the exercised limb of a myasthenic patient. In 1944 Wilson 
and Stoner applied serum from a myasthenic patient to a frog nerve- 
muscle preparation, and demonstrated that it had a blocking effect 
following stimulation of the nerve. The blocking effect has, however, 
proved to be extremely variable. Nastuk et al. (1959) only 
occasionally found a blocking effect, while Parkes and McKinna (1966) 
observed significant reductions in the contractile responses of 
indirectly stimulated rat diaphragm muscles, and were able to reverse 
the decrement with anticholinesterase drugs.
In 1960 S i m p s o n  p r o p o s e d  t h at m y a s t h e n i a  g r a v i s  is an 
a u t o i m m u n e  di s o r d e r .  The s u b s e q u e n t l y  a c c u m u l a t e d  e v i d e n c e  
s u p p o r t i n g  an a u t o i m m u n e  ba s i s  f o r the d i s e a s e  c a n be s u m m a r i s e d  as 
f o l l o w s  :
1. Myasthenia resembles systemic lupus erythamatosis (SLE), a 
known autoimmune disorder, in being more common in females 
and in having the highest incidence of onset in the third 
decade.
2. Myasthenia is often associated with other autoimmune disorders 
such as rheumatoid arthritis, SLE, Sjogren's syndrome and 
Raynaud's syndrone.
3. The infiltration of lymphocytes within some of the myasthenic 
muscles is suggestive of an autoimmune disorder.
4. There is a high incidence of thymic abnormalities (thymic 
hyperplasia and thymoma) in myasthenia, êind it is known that 
the thymus gland has an important role in immune mechanisms 
(for review see Yunis et al.,1971).
5. At about the same time that Simpson put forward his 
hypothesis, Strauss et al. (1960) reported the presence in a
43.
significant proportion of myasthenic patients of circulating 
emtibody to the A - band of striated muscle fibres. This 
finding has since been confirmed in many laboratories, and 
also extended by the demonstration that nearly every 
myasthenic patient with a thymoma carries these antibodies.
6. Daily injections of immunoglobulin from myasthenia patients 
intraperitoneally into mice for periods of 10 - 14 days 
resulted in the animals acquiring a number of myasthenic 
features (Toyka et al., 1975).
7. The development of transient myasthenia in the infants of 
affected mothers is indicative of a neurohumoral agent 
traversing the placenta. It is known that IgG can be 
transported from mother to foetus via the placenta.
8. Nearly all patients with myasthenia gravis carry serum 
antibodies to AChR (Lindstrom et al., 1976d).
9. Immunosuppressant drugs are found to be beneficial in the 
treatment of myasthenia.
10. Plasma exchange can induce a short-term remission in 
acquired myasthenia.
11. Experimental models can be produced by immunising animals 
with preparations of muscle, thymus or AChR.
The evidence for myasthenia's being an immune disorder princi­
pally affecting the AChR is now overwhelming, and is detailed more 
fully below.
Animal models of myasthenia gravis
1. The Goldstein model; In 1966 Goldstein and Whittingham showed 
that it was possible to induce an autoimmune inflammatory response
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when animals were injected with a saline extract of thymus or striated 
muscle. These animals also exhibited a transient block of neuro­
muscular conduction which had several features in common with 
myasthenia gravis. Goldstein and Manganaro (1971) identified two 
polypeptides from the normal thymus, each having a molecular weight 
of .7000 daltons. One of these, thymin, was considered responsible 
for inducing the neuromuscular block, while the other, thymotoxin, 
was thought to cause the inflammatory responses in the muscles which 
the experimentally-treated animals commonly showed. This led Goldstein 
et al. (1976) to present the hypothesis that thymin imbalances are 
involved in the aetiology of autoimmune diseases.
2. Experimental autoimmune myasthenia gravis (EAMG): An early
observation in the course of raising antibodies for the immunochemical 
characterisation of purified AChR was that rabbits immunised repeated­
ly with receptor in adjuvant developed profound muscle weakness 
(Patrick and Lindstrom, 1973; Sugiyama et al., 1973). This obser­
vation led to the EAMG animal model of myasthenia gravis (Lennon 
et al., 1975). EAMG is readily induced in some mammals by a single 
intradermal inoculation of microgram quantities of AChR purified from 
either electric fish or skeletal muscle, and resembles spontaneously 
occurring myasthenia in almost every respect (for review see Lennon,
1976). Since the original report EAMG has been induced in many other 
animals including rats, mice, guinea pigs, goats, monkeys, frogs (for 
review see Lindstrom, 1979), chicken, sheep (Barkas et al., 1978) and 
dogs. EAMG is caused only by AChR, rather than any minor contaminant 
of the receptor preparation (Claudio and Raftery, 1980).
Immunisation of Lewis rats with purified AChR plus adjuvant or 
pertussis results in a biphasic form of EAMG, consisting of an acute
45.
followed by a chronic phase. Figure G shows the characteristics of fehe 
chronic phase<rhe acute phase occurs about 8 - 1 1  days post inocula­
tion, and is associated with a massive invasion of the end-plate 
region by mononuclear inflammatory cells which destroy the post- 
synaptic membrane (Engel et al., 1976a,b). A human counterpart of 
this acute phase has not been recognised, but the occurrence of 
lymphorrhages and the occasional association of polymyositis with 
myasthenia gravis (Johns et al., 1971) may be evidence of a similar 
cellular contribution to the pathogenesis of myasthenia in man.
After day 12 the rats recover and inflammatory cells disappear.
Around day 30 a chronic phase of weakness ensues which usually 
progresses to death over several weeks. In the chronic phase, the 
post-synaptic membrane is highly simplified, with loss of its 
intricate folding and a widening of the synaptic gap (Engel et al., 
1976a,b). This picture is identical with the appearance of human 
neuromuscular junctions in established myasthenia gravis (see Figure 
6 ). A further similarity is that EAMG can be induced by passive 
transfer by injection of serum from rats with chronic EAMG (Lindstrom 
et al., 1976b; Lennon et al., 1978; Engel et al., 197$). Passively 
transferred EAMG is similar to the acute phase of the experimental 
disease (Engel et al., 197g). The major points of similarity between 
myasthenia gravis and chronic EAMG are summarised in Table 2.
Analysis of the serum of animals with EAMG has demonstrated the 
presence of circulating AChR antibodies to both the foreign immunogen 
(Patrick and Lindstrom, 1973) and to the host AChR (Aharonov et al.,
1977). Additionally the presence of antibodies bound to AChR in the 
muscle membrane has been demonstrated (for review see Lindstrom,
1979). The serum concentration of anti-AChR antibodies is lower 
during acute EAMG, and the degree of cross-reaction with muscle AChR
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TABLE 2. Similarities between myasthenia gravis and it's animal 
model,experimental autoimmune myasthenia gravis (EAMG) 
( Adapted from Lennon, 1976 ) .
Clinical Muscle weakness with easy fatigability. 
Temporary improvement by rest and by anti­
cholinesterase drugs.





Decrementing response of muscle during repet­
itive motor nerve stimulation at low rates. 
Post-activation facilitation followed by 
exhaustion induced by rapid repetitive 
stimulation.
Electrophysiological defect repaired by 
anticholinesterases.
Amplitude of miniature end-plate potentials 
reduced,but with normal numbers of transm­
itter quanta released by a nerve impulse.
Curare sensitivity increased.
125Number of I-ol-BGT binding sites at the 
neuromuscular junction greatly reduced.
Ultrastructural Appearance of motor endplates in EAMG indi­
stinguishable from those of myasthenic 
patients ( Figure 6 . ).
Immunological Antibodies and cellular immunity to AChR 
demonstrable.
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is lower than that at later stages (Lindstrom et al., 1976a,b).
The autoimmune response in myasthenia gravis
Following the demonstration of circulating anti-receptor anti­
bodies in EAMG similar antibodies were sought in human myasthenic 
sera using a variety of techniques (Table 3).
Mittag et al. (1976) showed that the highest percentage of 
positive results was found when immunoprécipitation of IgG -0(-BGT - 
labelled AChR was used, and this assay has now become standard 
practice (for review see Newsom-Davis and Vincent, 1982) with the 
parameters of the assay having been optimised (Carter et al., 1981).
Circulating anti-AChR antibodies are present in at least 90% of 
clinically diagnosed myasthénies (Lindstrom et al., 1976a; Monnier 
and Fulpius, 1977) . The level of antibody is, however, generally 
found not to correlate with disease severity (Vincent and Newsom- 
Davis, 1979; Barkas et al., 1979). Nevertheless, Lefvert et al.
(1978) and Carter et al. (1980) found good correlation when the anti­
body titre was compared with an individual's clinical progress. 
Patients with ocular myasthenia only have generally lower titres 
than more severe cases (Lindstrom et al., 1976a; Lefvert et al.,
1978). Patients with thymoma tend to have higher titres, reflecting 
the fact that the thymus is a site of anti-AChR antibody production 
in some myasthenic patients (for review see Newsom-Davis and Vincent, 
1982). Among those with generalised disease, titres can range over 
2 or 3 orders of magnitude for patients with similar disease severity. 
Factors such as age, sex, duration of disease, or treatment with 
steroids or thymectomy, do not appear to influence anti-receptor 
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have been detected in neonatal myasthénies (Lefvert et al., 1978) and 
also in the cerebrospinal fluid of some patients (Bergstrom et al., 
1978; Keesey et al., 1978). They have also been detected in the serum 
of rheumatoid arthritis patients treated with D-penicillamine who 
developed symptoms of myasthenia (Vincent et al., 1978; Argov et al., 
1980). These symptoms were responsive to anticholinesterase drugs, 
and disappeared on withdrawal of D-penicillamine.
Other autoantibodies in myasthenia gravis
Various autoantibodies other than anti-AChR antibodies are found 
with increased frequency in myasthenic patients. Some of these anti­
bodies are associated with immune diseases, but their incidence is 
much higher than clinical symptoms of other disorders. The incidence 
of autoantibodies other than anti-AChR antibodies in myasthenia is 
summarised in Table 4.
The overall incidence of anti-striated muscle antibody is about 
40% of myasthenic patients. Investigations by Beutner et al. (1962) 
showed that antibodies could be classified as either anti-striated 
muscle only (anti-SM) or anti-striated and cardiac muscle (anti-SH),
It was soon realised that almost all patients with thymoma have anti- 
SM antibodies (Van der Geld et al., 1963; Oosterhuis et al., 1968). 
Anti-SM antibodies are also associated with the HLA - A antigen 
(Feltkamp et al., 1974) and the presence of DR2 (Compston et al., 1980)
Characterisation of the immune response in myasthenia gravis
The lack of correlation between anti-AChR antibody titre and 
disease severity implies that myasthenic sera contain a heterologous 
population of anti-receptor antibodies, not all of which are patho­
genic. This is also true of sera from animals with EAMG. Such a
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TABLE 4. Incidence of autoantibodies other than anti-AChR antibody 
in myasthenia gravis compared to the normal population. 
(Adapted from Vincent and Newsom-Davis, 1982)
Autoantibody Percentage of patients possessing 
the autoantibody.














heterogeneous antibody population would be expected to differ not 
only in their antigenic specificity, but also in their binding 
affinity, and ability to interact with other immune effectors such as 
complement and phagocytes. Thus disease state may be better related 
to specific subpopulations of anti-AChR antibodies.
Three basic types of technique have been used in elucidating 
the characteristics of anti-AChR antibodies, and the nature of AChR 
antigenicity and immunogenicity.
Firstly the effects of myasthenic sera, or sera from animals 
immunised with whole native AChR, on a range of biochemical reactions 
of the receptor, such as ligand binding, ion-channel function, and 
turnover of the receptor in situ, have been studied. The physical, 
immunological and kinetic properties of the antibody population 
itself have also been examined.
Secondly, molecular modifications of the purified AChR have been 
made, and used both for immunisation of experimental animals, and for 
cross-reaction studies with antisera raised against native receptor. 
The rationale behind such an approach is that modification of the 
AChR, followed by pharmacological and immunological analysis may lead 
to the isolation and characterisation of small fragments of the 
molecule which are responsible for the specific pathological 
myasthenic activity of the receptor (Fuchs et al., 1981).
Thirdly, monoclonal antibodies (mAbs) to AChR have been pre­
pared. Such antibodies have the potential to be excellent probes 
for the AChR, as they have specificities that can be strictly defined. 
A number of workers have begun to map the binding characteristics of 
panels of anti-AChR mAbs. These mAbs have also been used as
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competitive ligands to map the cintibody specificities present in 
heterogeneous antisera to AChR and myasthenic sera, and for the passive 
transfer of EAMG.
Characterisation of anti-AChR antibodies
Using the three approaches outlined above much information has 
accrued about the nature of anti-AChR antibodies. For ease of dis­
cussion these characteristics are considered separately for antibodies 
in the animal model, EAMG^and those in myasthenia gravis itself,
EAMG
When rats were inoculated with eel AChR, antibodies to both eel 
receptor and rat muscle receptor could be detected in the serum of the 
animals as early as 3 days after immunisation. By day lO more than 
50% of the antibody population was IgG, with the rest being IgM. 
Anti-receptor antibodies in rabbits immunised with eel AChR are also 
IgG (Penn et al., 1976).
In rabbits with chronic EAMG the time course of antibody pro­
duction correlates with that of disease activity. The intensity of 
disease appears to have a closer correlation with the titre of anti­
body to the immunogen than that of antibody directed specifically 
against the host receptor (Ueno et al., 1980), strongly suggesting 
that cross-reaction of antibody to conserved antigenic sites, rather 
til an an induced autoimmune reaction to host receptor, plays the major 
role in the development of EAMG.
In chronic EAMG anti-receptor antibodies are in large excess 
over muscle AChR, with a large fraction of the muscle receptors having 
bound antibody, as demonstrated by both direct extraction of antibody-
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receptor complexes from muscle (Lindstrom et al., 1976a,b; Lindstrom 
and Lambert, 1978), and by ultrastructural localisation of bound anti­
body by staining with peroxidase-conjugated protein A (Sahashi et al.,
1978). These bound antibodies are able to bind complement, leading 
to focal lysis of the post-synaptic membrane (Engel et al., 1977; 
Sahashi et al., 1978). Anti-AChR antibodies are relatively species 
specific, with only a small percentage of antibodies to eel or 
Torpedo AChR showing binding to skeletal muscle receptor from several 
species (Lindstrom, 1978). This interspecies cross-reaction seems to 
be dependent on conformationally-dependent antigenic determinants 
which are not present after receptor dénaturation (Lindstrom et al., 
1979a).
Antisera to electric fish AChR raised in experimental animals 
may have a direct effect on AChR function. Greater than 80% blockage 
of the depolarising response of eel electric organ to carbamycholine 
can be achieved by preincubation of the organ with anti-receptor anti­
body (Patrick et al., 1973; Lindstrom et al., 1977). Electrophysio­
logical studies of AChR 'noise' in rat muscle cultures exposed to 
anti-AChR antibodies show a decrease in the mean open time of 23% 
(Heinemann et al., 1977). Similar results have been observed with
human muscle cells in culture (Sevan et al., 1978). Anti-AChR sera,
125IgG and Fab fragments have been shown to inhibit I -0(-BGT binding 
to both detergent-solubilised and membrane-bound AChR (Penn et al., 
1976; Zurn and Fulpius, 1977; Aharonov et al., 1977; Karlin et al., 
1978; Claudio and Raftery, 1980; Desouki et al., 1981). Zurn and 
Fulpius (1977) showed that the titre of antibody which blocks o(-BGT 
binding increased more strongly than antibody directed against other 
sites just prior to the appearance of paralysis in inoculated animals.
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Gomez and Richman (1983) found that 3 mAbs binding at or near the
cholinergic binding site had a unique ability to induce an acute
neuromuscular disease in chicks, resembling myasthenia gravis,
suggesting that the mechanism of immunopharmacological blockade of AChR
function is capable of playing a significant role in the pathogenesis
of myasthenia. IgG from rabbits and sheep inoculated with Torpedo
22 +AChR also inhibit the AChR-induced Na - flux in Torpedo electric 
organ membranes, but do not directly block histrionicotoxin binding 
to the receptor ion-channel (Desouki et al., 1981).
Anti-receptor antibodies and F(ab^ ) 2 fragments have been shown 
to increase the rate of degradation of AChR from both muscle cells in 
culture, and of innervated muscle in organ culture (Prives et al.,
1979; Lindstrom and Einarson, 1979; Merlie et al., 1979). Corres­
ponding Fab fragments were without effect (Prives et al., 1979), 
unless a bivalent second antibody was also added (Lindstrom and Einarson,
1979). This phenomenon resembles the antibody-induced degradation
of some lymphocyte surface antigens (Old et al., 1968; Cohen and Liang,
1976) and is known as antigenic modulation. It is inhibited by low 
temperature, and by inhibitors of energy metabolism (Heinemann et al., 
1978) and is probably, though not necessarily, dependent on cross- 
linkage of AChR by the antibody (for review see Patrick and Berman,
1980).
Myasthenia Gravis
Sera from myasthenic patients contain a heterogeneous population 
of anti-AChR antibodies directed at several antigenic determinants.
In most patients anti-receptor antibodies are of the IgG class, with 
IgA or IgM also being produced in a few (<5%) patients (Tindall, 1981). 
Studies on the subclass distribution of anti-AChR antibodies have
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produced differing results, with a predominance in the IgG 1 or 3 
subclasses in one report (Lefvert, 1981) and IgG 1 and 2 subclasses in 
another (Newsom-Davis and Vincent, 1982).
Four distinct reactivities with AChR have been ascribed to 
myasthenic antibodies.
1. Antibodies causing a direct immunopharmacological blockade 
of AChR function. Reductions of ol- BGT binding and 
acetylcholine sensitivity of receptor by myasthenic sera,
IgG and F(ab^ ) 2 fragments have been demonstrated (Mittag 
et al., 1976, 1978; Lefvert and Bergstrom, 1977; Harvey
et al., 1978; Dwyer et al., 1979; Fulpius et al., 1980; 
Lefvert et al., 1981). Fulpius et al. (1980) found the 
oC- BGT blocking activity in IgG subclasses 1 and 3, or in 
some cases exclusively in subclass 3. The presence of 
antibodies which block toxin binding has been reported to 
correlate with disease severity, being present only in 
patients with stage IIB, III or IV disease according to the 
Osserman classification (Lefvert et al., 1981). The 
existence of anti-K-BGT site antibody is not common to all 
myasthenia gravis patients. In a study of 12 patients 
Whiting et al. (1983) found that anti-toxin site antibodies 
varied from O - 33% of the total anti-AChR antibody 
population.
2. Antibodies with determinants present exclusively on extra- 
junctional AChR (Weinberg and Hall, 1979; Dwyer et al., 
1981b).
3. Antibodies interacting with the carbohydrate moiety of the 
AChR (Mittag et al., 1976, 1978, 1981a,b; Dwyer et al., 
1981b).
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4. Antibodies reacting with determinants outside of the ligand 
binding site, or carbohydrate groups.
Lefvert (1982) found that anti-AChR antibodies reacted better 
with a detergent extracted receptor from denervated or myasthenic 
human muscle than that of normal muscle. A few patients with moderate 
to severe clinical symptoms possessed antibodies which would react 
only with myasthenic muscle, and the antibody population of one pat­
ient would react only with the patient's own muscle AChR. Vincent and 
Newsom-Davis (1982) also found anti-'normal' AChR antibody titres to 
be generally lower than the corresponding anti-'denervated' AChR 
antibody titre. In contrast Lotwick et al. (1983) found essentially 
no difference between anti-'normal adult muscle' AChR antibody titre, 
and the titre against foetal muscle AChR.
Despite the heterogeneity of antibody specificities in myasthenia 
gravis sera, the serum of each patient seems to be dominated by one 
antibody type. Thus Bray and Drachman (1982) found that Scatchard 
analysis of the binding of 15 different myasthenic sera to AChR all 
showed linearity. The pattern of anti-receptor antibody reactivity i 
to the AChR from different sources is also relatively constant over 
extended times for any individual patient (Harrison et al., 1981) 
which is suggestive of an initial limited exposure of the AChR anti­
gen to the immune system.
Myasthenic sera and antibodies are able to produce antigenic 
modulation (Appel et al., 1977; Heinemann et al., 1977; Drachman 
et al., 1978, 1982), complement-mediated focal lysis of the neuro­
muscular junction (Engel et al., 1981; Rash et al., 1981), and 
specific myolysis of muscle in culture (Liveson et al., 1976). The 
titre of antibodies able to cause modulation in myasthenic sera was
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found to correlate reasonably well with severity of the disease 
(Drachman et al., 1982).
Antigenicity of the AChR
The classic studies of Atassi (1975, 1978) made it clear that 
not all parts of a protein are antigenic or immunogenic. A complex 
multisubunit molecule such as the AChR would be expected to possess 
a number of antigenic determinants. Lindstrom et al. (1981) pre­
dicted a figure of about 1 0  such determinants, and more recently 
Gullick and Lindstrom (1982) claimed to have defined a minimum of 28 
antigenic determincints of purified Torpedo AChR, although not all of 
the antigenic determincints were myasthenogenic, and may thus be 
considered less functionally important.
Although anti-AChR antibodies can block o(- toxin or acetylcho­
line binding to the receptor there is still uncertainty as to whether 
this is due to a steric hindrance or to direct blockade of the ligand 
binding site. Fulpius et al. (1980) found antibodies of the IgG 3 
subclass in myasthenic sera whose interaction with the AChR was both 
mutually exclusive with o(- BGT, and competitive with low concentra­
tions of some nicotinic, but not muscarinic, ligands. Despite this 
finding, the overall balance of evidence suggests that the binding 
site itself is not a major antigenic determinant on the AChR. Thus 
antibody-receptor complexes extracted from muscle of rats with EAMG 
were still capable of binding o(- BGT (Lennon, 1976). The presence of 
a free (Xr BGT binding site on the receptor is also not a requirement 
for the induction of EAMG (Fulpius et al., 1978).
Antibodies which inhibit Concanavalin A binding to the AChR may 
do so by steric hindrance rather than by direct binding to the carbo-
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hydrate moiety of the receptor, since glycosidase treatment resulting 
in extensive loss of carbohydrate from Torpedo AChR had no effect on 
its antigenicity (Weinberg and Hall, 1979; Wonnacott et al., 1980a).
In contrast to this Dwyer et al. (1981a) found a greater inhibition of 
Ot- BGT binding to extrajunctional AChR than to junctional receptor by 
some myasthenic sera, which was abolished by treatment of the extra- 
junctional receptor with glycosidase.
Atassi defined two types of antigenic determinant. "Continuous" 
determinants are those in which amino acid residues forming the 
determinant are adjacent. "Discontinuous" determinants, on the other 
hand, are formed by amino acids from different parts of the sequence 
brought into close proximity due to folding back of the polypeptide, 
or by two adjacent polypeptide chains. Antibodies to continuous 
determinants can bind to the denatured protein chain, while antibodies 
to discontinuous determinants can bind only to the intact and correctly 
folded chain. An irreversibly denatured AChR (reduced, carboxymethy- 
lated receptor) reacted with only a portion of the antibody population 
in anti-AChR sera indicating the presence of conformationally- 
dependent determinants on the intact AChR (Bartfield and Fuchs, 1977). 
This denatured receptor was unable to induce EAMG in experimental 
animals, suggesting that discontinuous, conformational determinants 
are primarily responsible for the myasthenogenicity of the AChR. 
SDS-denatured AChR was similarly immunogenic (although significantly 
less so than native receptor) but not myasthenogenic in experimental 
animals (Lindstrom et al., 1976c).
Each of the subunits comprising the AChR is myasthenogenic 
(Lindstrom, 1978). Thus, although they are much less immunogenic 
than native receptor, immunisation with any one of the four polypeptide
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chains produces EAMG, with the C< - and ^ - chains being most effect­
ive . Antibodies raised against the polypeptide chains are directed 
at determinants which normally account for little of the immunogenicity 
of native AChR, since antibodies to native receptor showed little 
reaction with the individual polypeptide chains, whereas antibodies to 
the subunits react quite well with native AChR (Lindstrom et al.,
1979b).
Fuchs and coworkers have studied the effects of a number of 
chemical modifications of the AChR on its antigenicity. Trypsinisation 
of the receptor led to isolation of a small (27000 dalton) polypep­
tide which appeared to come from the (X- subunit, and bound cholinergic 
ligands. This trypsinised receptor fragment was able to induce EAMG 
in rabbits, and thus localised at least one antigenic determinant to 
a site on the o(- subunit, relatively close to the (X- toxin binding 
site (Bartfield and Fuchs, 1979). polyalany1 ated AChR (Tarrab-Hazdai 
et al., 1980) bound cholinergic ligands, but was not myasthenogenic, 
adding further weight to the argument that the ligand binding site is 
not an important antigenic determinant in EAMG. Treatment of AChR 
with tetranitromethane specifically modifies tyrosine residues 
(Sokolovsky et al., 1966) . Such a nitrated receptor was devoid of 
myasthenogenic activity (Fuchs et al., 1981), suggesting that at least 
some tyrosine residues in the AChR are crucial to its immunogenicity.
In recent years more detailed studies of AChR antigenicity 
have been made by using mAbs raised against the receptor. Such mono- 
specific antibodies have been elicited by several laboratories (Dwyer 
et al., 1981b; Gomez et al., 1979; James et al., 1980; Lennon and 
Lambert, 1980; Mochly-Rosen et al., 1979; Tzartos and Lindstrom, 1980) 
and are ideal probes to define both the structure of the AChR, and the
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specificities of antibodies in myasthenic sera. The most extensive 
study to date is that of Lindstrom and coworkers who have raised a 
large library of mAbs aginst Torpedo AChR eind have mapped their anti­
genic specificities on the receptor. A minimum of 28 determinants 
have been elucidated by this mapping technique (Gullick and Lindstrom, 
1982), which are present on all four receptor subunits. About half of 
the mAbs raised by these workers reacted detectably with denatured 
subunits or characteristic peptide fragments of the subunit (Tzartos 
and Lindstrom, 1980; Gullick et al., 1981). Tzartos and Lindstrom 
(1980) also detected a "main immunogenic region" (MIR) on the 0(- 
subunit composed of at least two adjacent antigenic determinants. At 
least 50% of the antibodies in an antiserum to native AChR were 
directed at this region. A comparable determinant was also present 
on the AChR from human muscle (Tzartos and Lindstrom, 1981). The 
determinants forming the MIR are conformationally dependent, and 
situated on the extracellular surface of the AChR in situ. The region 
is included in a peptide fragment containing the cx- toxin binding 
site, but is not the binding site itself (Lindstrom et al., 1981). 
Competition experiments between myasthenic sera and mAbs directed at 
the MIR showed that this region is also highly immunogenic in myasth­
enia patients. Regions on the /S- and ^ - subunits were also found 
to be substantially immunogenic (Tzartos et al., 1982).
Finally, several groups have found that extrajunctional rat AChR 
contained additional antigenic determinants not present on junctional 
receptor, and that myasthenic sera reacted better with this extra- 
junctional AChR (Weinberg and Hall, 1979; Dwyer et al., 1981a;
Harrison et al., 1981). This finding has yet to be reproducibly con­
firmed for human AChR (Lotwick et al., 1983) but has important 
implications for the aetiology of myasthenia gravis.
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Antibody and cell-mediated cytotoxicity in myasthenia gravis
It has been found that sera from myasthenic patients have 
haemolytic complement activities which range widely outside the values 
for normal subjects (Nastuk et al., 1960). The C3 and C9 components 
of the complement cascade have been demonstrated at the ultra- 
structural level in fresh - frozen sections of myasthenic end-plates, 
with a localisation identical to that of IgG (Engel et al., 1981).
The loss of end-plate function is correlated with at least two phases 
of immunologically mediated destruction. In the first phase, anti- 
AChR IgG and complement factors Clq and C3 bind to the crests of the 
junctional folds. In the second, or lytic, phase the crests of the 
junctional folds are progressively destroyed by IgG - activated 
complement factors (C5b - C9) resulting in the extrusion of perforated 
vesicular debris, and extensive lytic damage to the remaining sub- 
synaptic membrane (Rash et al., 1981). In EAMG complement activation 
is required for a decrement of compound muscle action potential, and a 
mononuclear inflammatory response to occur at the motor-end plate 
following passive transfer of anti-AChR antibodies (Lennon et al.,
1978). The activation of complement occurs via the classical pathway 
(Cl^ C2-> C4-* C3-* C5-> 9) , rather than the alternative pathway in which 
the requirements for Cl, C2 and C4 are bypassed (Lennon and Lambert,
1981).
Studies of muscle biopsies from myasthenic patients reveal a 
number of abnormalities including denervation, type II fibre atrophy, 
lymphocyte infiltration, and fibre necrosis with phagocytosis (Werneck,
1982). Cytolytic effects of peripheral and thymic lymphocytes (Kott 
and Rule, 1973) and sera (Liveson et al., 1976) from myasthenic 
patients have also been reported. It is not known whether the 
myolytic effects of sera are caused by anti-AChR antibodies or by
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anti-striational muscle antibodies.
The mechanism of the autoimmune response in EAMG and myasthenia gravis
The development of EAI4G is thought to follow the mechanism 
outlined below. The injection of heterologous AChR possessing cross­
reactivity with self AChR induces breakdown of immunological tolerance
to the latter receptor, and the animals then start to produce "auto­
antibodies" (Patrick and Lindstrom, 1973; Lennon, 1976; Aharanov 
et al. , 1977) . Such a brecik in immunological tolerance has been 
clearly demonstrated in mice, where 40% of mice immunised with Torpedo 
AChR possessed a small amount of antibody reactive with antigenic 
determinants present on mouse AChR, but not present on the Torpedo 
receptor. Lindstrom (1977, 1979) suggested that the immune response
in EAMG is caused by heterologous AChR, but is sustained by auto­
stimulation with self-receptors from muscle destroyed during the 
initial immune response. Berman et al. (1981) found that the 
susceptibility of mice to EAMG is a heritable trait, and that regions 
of the mouse genome which regulate immune responsiveness (MHC and 
IgĈ ) can profoundly affect the probability with which a mouse 
immunised with AChR can be expected to become paralysed.
The initiating factor of the autoimmune response in myasthenia 
gravis is not known. The evidence to date suggests that the auto­
antigen is the AChR. Because sera from myasthenic patients may react 
better with extrajunctional than junctional receptor, the initiating 
antigen may be other than normal junctional AChR. It is not known 
whether the antibody present in myasthenic serum is directed solely 
at antigenic determinants on the extracellular surface of the AChR, or 
whether intracellular determinants are also important. If intra- ■' 
cellular determinants are involved it would suggest that the initiating
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factor in myasthenia may be the shedding of receptor from the post- 
synaptic membrane, creating an effectively foreign antigen.
The thymus has long been thought to be involved in the patho­
genesis of myasthenia gravis. Thymic abnormalities such as hyper­
plasia, increased numbers of B - cells and decreased numbers of T - 
cells may be be found in the myasthenic thymus (Castleman, 1966;
Abdou et al., 1974; Levine and Rice, 1977), and thymectomy is known 
to benefit many patients (Simpson, 1958; Papatestas et al., 1971).
The thymus may be involved in the pathogenesis of myasthenia, firstly 
by serving as a potential site of antigen, which plays a role in the 
breakage of tolerance toward self - AChR, and secondly as a site of 
anti - AChR antibody synthesis. In support of the latter is the 
presence of anti - AChR antibody in the myasthenic thymus (Mittag 
et al., 1976) and the spontaneous synthesis of anti - AChR antibody 
by thymic cells from myasthenic patients in culture (Vincent et al.,
1978). Thymic epithelial cells appear to bear AChR (Engel et al.,
1977)y and myoid (muscle-like) cells grown out in explant culture from 
rat and human thymus express AChR (Kao and Drachmae, 1977). In 
addition, immunofluorescence studies using EAMG sera have shown 
binding to about 80% of mouse thymocytes, suggesting the presence of 
an AChR-like antigen on the surface of these cells.
Altered immunoregulatory functions may be operative in myas^ 
thenia gravis. Studies of suppressor T - cell activity in myasthenia 
have been extensive, but have yielded conflicting results. Suppressor 
T - cell activity as measured by Concanavalin A eind phytohaemagglutinin 
has been reported to be diminished by some authors, while others have, 
found no suppressor differences between controls and myasthenic 
patients (Koethe et al., 1981). Percentage estimates of T - cell
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subsets using mAbs have also yielded equivocal results. 0KT8 - 
positive cells (representing suppressor/cytotoxic cells) have been 
variously reported as decreased, normal or increased. Levels of T - 
cells bearing the Fc receptor for ÿ - immunoglobulin (also thought to 
represent suppressor cells) were also found to be elevated, depressed 
or normal in a stable myasthenic population (for review see Seybold,
1983). Newsom-Davis et al. (1981) have shown that thymus cells can 
selectively enhance anti - AChR antibody production by autologous 
peripheral blood lymphocytes. Other immunological abnormalities in 
myasthenia gravis include the presence of anti - T cell antibodies, 
and elevated levels of thymosin (a polypeptide which is a potent 
immunopotentiating agent that can increase cell growth, influence 
antibody response, or affect maturation and differentiation of T - 
lymphocytes) in epithelial cells of the myasthenic thymus. An 
additional argument for an immune dysfunction is that more them one 
autoimmune disorder often occurs concurrently in the same patient 
(Waldmann et al., 1978).
It is possible that myasthenia gravis may be the result of a 
genetic predisposition to an altered immune response. Thus in some 
patients there is a significantly increased frequency of the major 
histocompatability complex gene products HLA - B8 and DRw3 
(Safwenberg et al., 1978) and HLA - B12 in others (Yoshida et al.,
1977). The high incidence of HLA - B8 is also found in other auto­
immune disorders, and suggests that these antigens are responsible 
for an increased susceptibility to autoimmune disorders rather than 
the initiation of an immune response specifically to the AChR 
(Lindstrom, 1979).
The study of myasthenia gravis has far-reaching consequences in
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that, as an established autoimmune disorder where the auto-cintiigen is 
known, it may be useful in gaining a deeper understanding of other Z' 
autoimmune disorders. In this study the antigenic nature of purified 
Torpedo AChR has been examined with particular reference to the role 
of the (K- toxin binding site, and the carbohydrate moiety of the 
receptor in its antigenicity. Because the AChR is an integral 
membrane protein, a considerable portion of its structure may be 
hidden from humoral circulation. Therefore, the cross-reaction of 
anti-Torpedo AChR antibodies with the AChR of muscle cells in 
culture has also been studied. Such an approach also has the 
advantage of detecting only cross-reacting and presumably highly con­
served determinants which might be expected to have a functional 
significance in the pathogenicity of EAMG.
The contribution of antibody-mediated muscle cell deunage in the 
pathology of myasthenia gravis has been relatively little studied.
The second aim of this study has, therefore, been to make an assess­




Preparation of chick embryo extract
10 - 12 day old chick embryos (Maurice Millard Ltd, Freshford, 
Bath) were aseptically squeezed through a 50 ml syringe, and diluted 
with an equal volume of sterile Earle's balanced salt solution (BSS). 
After standing at 22°C for 2 h the suspension was centrifuged in 
sterile tubes at SCpOQg. for a further 2 h. The supernatant was 
removed aseptically, and aliquots (5 ml) were stored in sterile glass 
universal bottles at -20°C.
Preparation of rat-tail collagen
Collagen was prepared from rat tails essentially according to 
the procedure of Ehrmann and Gey (1956). A single rat tail was 
washed with 70% alcohol for 10 min. The skin was stripped off and 
the tendons aseptically dissected out using sterile instruments.
The tendons were placed in sterile 0.1% (v/v) acetic acid (50 ml) for 
24 h at 4°C. At the end of this period the residue of the tendons 
was removed by centrifugation (20pOO g) at 4°C for 90 min,in sterile, 
capped centrifuge tubes. The supernatant collagen solution was 
transferred to a sterile media bottle and stored at 4°C until 
required.
Collagen coating of tissue culture dishes
Collagen solution (50 ;il) and sterile 6 % (w/vj sodium chloride 
solution (20 ̂ 1) were placed separately in the bottom of a 35 mm 
diameter tissue culture dish (Gibco Nunc Ltd, Paisley, Scotland), 
and then mixed and spread evenly over the surface using a sterile 
L - shaped glass rod. The collagen matrix was precipitated by 
leaving the dishes for at least 48 h at 37°C.
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The preparation of myotube cultures from chick embryos
Myotube cultures were produced from the hind limbs of 10 - 11
day old chick embryos by a procedure based on the methods described
by Harvey and Dryden (1974 ) . The dissociation procedure is shown 
schematically in Figure 7.
10 - 11 day fertilised eggs were washed with 70% (v/v) alcohol
and placed in a laminar flow cabinet. Each egg in turn was broken
into a sterile glass Petri dish. The embryo was picked out using 
sterile forceps, and placed into a sterile glass dish containing BSS 
(approximately 100 ml). One embryo was then placed into another 
sterile glass Petri dish on the stage of a Swift zoom dissecting 
microscope set at approximately 7 - 10 times magnification. One leg 
was held away from the body using a pair of sprung-loaded irridectomy 
scissors (Johan Weiss Ltd, London). The leg was then cut along the
arc line joining the thigh to the trunk, and carefully removed to a
sterile glass Petri dish containing BSS. The embryo was turned, and 
the second leg similarly removed. The procedure was repeated for 
each embryo. When all the legs were removed, one leg was transferred 
back to the Petri dish on the microscope stage and the magnification 
increased to 10 - 20 times. Remaining skin was removed from the leg, 
and muscle was teased away from bone and tendons using two pairs of
sterile Dumont number 5 watchmeücers forceps. This procedure was
repeated for each leg. The muscle mass obtained was kept moist with 
BSS during the dissection procedure. The muscle mass was finely 
minced with sterile irridectomy scissors, and transferred into a 
solution ( 1 0 ml) of sterile trypsin (0 .1 % (w/vj in calcium and 
magnesium-free BSS: formulation shown in Table 5) using a sterile 
10 ml glass pipette. The suspension was vigorously agitated with 
a whirlimixer, and incubated for 30 min at 37°C, whirlimixing once
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FIGURE 7. Preparation of a single-cell suspension from chick 
embryo hind limb muscle.
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TABLE 5. Composition of physiological salt solutions used in the 
preparation and assay of muscle cultures.









Made up to 1000ml with double distilled water. 
Sterilised by filtration to 0.22yun








Made up to 1000ml with double distilled water.
71.
halfway through the incubation, and again at the end of the incubat­
ion. Following this, an equal volume of cold (4°C) minimal Eagle's 
medium, containing 5% (v/v) chick embryo extract and 15% (v/v) heat 
inactivated horse serum (MEM(i)) was added to the muscle cell 
suspension, and the suspension triturated with a 10 ml pipette to 
remove any lumps. The suspension was filtered through two layers of 
sterile 50 pm mesh nylon cloth (Simon Textiles Ltd, Cheshire) into 
two 10 ml sterile centrifuge tubes, and centrifuged at 80 g for 15 
min at room temperature. The resulting supernatant was discarded, 
and the cell pellet resuspended in MEM (i) (10 ml) by gentle
trituration with a Pasteur pipette. The cell suspension, comprising 
mostly myoblasts, with a few fibroblasts and erythrocytes, was 
counted in a haemocytometer. Erythrocytes were clearly identifiable 
and were excluded from the count. The cell suspension was diluted 
with MEM (i) to give a suspension containing 5 x 10^ cells/ml, and 
plated out into collagen-coated 35 mm tissue culture dishes at a 
density of 1 x 10^ cells/dish. The dishes were placed in an incu­
bator at 37°C under an atmosphere of 5% CO^ in air.
After approximately 52 h incubation (when myoblast fusion was 
essentially complete) the medium was replaced with MEM (ii) (formu­
lation as for MEM (i) but containing only 2.5% (v/v) chick embryo 
extract) containing 10  ̂M cytosine arabinoside (2 ml/dish) and the 
dishes re-incubated. After a further 60 h incubation, the medium 
was replaced with MEM (ii) without cytosine arabinoside (2 ml/dish) 
and the dishes incubated as previously. Myotube cultures were used 
for further experiments at 6 - 9 days after initial plating.
Preparation of human foetal myotube cultures
Limbs were obtained from suction terminations of 8 - 14 week
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old foetuses, by sieving the aspirate through a sterilised metal 
kitchen sieve under running tap water. The limbs were transported 
dry to the laboratory, and then immediately placed into sterile cult­
ure medium.
Disaggregation of tissue; Muscle was teased away from the limbs, after 
removal of the skin, using Dumont number 5 watchmakers forceps. The 
muscle mass obtained was finely minced with sprung-loaded irridectomy 
scissors.
The minced muscle was disaggregated by either mechanical or 
enzymatic means.
(i) Mechanical disaggregation; Minced muscle was placed in sterile 
PBS (5 ml) and agitated for 1 min on a vortex-mixer, then vigorously 
triturated with a Pasteur pipette. Large lumps were allowed to
settle, and the cell suspension was filtered through two layers of
sterile 50 pm mesh nylon cloth. The resulting cell suspension was 
passed through a syringe fitted with a 19 - gauge needle to disaggre­
gate any remaining cell clusters.
(ii) Enzymatic disaggregation: The minced muscle was placed in PBS
(5 ml) containing either trypsin (0.1% (w/v)), or collagenase (type II; 
0.5% (w/v)) and deoxyribonuclease (0.002% (w/v)), and incubated at
37°C for 30 or 60 min with a brief mix on a vortex mixer every 15 min. 
Following this incubation, cold (4°C) culture medium (5 ml) was added, 
and the suspension was triturated with a Pasteur pipette. The suspen­
sion was filtered through two layers of 50 /im mesh nylon cloth and 
then passed through a syringe fitted with a 19 - gauge needle to remove
any remaining cell aggregates.
To compare the disaggregation methods, the minced muscle mass
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from a single foetus was divided into roughly equal portions, and the 
portions were placed into the disaggregation solutions. The weight 
of muscle was determined, and the disaggregation procedures followed.
Plating out and culture of muscle cell suspensions: Disaggregated
cell suspensions were centrifuged (80 ĝ, 10 min) . The medium was 
decanted, and the pellet was resuspended in culture medium (20 ml).
The suspension was re-centrifuged, and the cell pellet was resuspended 
in fresh culture medium. The viability of the resulting cell sus­
pension was determined by mixing a sample (200 pi) 1:1 with 0.2% 
trypan blue (Phillips, 1973), and the viable nucleated cell count 
calculated. The cell suspension (2 ml) was plated out into collagen- 
coated 35 mm diameter culture dishes at a viable cell concentration
of 10^ - 10^ cells/dish. Some cell suspensions were "preplated" into
275 cm surface area tissue culture flasks before plating out into
culture dishes. To do this, the cell suspension (1 - 1.5 x 10^ cells/
2ml; total volume 10 ml) was placed into a 75 cm flask for 40 min at 
37°C. Following this, unattached cells were removed by decanting off 
the medium. This cell suspension was then plated out into culture 
dishes.
The medium in the culture dishes was changed every 2 - 3  days. 
Cytotoxic drugs were added at days 3 - 5 in culture, and incubated 
with the cell monolayers for 24 - 60 h.
Cell staining
Muscle cell monolayers were stained with haematoxylin and eosin 
by the following procedure. Medium was decanted from culture dishes, 
and the cell monolayer was washed once with PBS (2 ml). The cell 
monolayer was fixed with industrial alcohol for 2 min. Harris 
haematoxylin (approximately 1.5 ml) was added and the cells were
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stained for a further 2 min. The stain was removed, and the cells 
were rapidly washed with running tap water. Eosin (1% (w/v) eosin Y 
in distilled water) was added, and the cell monolayer was counter­
stained for 2 min. Excess stain was removed by rinsing with tap water, 
The stained monolayers were mounted with Apathy aqueous mounting 
medium, and photographed on a Zeiss Ergoval bright-field microscope 
using Kodak Ekta 50 or 160 ASA colour film.
Preparation of sheep sera
For preparation of normal sheep serum^blood was collected into 
one litre centrifuge bottles after cutting the jugular vein of stunned 
sheep (this procedure was kindly performed by staff at the Bath 
abattoire). The blood was clotted at 37°C for 1 h, and then centri­
fuged (lOOO g_) for 30 min at room temperature. The serum was removed 
by aspiration, and aliquots (20 ml) stored frozen at -20°C.
To prepare sheep anti-(Torpedo AChR) antiserum, purified AChR 
from Torpedo marmorata (80 jag) in Complete Freund's adjuvant was 
injected intramuscularly, followed by a similar injection 3 weeks 
later. Five days after the second injection the sheep became para­
lysed and was killed. Blood was collected and serum obtained as 
described for normal sheep serum.
Preparation of IgG from sheep serum
IgG was prepared from sheep anti-(Torpedo AChR) antiserum, or 
normal sheep serum by ammonium sulphate precipitation, and ion- 
exchange chromatography following the method of Stevenson and Dorring- 
ton (1970). Serum was made to 45% saturation with ammonium sulphate, 
by the addition of saturated ammonium sulphate solution (60 ml per 
100 ml of serum). The solution was stirred gently for 30 min , and
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the resulting precipitate collected by centrifugation (500 ĝ) for 15 
min at 4°C. The precipitate was redissolved in 0.2 M Tris buffer, 
pH 8.0 to the original serum volume, and re-precipitated by the 
addition of saturated ammonium sulphate (60 ml per 100 ml redissolved 
precipitate). This procedure was repeated until a white precipitate 
was obtained. The final precipitate was dissolved in 0.03 M sodium 
phosphate buffer, pH 7.3, and the solution dialysed against the same 
buffer (2 1) at 4°C overnight. The dialysate was applied to a 
column (10 X 2 cm) of DEAE - cellulose (DE52, microgranular form) pre­
equilibrated with dialysis buffer. The column was eluted using the 
same buffer. IgG passed straight through the column, while other 
immunoglobulins remained bound to the ion-exchange resin. Elution of 
IgG from the column was monitored by absorbance at 280 nm of the 
eluate using an LKB Uvicord I ultraviolet monitor, and the IgG 
collected as a single fraction. The IgG peak fraction was concen­
trated on a millipore ultrafiltration unit to a final concentration of 
10 - 20 mg/ml, and stored at -20°C for further use.
Preparation of F(ab^ ) 2  fragments from sheep IgG
F (ab'̂ ) 2 fragments were prepared by peptic digestion of IgG by a 
modification of the method of Hudson and Hay (1976). IgG (20 mg/ml in 
0.03 M sodium phosphate buffer, pH 7.3) was dialysed for 3 h against 
0.1 M sodium acetate (2 1), and the pH of the resulting dialysate 
adjusted to 4.5. Lyophilised pepsin (2 mg per 100 mg IgG) was added 
to the dialysate, and the mixture incubated at 37°C for 24 h. The 
solution was then centrifuged (lOOO £) for 15 min at. room temperature, 
and any precipitate discarded. The pH of the supernatant was 
adjusted to 7.4, and it was then loaded onto a column (100 x 3 cm) of 
Ultrogel ACA34. The column was eluted with 0.1 M Tris buffer contain­
ing 0.15 M NaCl, pH 8.0. Fractions (7 ml) were collected, and the
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absorbance at 280 nm of the column eluate was monitored. The fractions
corresponding to Ffab^ig were pooled, dialysed against 0.1 M sodium
phosphate buffer, pH 7.0, and concentrated to 3 mg/ml. Samples (1 ml)
were stored at -20°C for further use. F (ab^)̂  fragments from normal
sheep IgG were termed 'non-immune' F(ab^) and those from sheep anti-
/(Torpedo AChR) IgG, 'immune' F(ab ) .̂
Affinity purification of anti-(Torpedo AChR) FXab^)^ fragments
o<-BGT (2 mg) was coupled to cyanogen bromide-activated Sepharose 
4 B (20 ml in 0.2 M NaHCO^, pH 9.4) following the method of March 
et al. (1974). Any unreacted groups were blocked with IM glycine, pH 
9.0, and the beads were washed successively with 0.1 M sodium acetate, 
pH 4.0 containing IM NaCl, and 0.1 M sodium borate, pH 8.0 containing 
IM NaCl. The toxin-Sepharose was stored in 10 mM phosphate, pH 7.2, 
containing 0.1% (w/v) NaN^ at 4°C.
Purified Torpedo AChR was bound to the toxin-Sepharose as 
follows. AChR (1.5 nmoles oc-BGT binding sites) in 10 mM sodium 
phosphate buffer, pH 7.2, containing 1% (v/v) Triton XlOO was added 
to toxin-Sepharose (2.5 ml; 25 nmoles cx-BGT) in a 5 ml glass pipette 
The AChR solution was allowed to drain down, and the pipette was then 
stoppered and left at 4°C overnight. The column was washed success­
ively with 10 mM sodium phosphate buffer, pH 7.0,containing 0.15 M 
NaCl and 0.1% (v/v) Triton XlOO (5 ml), 10 mM sodium phosphate, pH
7.0 containing 0.15 M NaCl alone (5 ml), and 0.2 M ammonium hydroxide
/(5 ml) to reproduce the F(ab )  ̂elution conditions. Assay of the 
effluent for o(.-BGT binding sites indicated that more than 99% of the 
AChR was bound. Tlie column was washed and stored in 10 mM sodium 
phosphate, pH 7.0, containing 0.15 M NaCl, at 4°C.
Immune F(ab^ ) 2 fragments (1.5 ml; 3 rag/ml) were applied to the
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c o l u m n  and a l l o w e d  t o  d r a i n  down. The c o l u m n  was s t o p p e r e d  and left f o r  
90 m i n at r o o m  t e m p e r a t u r e ,  or o v e r n i g h t  at 4 ® C  to a l l o w  a n t i - A C h R  
FC a b ' ) ^  f r a g m e n t s  to bind. The c o l u m n  was w a s h e d  w i t h  10 m M  s o d i u m  
p h o s p h a t e  b u ff er, pH 7.0, c o n t a i n i n g  0 . 1 5  M NaCl until the a b s o r b a n c e  o f  
the e f f l u e n t  at 2 8 0  n m  r e t u r n e d  to zero. The i m m u n o s p e c i f i c a l l y  b o u n d  
F ( a b ' > 2  f r a g m e n t s  w e r e  e l u t e d  w i t h  0.2 M a m m o n i u m  h y d r o x i d e  ( M a r t i n e z  
et a l ., 1977). F r a c t i o n s  s h o w i n g  an i n c r e a s e  in a b s o r b a n c e  at 2 8 0  nm  
we re q u i c k l y  d e s a l t e d  by p a s s a g e  t h r o ugh S e p h a d e x  G 5 0  (2 ml in a P a s t e u r  
p i pe tte ) p r e - e q u i 1 i b r a t e d  w i th 0.1 M s o d i u m  p h o s p h a t e  b u f f e r ,  pH 7.0, and 
the peak tubes w e r e  d i a l y s e d  a g a i n s t  the same b u f f e r  at 4 ° C  o v e r n i g h t .
The d i a l y s a t e  was c o n c e n t r a t e d  by us i n g  a Mi ni con c o n c e n t r a t o r  to g i ve a
final p r o t e i n  c o n c e n t r a t i o n  of 100 - 200 p g / m l , and was s t o r e d  at 4°C.
It could be r e - u s e d  w i t h  r e p r o d u c i b l e  r e s u l t s  several ti me s o v e r  a p e r i o d  
o f  a few w e e k s .
A f f i n i t y  c h r o m a t o g r a p h y  was used p r i m a r i l y  to g i ve a m e a s u r e  o f  the 
p e r c e n t a g e  o f  s p e c i f i c  a n t i - T o r p e d o  A C h R  a n t i b o d y  w i t h i n  the p a r e n t  
immune F ( a b ' ) 2  p r e p a r a t i o n  (see R e s u l t s  p . 138). The r e s u l t i n g  a f f i n i t y  
p u r i f i e d  a n t i - A C h R  F ( a b ' ) 2  f r a g m e n t s  were u s e d  o n l y  to s h o w  the p u r i t y  
of  the i o d i n a t e d  p a r e n t  immune F ( a b ' ) 2  p r e p a r a t i o n  in a c o m p e t i t i o n  
e x p e r i m e n t  ( F i g u r e  40). For all o t h e r  e x p e r i m e n t s  in this t h e s i s  
i n v o lvi ng u n l a b e l l e d  or io d i n a t e d  immune F ( a b ' ) 2 , the w h o l e  F ( a b ' ) 2  
p o p u l a t i o n  f r o m  s h e e p  a n t i - T o r p e d o  A C h R  anti s e r u m  was used, w i t h o u t  
f u r t h e r  p u r i f i c a t i o n  o f  the sp ec i f i c  a n t i - A C h R  F ( a b ' ) 2 , a n d it is this
u n p u r i f i e d  F ( a b ' ) 2  p r e p a r a t i o n  wh i c h  is r e f e r r e d  t h r o u g h o u t  as " i m m u n e
F(ab')2".
P r e p a r a t i o n  o f  Fab f r a g m e n t s  f r o m  sheep IgG
IgG was d i a l y s e d  o v e r n i g h t  at 4 ° C  a g a i n s t  0.1 M s o d i u m  p h o s p h a t e  
buffer, pH 7.0, c o n t a i n i n g  10 m M  c y s t e i n e  and 2 m M  E D T A  (2 1), and the 
c o n c e n t r a t i o n  of the d i a l y s a t e  was a d j u s t e d  to 10 mg / m l .  L y o p h i l i s e d  
pa pain (1 mg per 100 mg IgG) was added, and the m i x t u r e  was i n c u b a t e d  at 
37°C for 16 h. The d i g e s t  was d i a l y s e d  a g a i n s t  10 m M  s o d i u m  p h o s p h a t e  
buffer, pH 8 . 0 (2 1) o v e r n i g h t  at 4*C, and the r e s u l t i n g  d i a l y s a t e  
a p pl ied to a c o l u m n  (10 x 1.5 cm) o f  D E AE - c e l l u l o s e  (DE 52) 
p r e - e q u i 1 ib ra ted in d i a l y s i s  buffer. Fab f r a g m e n t s  p a s s e d  s t r a i g h t  
through the co lumn, w h i l e  Fc f r a g m e n t s  and a n y u n d i g e s t e d  IgG r e m a i n e d  
bound to the i o n - e x c h a n g e  resin. The e l u a t e  f r a c t i o n s  c o n t a i n i n g  Fab 
were pooled, d i a l y s e d  a g a i n s t  0.1 M p h o s p h a t e  bu f f e r ,  pH 7 . 0  and 
c o n c e n t r a t e d  to 3 m g / m l .  A l i q u o t s  (1 ml) w e r e  s t o r e d  at - 2 0 ° C .  Fab
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fragments were designated 'immune' and 'non-immune' as for Ffab^lg 
fragments.
Preparation of ok-toxin affinity beads
01-toxin purified from Naja naja siamensis crude venom (Cooper 
and Reich, 1972) was coupled to Sepharose 4 B following the method of 
March et al. (1974). Sepharose 4 B (50 ml packed beads) was washed with 
0.1 M NaCl (1000 ml), and distilled water (500 ml). The beads were 
resuspended in ice cold distilled water to give a final volume of 
lOO ml, and 2 M Na^CO^ (lOO ml) was added. The solution was left to 
stir at 4°C. oC-toxin (25 mg) was dissolved in 0.2 M NaHCO^, pH 9,4 
(100 ml) and the absorbance at 280 nm measured. Cyanogen bromide (3g) 
dissolved in acetonitrile (1.5 ml) was added to the Sepharose 4B 
solution, and stirred for 2 min at 4°C. The mixture was rapidly 
filtered and washed with ice-cold distilled water (500 ml). The 
Sepharose 4 B beads were added to the ol-toxin solution, and stirred 
overnight at 4°C. The beads were washed with distilled water (400 ml), 
resuspended in 2 M glycine, pH 9.0 (200 ml) and stirred overnight at 
4°C. The affinity beads were collected by filtration, and washed 
successively with 0.1 M sodium acetate buffer, pH 4.0 containing 1 M 
NaCl (150 ml), and 0.1 M borate buffer, pH 8.0 containing 1 M NaCl 
(150 ml). The process was repeated three times, and the affinity 
beads were then equilibrated with 10 mM potassium phosphate buffer, pH 
7.4 containing 0.1% (v/v) Triton XlOO. The beads were stored at 4°C 
in the presence of 0.02% (w/vj NaN^. After use, the affinity beads 
were regenerated by washing with 10 mM phosphate buffer, pH 7.4 
containing 1 M NaCl (300 ml) followed by buffer alone (500 ml). Over 
95% of the oi.-toxin was bound to the Sepharose 4 B during the coupling 
process.
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Purification of the AChR from Torpedo marmorata
Figure 8 shows the basic procedure for the purification of the 
AChR from Torpedo marmorata electric organ.
Buffer A contained 10 mM potassium phosphate, 10 mM EDTA, 0.02% 
(w/v) NaN^ and 0.1 mM phenyl methyl sulphonyl fluoride (PMSF) at pH 
7.4. Homogenisation was performed in a Sorvall Omnimix for 3 periods 
of 1 min at full speed. The 100̂ 000 ĝ supernatant recovered from the 
extraction procedure was applied as a batch to the affinity beads and 
stirred overnight at 4°C. The beads were packed into a column (3 x 
9 cm) and washed with buffer B (10 mM phosphate, pH 7.4, 10 mM EDTA, 
0.2% (w/v) NaNg, 0.1% (v/v) Triton XlOO, 0.1 mM PMSF,containing 1 M 
NaCl (150 ml), followed by buffer B alone (150 ml). AChR was eluted 
from the column with 1 M carbamylcholine in buffer B (50 ml) over 3 h 
at 22°C. Dialysis was carried out against buffer C (2 1; 10 mM phos­
phate, 0.1% (v/v) Triton XlOO, 0.2% (w/v) NaN^, and 0.1 mM PMSF, pH 
7.4). Residual carbamylcholine was removed by passage through a col­
umn ( 1 x 1  cm) of DEAE - cellulose (DE 52), and the column was washed 
with buffer C (2 1). The AChR was eluted with buffer B without PMSF, 
but containing 0.5 M NaCl. Twenty fractions (1 ml) were collected 
and analysed for o(.-BGT binding. The peak fractions were pooled and 
dialysed against buffer C without PMSF (2 x 2 1). The purified AChR 
was stored at 4°C.
125Preparation of I -(X-BGT
125 125OC-BGT was labelled with Iodine ( I) by the method of
125Urbaniak et al. (1973). Carrier-free Na I (lOOmCi/ml) in dilute 
NaOH solution (10 pi) was added to CX-BGT (10 pg) dissolved in 50 mM 
potassium phosphate buffer, pH 7.5 (20 pi). Chloramine T (0.5% (w/v) 
in the same buffer; 10 pi) and buffer alone (10 pi) were added. The
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FIGURE 8. Preparation of AChR from Torpedo marmorata electric organ,
400g Torpedo electric organ 
Slice + 400ml buffer A
IHomogenise
I o20,000g Ih 4 C
Supernatant I Pellet I
Resuspend with buffer A + 1% Triton XlOO 
Stir 2hh at 22°C
100,000g Ih 4 C
Supernatant II
Stir with toxin-sepharose beads 
overnight at 4°C
Add beads to column
Pellet II
-Non-bound AChR
Wash with buffer B + 0.5M NaCl 
Elute AChR with carbachol
IDialyse for 2h against buffer C 
to remove carbachol





Dialyse against buffer C to 
remove NaCl
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mixture was stirred at 22°C for 1 min , after which 0.016% (w/v) sodium
metabisulphite in buffer (750 pi), and 1% (w/vj potassium iodide in
125buffer (200 pi) were added to stop the iodination reaction. I -
125(X-BGT was separated from free I by passage through a Sephadex G25 ■
column (25 X 1 cm) pre-equilibrated with 10 mM potassium phosphate
buffer, pH 7.4, containing 1% (w/vj bovine serum albumin, and eluted
with the same buffer. Fractions (1 ml) were collected and samples
(5 pi) counted in an LKB 1280 Ultrogamma counter. Peak tubes were
125pooled and the specific activity of the I -Cd-BGT calculated, assum­
ing 100% recovery of protein. The biological activity of the toxin,
125and the amount of I - protein precipitated by 6% (w/vj trichloro­
acetic acid (TCA) were determined. -oi-BGT was stored at 4°C in
elution buffer for up to 3 weeks.
125Biological activity of I -CX-BGT
125The biological activity of the I - (X-BGT was determined by
125measuring the amount of I - toxin bound to an excess of purified 
Torpedo AChR. The assay used was a modification of the method of 
Schmidt and Raftery (1973), which is detailed below.
125Acid precipitability of I -o(-BGT
The radiolabelled o(-BGT was diluted 1 in 100 with 10 mM potass­
ium phosphate buffer, pH 7.4, containing 1% (w/v) bovine serum 
albumin. Four replicate samples of the diluted toxin (50 pi) were 
placed on ice, and 12% (w/vj TCA (50 pi) added. After 30 min the 
precipitate was collected on a Whatman GFC filter, washed with 6% 
(w/v) cold TCA (5 ml) and counted in an LKB 1280 Ultrogamma counter. 
Acid-precipitable radioactivity was expressed as a percentage of the 
total radioactivity added.
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125Fractionation of I -6L-BGT
125I -OC-BGT was separated into mono- and di-iodinated species by
125the method of Vogel et al. (1972). Fractions containing I - bound 
to oC-BGT after elution from Sephadex G25 were pooled and diluted 1 in 
3 with double distilled water. The diluted solution was applied to a 
column ( 1 x 1  cm) of ON - Sephadex C 50 pre-equilibrated with 3.3 mM 
sodium phosphate buffer, pH 7.4 containing bovine serum albumin 
(2 mg/ml). The column was washed with the same buffer to remove any 
remaining free iodine, and fractions (1 ml) were collected. The 
column was eluted with a linear gradient consisting of 40 ml of 3.3 mM 
phosphate buffer, pH 7.4 containing bovine serum albumin (2 mg/ml), 
and 40 ml of the same buffer with the addition of 80 mM NaCl. Fract­
ions (1 ml) were collected, and samples (5 pi) of each fraction were 
counted in an LKB Ultrogamma counter.
125For preparative fractionation of I -oC-BGT, toxin was first
labelled at lO times the concentration of the normal iodination proce-
125dure. This was done by increasing the volume of ô -BGT, Na I and 
chloraraine-T by 10-fold, and omitting the buffer addition. The 
volume and concentration of potassium iodide were increased to 1 ml 
and 20 mg/ml respectively. The concentration of sodium metabisulphite 
was increased to 8 mg/ml, and the volume reduced to 200 pi. All other 
conditions were as described above.
Iodination of F(ab^ ) 2 and Fab fragments
Immune and non-immune F(ab^ ) 2 and Fab fragments were labelled 
125with I essentially according to the method of McConahey and Dixon 
(1966) .
F (ah' ) 2 or Fab (3 mg in 1 ml of 0.1 M phosphate buffer, pH 7.0)
125were labelled with carrier-free Na I (100 mCi/ml) in dilute NaOH
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solution (10 pi) by the addition of chloramine - T (200 pg/ral in
double distilled water; 100 pi). After 5 minutes stirring at 22°C
sodium metabisulphite (200 pg/ml in double distilled water; 100 pi)
was added to stop the reaction. The iodinated protein was separated 
125from free I by passage through a Sephadex G 50 column (25 x 1 cm) 
pre-equilibrated with 0.1 M sodium phosphate buffer, pH 7.0, contain­
ing 1% (w/v) bovine serum albumin, and eluted with the same buffer. 
Fractions (1 ml) were collected, and samples (5 pi) of each fraction
were counted in an LKB 1280 Ultrogamma counter. The peêüc tubes were
125pooled, and the specific activity of the I - protein calculated,
125 /assuming 100% recovery of protein. I - F(ab )  ̂and Fab were stored 
at 4°C in elution buffer until required.
SDS - polyacrylamide gel electrophoresis
The purity of Torpedo AChR and F(abS 2 and Fab preparations was 
assessed by polyacrylamide gel electrophoresis under denaturing con­
ditions according to the method of Weber and Osborn (1969). AChR was 
run under reducing conditions, while Fab and F(ab* ) 2 fragments were 
run under non-reducing conditions. To prepare samples for electro­
phoresis, AChR (20 - 50 pg) was boiled for 2 min in a solution con­
taining 3% (w/v) sodium dodecyl sulphate (SDS) and 1% (v/v) 2 - 
mercaptoethanol in 8 M urea. F(ab and Fab (30 - 60 pg in 10 - 20 
pi 0.1 M phosphate buffer, pH 7.0) were mixed with a solution of 3% 
(w/vj SDS in 8 M urea (80 pi).
Electrophoresis was carried out in 8% acrylamide slab gels. 
Samples were loaded at 30 mA per gel and run at 100 mA for 2 h at 22°C, 
Bromophenol blue (0.05%) in 50% glycerol was used as a tracking dye. 
BDH standard molecular weight markers (14300 - 71500 daltons) were 
used in determining the molecular weights of stained bcinds. Gels were
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stained with 0.1% (w/v) Coomassie Brilliant Blue R (Sigma Chemical 
Co. Ltd) in 10% (v/v) acetic acid, 20% (v/v) alcohol. They were 
destained prior to photography with 10% acetic acid, 20% alcohol, by 
washing the gel four times for 2 h each.
Protein estimation of myotube cultures
The incubation medium was removed from myotube culture dishes, 
and each dish was washed three times with Dulbecco's phosphate buffer­
ed saline (PBS; 2 ml). 0.1 M NaOH (1 ml) was added to each dish, and 
the dishes were incubated at room temperature for 10 - 30 min. At the 
end of this incubation the suspended cells were transferred to a 
stoppered tube. Each dish was washed with 0.1 M NaOH (1 ml), and the 
washings were transferred to the appropriate tubes. Cell suspensions 
were vortex-mixed thoroughly before assaying for protein.
Protein determination was performed by the method of Lowry et. 
al. (1951). Bovine serum albumin was used as the standard protein, 
and the standard calibration curve is shown in Figure 9A. Cell sus­
pensions were diluted 1 in 5 for protein determination. The protein 
content of a cell-free plate was taken as a blank in the estimation 
of total cell protein in myotube cultures.
Protein estimation of F(ab )  ̂and Fab fragments
Protein estimation of the F(ab^ ) 2  and Fab preparations used in 
this study was performed by the Biuret method (Layne, 1957). Bovine 
serum albumin was used as the standard protein, aind the standard cali­
bration curve is shown in Figure 9B.
12 5I -t(-BGT binding to Torpedo AChR 
125I - ol-BGT binding to purified Torpedo AChR was assayed by a
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FIGURE 9. Standard curves for protein estimation,
A : Lowry method.
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modification of the DEAE cellulose filter method of Schmidt and Raftery
(1973). AChR (100 ̂ 1) in 10 mM potassium phosphate buffer, pH 7,4,
containing 1% (v/v) Triton XlOO, and 0.1% (w/v) bovine serum albumin,
125was incubated with I -«.-BGT (1 - 1.5 nM; 50 pi) in the same buffer 
for 90 min at room temperature. Termination of the reaction was 
achieved by the addition of cold (4°C) buffer (1 ml). The sample was 
filtered through two DE 81 cellulose filter discs (2 cm diameter), 
and the discs were washed with buffer (5 ml). The washed discs were 
counted in an LKB 1280 Ultrogamma counter. Blank samples containing 
no AChR were used to determine non-specific binding, and AChR activity 
was expressed as the molarity of oC-BGT binding sites.
125I - ok-BGT binding to chick myotube cultures
Incubation medium was removed from culture dishes, and each dish
was washed three times with PBS (2 ml). To each dish was then added
assay medium (1 ml; MEM, 20 mM HEPES,buffered to pH 7.2 with NaOH,
containing 2 mg/ml bovine serum albumin), with or without decameth- 
-5onium bromide (10 M final concentration), and the cultures were
125incubated at room temperature for 30 min. Following this, I -ot-BGT 
(10 - 60 jil to give a final concentration of 2.5 - 15 nM) was added to 
each dish, and the cultures were incubated for a further 60 min at 
room temperature. The assay medium was then removed, and each dish 
was washed three times with PBS (2 ml). The myotube monolayer in 
each dish was suspended with 0.1 M NaOH (2 x 0.75 ml) and the suspen­
sion counted in an LKB Ultrogamma counter. Non-specific binding was
-5taken to be binding in the presence of 10 M décaméthonium bromide. 
Specific binding was determined by subtraction of non-specific bind­
ing from the total bound radioactivity. All assays were performed on 
triplicate culture dishes.
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125I -«c-BGT binding to human foetal myotube cultures
Culture medium was removed from culture dishes, and each dish 
was washed twice with 199 medium, buffered with 20 mM HEPES and con­
taining 10% donor horse serum (assay medium). Following this, 
cultures were incubated in assay medium (1 ml) with or without
-3décaméthonium bromide (final concentration 10 M) for 45 min at room 
125temperature. I -c<-BGT was then added to a final concentration of
10 - 30 nM, and the cultures were incubated for a further 50 min at 
room temperature. At the end of this incubation, each dish was washed 
three times with assay medium (2 ml). The cell monolayer was then 
solubilised with 0.1 M NaOH (1.5 ml). The radioactivity in the solu­
bilised cell suspension was counted in an LKB 1280 Ultrogamma counter.
Non-specific binding was taken to be the binding in the presence of 
-310 M décaméthonium bromide.
125 /Inhibition of I - oL-BGT binding to Torpedo AChR by F(ab ) ̂ and Fab
fragments
Purified Torpedo AChR (100 ̂ 1) was incubated for 30 min at 22°C 
with immune or non-immune F(ab* ) 2 or Fab fragments (50 )il), prior to 
assaying for ^^^I -(X-BGT binding as described above. F(ab' ) 2  and Fab 
fragments were tested over the range of 0.01 - 1 mg/ml.
Inhibition of -CX-BGT binding to chick myotube cultures by F (ab^),
and Fab fragments
Myotube cultures were washed three times with PBS (2 ml) , and 
then incubated overnight at 4°C in assay medium (see above; 1 ml) con­
taining immune or non-immune F(ab' ) 2  or Fab fragments (10 - 100 ̂ 1).
At the end of this incubation, each culture dish was washed three
125times with PBS (2 ml), before assaying the cultures for I - (X-BGT
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125binding activity as detailed above. I -(X-BGT was used at a final
concentration of 10 - 15 nM in these experiments.
Determination of AChR turnover in chick myotube cultures
AChR turnover from chick embryo myotube cultures was determined
in the absence or presence of immune F (ab^)  ̂fragments, at 4°C and
37°C. Cultures were labelled with -cX-BGT in the presence or
-5absence of décaméthonium bromide (10 M), and each culture dish was 
then washed 7 times with PBS. Immune F (ab^)  ̂ (300 ̂ g in 1 ml of assay 
medium) or assay medium alone was then added to each dish, and the 
cultures were incubated at 4°C or 37°C. At various time intervals the 
medium (1 ml) plus a single wash with PBS (1 ml) was removed from 
duplicate dishes containing myotubes labelled with af-BGT in the pres­
ence of décaméthonium, and duplicate dishes labelled with o(-BGT 
alone, and counted in an LKB Ultrogamma counter.
125 /I - F(ab ) 2 and Fab binding to chick myotube cultures
Culture medium was removed from triplicate culture dishes, and
each dish was washed three times with PBS (2 ml). To each dish was
125 /added assay medium (1 ml) containing I - F(ab )  ̂ (0.25 - 2.5 ^
125final concentration) or I - Fab (0.5 - 6 pM final concentration),
and the dishes were incubated for 30 min at 37°C, then overnight at
4°C. At the end of the incubation the assay medium was removed, and
the cultures were washed three times with PBS (2 ml). The myotube
monolayer in each dish was suspended with 0.1 M NaOH (2 x 0.75 ml)
and counted in an LKB Ultrogamma counter. Specific binding of 
125 /I - F(ab ) 2 or Fab to AChR was taken to be the difference between 
binding of immune and non-immune fragments.
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F(ab^)^ binding to Torpedo AChR
binding to purified Torpedo AChR was assayed by
a DEAE - cellulose filter assay. AChR (0.1 - 2 pmol in 100 pi of 10 mM
potassium phosphate buffer, pH 7.4^containing 1% (v/v) Triton XlOO
and 0.1% (w/v) bovine serum albumin (binding assay buffer)) was incu- 
125 /bated with I - F(ab )  ̂ (0.1 - 4 ^  final concentration) for 2 h at 
22°C, or overnight at 4°C. Termination of the reaction was by the 
addition of cold (4°C) assay buffer (1 ml). The sample was filtered 
through two DE 81 cellulose filter discs (2 cm diameter) , cind the 
discs were washed with assay buffer (5 ml). Blank samples contained 
no AChR. The washed discs were counted in an LKB Ultrogamma counter. 
Bound radioactivity in the blank samples was considered to represent 
non-specific binding.
Unlabelled F(ab' ) 2 fragments and affinity purified F(ab^)^
125 /fragments were assayed by competition with parent I - F(ab )̂
fragments for binding to Torpedo AChR. Receptor (50 ̂ 1; 0.1 pmol 
diluted in binding assay buffer) was preincubated for 90 min at 22°C 
with unlabelled F(ab^ ) 2 fragments (50 ̂ 1) before addition of
- F (ab^ ) 2 fragments (10 pmol) and assay for binding as described 
above.
Mathematical analysis of binding data
125 /Binding data of I - F(ab ) 2 to Torpedo AChR and myotube cult­
ures was
subjected to Scatchard analysis for determination of the dissociation 
constant (K̂ ) using the equation
[rlI _ -1 [rl] + 1 [r 1 (1)
where {̂ RL̂  = bound ligand
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= free ligand
= initial receptor concentration 
= dissociation constant
The ratio of ĵBound̂  ligand was plotted against [Bound] ligand, and 
[Free]
the calculated from the gradient of the line. When half the recep­
tor binding sites are occupied by ligand (ie^Rb] = h L^q J ) then 
equation (1) reduces simply to
Kq = L O  (2)
An approximation of can, therefore, also be made from the 
ligand concentration giving half maximal saturation of binding.
In addition the
125inhibition of I - (X-BGT binding to Torpedo AChR and myotube cultures 
by FCab^)^ and Fab fragments were analysed by use of the Hill equation.
loGin f B ] _ n log,^ [l] - log,^K
where B
10 ( i-----^1 = "10 ' " ’10max
= [rl]
B = maximum bound ligandmax
[b] = free ligand
n = the Hill coeffieient
K = dissociation constant
In tlie case of ^^^I - F(ab'). binding, B was taken to be the2 max
amount of bound ligand at saturation. For inhibition ofc%-BGT bind­
ing the fractional saturation/ B \was calculated from the
I B - b /\ max /
inhibition curve, using the maximum inhibition as a measure of Bmax.
A plot of log^^l B \ against log^^ [bjyields a
^max
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straight line with gradient, n, and x - intercept (B = half B^^^) of
- ^ n
Inhibition of - FCah/)^ binding to Torpedo AChR by O^-BGT
125 fInhibition of I - F(ab )  ̂binding to Torpedo AChR by unlab­
elled oC-BGT was performed by preincubation of AChR (0,1 - 2 pmol in 
binding assay buffer (100 ̂ 1)) with ô -BGT (100 pmol) in the same
buffer (10 ̂ 1), or with buffer alone, for 90 min at 22°C prior to 
125 Vassaying for I - F(ab )  ̂binding as described above.
125 /Inhibition of I - F(ab )  ̂binding to chick myotube cultures by
oC-BGT
Myotube cultures were washed three times with PBS (2 ml) . To
each dish was then added assay medium (1 ml) containing 0(-BGT (10 -
20 pmol in 10, ̂ 1 PBS) or PBS alone, and the cultures were incubated
for 60 rain at 22°C. Dishes were then washed twice with PBS (2 ml)
125 Iprior to assaying for I - F(ab )  ̂binding as outlined above.
Inhibition of ^^^I - F(ab^ ) 2 binding to myotube cultures by purified
Torpedo AChR
125 /I - F(ab ) 2 was preincubated with Torpedo AChR in 10 mM
potassium phosphate buffer, pH 7.4 containing 0.1% (v/v) Triton XlOO,
at molar ratios of 2.5:1 up to 50:1, or with buffer alone, at 4°C
125 /overnight, prior to assaying for I - F(ab binding to myotube
125 /cultures. Binding of I - F(ab ) 2 was determined at a final con­
centration of 1 pM.
Physical and chemical modifications of Torpedo AChR
1) Heat inactivation: Torpedo AChR in 10 mM potassium phosphate
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buffer, pH 7.4 containing 0.1% (v/v) Triton XlOO was heated at 60°C 
for 10 - 30 min.
2) SDS - dénaturation: AChR was boiled for 2 min in the pres­
ence of SDS (0.5 - 1% (w/v) final concentration).
3) Periodate oxidation: AChR (750 yil) was incubated for 4 h at 
4°C in the dark with sodium metaperiodate (15 mM) in 50 mM sodium 
acetate buffer, pH 5.0, containing 1% (v/v) Triton XlOO and 0.1%
(w/v) bovine serum albumin (50 ̂ 1), or with buffer alone. At the end 
of the incubation the reaction was stopped by the addition of ethylene 
glycol (100 ̂ 1).
4) Glycosidase treatment: AChR was treated with a mixed gly- 
cosidase extract from Trichomonas foetus (T. foetus). The glycosidase 
extract has been found to contain fucosidase, mannosidase, galactosi- 
dase and hexosaminidase, but no protease activities (Watkins, 1966; 
Westwood et al., 1976). Lyophilised T. foetus extract was recon­
stituted at 4 mg/ml in 10 mM phosphate buffer, pH 6.4, containing 1% 
(w/v) bovine serum albumin. Torpedo AChR in the same buffer, contain­
ing 0.1% (v/v) Triton XlOO but no bovine serum albumin, was incubated 
at 37°C for 4 h with reconstituted T.foetus extract (40 ̂ 1) or with 
reconstitution buffer alone (40 ̂ 1).
125 /Binding of I - F(ab )  ̂to modified Torpedo AChR
Torpedo AChR was modified as described above. The modified
125 /receptor was assayed directly for I - F (ab )  ̂binding by the DEAE - 
cellulose filter method described above. In the SDS - denatured AChR 
preparation the final concentration of residual SDS was approximately 
0.001%, and was considered to be negligible. Control tubes, therefore, 
contained no SDS. For T. foetus treated AChR the binding assay was
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performed at 4°C to reduce any possible effect of glycosidase 
activity on the assay.
125 IInhibition of I - F(ab binding to chick myotube cultures by 
modified Torpedo AChR
125 fModified Torpedo AChR was preincubated with I - F(ab )  ̂as 
described above for untreated receptor at a molar ratio of 1 to 5
(AChR to ^^^I - F(ab̂  ) )̂ prior to assaying for ^^^I - F(ab^ ) 2  binding 
to myotube cultures.
For heat-inactivated AChR, untreated receptor was used as the 
control. For SDS - denatured AChR the final concentration of residual 
SDS in the culture dish was approximately 0.05%, and hence this con­
centration of SDS was included in the control cultures with untreated 
AChR.
For periodate - treated AChR three different controls were set
u p .
1) AChR treated with periodate - oxidation buffer alone, with 
the addition of ethylene glycol.
125 I2) I - F(ab )2 preincubated with periodate - oxidation
buffer and ethylene glycol, as for periodate - oxidation of AChR prior 
to binding assay. »
3) ^^^i - F (ab^ ) 2 preincubated with sodium metaperiodate and
ethylene glycol, as for periodate - oxidation of AChR, prior to bind­
ing assay.
For glycosidase - treated AChR three different controls were 
again used.
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1) AChR treated with buffer alone at 4°C or 37°C.
2) AChR treated with T. foetus extract at 4°C, under the same 
conditions as for preincubation with receptor at 37°C.
3) - Ftab'lg preincubated with T. foetus at 37°C, as for
preincubation of AChR, prior to binding assay.
C a r n i t i n e  u p t a k e  by m y o t u b e  c u l t u r e s
T r i t i a t e d  ( ^ H - m e t h y l )  c a r n i t i n e  (^H-C; s p e c i f i c  a c t i v i t y  
1-2 C i /mmol ( A m e r s h a m  I n t e r n a t i o n a l ) )  was d i l u t e d  in 199 m e d i u m ,  
c o n t a i n i n g  5% foetal c a l f  s e r u m  ( i n c u b a t i o n  m e d i u m )  to a final 
c o n c e n t r a t i o n  o f  1 pM. F o r the ^ H - C  u p t a k e  a s s a y ,  c h i c k  m y o t u b e s  
were gr o w n  in 35 m m  d i a m e t e r  c o l l a g e n - c o a t e d  petri d i s h e s  for 6-8 
days as d e s c r i b e d  in the m e t h o d s  sect ion . H u m a n  m y o t u b e  c u l t u r e s  
were gr o w n  in 35 m m  d i a m e t e r ,  c o l l a g e n - c o a t e d  petri d i s h e s  in 199 
me dium, c o n t a i n i n g  10 %  d o n o r  h o r s e  s e r u m  for 14-21 days. The 
c u l t u r e s  w e r e  then w a s h e d  o n c e  w i t h  i n c u b a t i o n  m e d i u m  (2 ml), and 
^H-C (1 nmol) in i n c u b a t i o n  m e d i u m  (1 ml) was a d d e d  to e a c h  dish. 
The c u l t u r e s  w e re then i n c u b a t e d  at 3 7 ° C  u n d e r  an a t m o s p h e r e  o f  5% 
CO^ in air for 18 h. At the end o f  this i n c u b a t i o n  e a c h  d i s h  was 
w a s h e d  twice w i th i n c u b a t i o n  m e d i u m ,  and f i n a l l y  f r e s h  i n c u b a t i o n  
m e d i u m  (0.9 - 1 ml) was a d d e d  to the c u l t u r e s  p r i o r  to a s s a y i n g  f o r 
m y o l y s i s  (see below).
S e r u m - m e d i a t e d  m u s c l e  cell lysis
To m e a s u r e  the lysis of m y o t u b e s  c a u s e d  by no rm al hu m a n  sera, 
or sera f r o m  m y a s t h e n i c  p a t i e n t s ,  m y o t u b e  c u l t u r e s  w e r e  f i r s t  
labelled w i th ^H-C as d e s c r i b e d  above. S e r u m  ( 2 . 5  - 10%. v/v) was 
then added to t r i p l i c a t e  c u l t u r e  d i s h e s  to g i v e  a final i n c u b a t i o n  
vo lu me o f  1 ml, and the c u l t u r e s  w e r e  i n c u b a t e d  at 3 7 * C  for 5 h. 
T r i p l i c a t e  control c u l t u r e s  r e c e i v e d  no serum. F o l l o w i n g  this 
incubation, e a c h  c u l t u r e  was w a s h e d  twice w i t h  i n c u b a t i o n  m e d i u m  
(2 ml), and the cell m o n o l a y e r  was s o l u b i l i s e d  w i t h  O . I M  N a OH 
(1ml). The s o l u b i l i s e d  cell s u s p e n s i o n  was t r a n s f e r r e d  to 
s c i n t i l l a t i o n  vials, and NE 2 6 0 s c i n t i l l a t i o n  f l u i d  ( N ew E n g l a n d  
Nuclear; 10ml) was a d d e d  to e a c h  vial. The v i a l s  w e r e  b r i e f l y  
mi xe d on a v o r t e x  mi xe r, and the r a d i o a c t i v i t y  in the s o l u b i l i s e d  
cell s u s p e n s i o n  was c o u n t e d  by u s i n g  a P a c k a r d  l i q u i d  s c i n t i l l a t i o n  
c o u n t e r .
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scintillation counter.
Serum - mediated myotoxicity was calculated by using the 
formula
Myotoxicity = 100 - ER^H - C x 100
TR^H - C
where ER^H - C is the retained - C in the presence of test serum,
3 3and TR H - C is the retained H - C in the absence of serum.
Absorption of sera with chicken liver homogenate
Chicken liver was washed free of blood with PBS, diced, and 
re-washed with PBS. The diced liver was mixed 1:1 with cold (4°C) PBS 
and homogenised using a Potter-Elvsham homogeniser. The homogenate 
was centrifuged at IĈ OOO ĝ for 15 min. The pellet was retained and 
stored at -20°C for further use.
Absorption of sera was carried out by stirring each sample (1 ml) 
of serum with thawed homogenate (0.5 ml) for 2 h at room temperature. 
The serum was recovered by centrifuging at 10̂ 000 ^ for 30 min.
Heat inactivation of sera, and effect of complement on myolysis
Sera were heat inactivated by incubation at 56°C for 30 min.
To test the effect of complement on serum - mediated myotoxicity, the 
heat - inactivated serum ( 2'5% y/v ), with or without guinea pig 
complement (Miles Laboratories) in commercial diluent (10% v/v)» was 
used in the myotoxicity assay described above.
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RESULTS
Preparation of chick embryo myotube cultures
Dissociation ; Limb muscle from 10 - 11 day incubated chick embryos 
was routinely dissociated by incubation with 0.1% trypsin. Cell 
aggregates were rare with this procedure, and were removed by passage 
of the cell suspension through two 50 ym pore-size nylon discs.
Yields of nucleated cells were regularly in the range 150 - 200 x 10^ 
cells per gram wet weight of muscle.
Initial plating densities ranged from 1 x 10^ - 1 x 10^ cells/
35 mm dish. At the lower densities the onset of fusion was signifi­
cantly delayed, whereas, at high densities, overcrowding in the cell 
monolayer led to rapid overgrowth with fibroblasts prior to myoblast 
fusion, and extensive cell death, with rounding-up and detachment of 
cells from the substratum. Thus an initial seeding density of 
1 X 10^ cells/dish proved optimal for growth and differentiation of 
muscle cells.
Growth and Differentiation: Mononucleated cells which settled onto
the collagen substratum were at first round in shape, with bipolar 
or multipolar morphologies appearing after
about 24 h in culture (Figure 10a). By day 2 in culture, myoblast 
fusion was extensive (Figure 10b) with small, multinucleated, elong­
ated cells present, some of which exhibited extensive branching. 
Myoblast fusion appeared to occur in approximate synchrony, and was 
essentially complete by day 3 in culture. By day 5 large myotubes 
had formed, and were abundeint in the culture (Figure 10c) . Nuclei 
in myotubes were arranged in rows, at first centrally placed, but later 
moving laterally to become sited under the plasma membrane (Figure 11).
FIGURE 10.
(a) Phase contrast micrograph of mononucleated cells in a 24h 
culture of dissociated chick embryonic muscle seeded at 
1x10^ cells/35mm dish.
(b) Occurence of cell fusion in a 48h culture of chick embryonic 
muscle seeded at 1x10^ cells/35mm dish. Numerous cell-cell 
contacts can be seen,with myoblasts aligning lengthwise. 
Multiple cell fusions are also apparent.
(c) Phase contrast micrograph of a 5-day culture of chick
embryonic muscle showing well formed multinucleate myotubes.









FIGURE 11. A 7-day culture of chick embr̂ ônic muscle showing the 




C r o s s - s t r i a t i o n s  were a l s o  found f r o m  da y  5 o n w a r d s  (F igure 12). 
Sp ontaneous c o n t r a c t i o n s ,  rhythmical o r  single, could be o b s e r v e d  in 
cultures c o n t a i n i n g  more ma tu re fibres.
Rapidly d i v i d i n g  m o n o n u c l e a r  cells in the c u l t u r e s  were ki l l e d  
by exposure to a D N A - s y n t h e s i s  inhibitor, cy to s i n e  a r a b i n o s l d e  (ara 
C). The fused m y o b l a s t s  were po s t - m i t o t i c ,  and hence u n a f f e c t e d  by 
the drug. C u l t u r e s  tr eated with ar a  C were e s s e n t i a l l y  free of 
co nt ami na ti ng m o n o n u c l e a r  cells (F ig ure 13b). By co ntrast, cult ure s  
not exposed to the drug be came o v e r g r o w n  with m o n o n u c l e a r  cells by 
day 5 in c u l t ure (Figure 13a). It is not po s s i b l e  to say wh e t h e r  
the co nt ami n a t i n g  m o n o n u c l e a r  cells were f i b r o b l a s t s  or un fused 
myoblasts on the basis o f  their m o r p h o l o g y  alone.
Protein estimation of chick myotube cultures
The total protein content of chick embryo myotube cultures was 
determined by the method of Lowry et al. (1951). Initial experiments 
were performed to determine the minimum extraction time with 0.1 M 
NaOH needed to solubilise completely the myotube monolayer. The 
results are shown in Table 6, and demonstrate that a 30 min extract­
ion was sufficient for efficient solubilisation.
Table 7 shows the cell protein content of 20 culture dishes 
from a single myotube culture, extracted with 0.1 M NaOH for 30 min. 
The mean cell protein was 255 yag/dish with a standard deviation of 
20 yug/ml, representing 7.8% of the mean. The mean protein content of 
cell-free dishes was 30 ̂ g/ral, probably representing serum components 
non-specifically adsorbed onto the collagen matrix. Routine protein 
estimations on chick myotube cultures during the course of this study 
were performed on triplicate cultures, and used a 30 min extraction 
time with 0.1 M NaOH. The mean protein content from culture to 
culture was variable, ranging from 188 - 576 jpg/dish, with an overall 
mean - standard deviation (S.D.) of 355 - 118 jag/ dish (n = 17).
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FIGURE 12. Mature myotubes in a 9-day culture of chick embryonic 
muscle.
Cross-striations can be observed in the large myotube 




FIGURE 13. The effect of cytosine arabinoside (ara c) on a culture 
of chick embryonic muscle.
(a) Untreated.Mononuclear cells have occupied all the spaces between 
the myotubes, and have also partially overgrown the myotubes 
themselves.
(b) T r e a t e d  wi th ara c. A r a c was added at 52h in cu lture, and was 
I n c u b a t e d  w i th the cells for 60h as d e t a i l e d  in the M e t h o d s  (p 71). 
A r e l a t i v e l y  pure p o p u l a t i o n  o f  m y o t u b e s  r e s u l t e d  f r o m  this 




TABLE 6 . The effect of extraction time on determination of the 
cell protein content of a culture of chick embryonic 
muscle.















Dishes 1-7 were extracted with O.lM NaOH for 30min. 
Dishes 8-14 were extracted with O.lM NaOH for 60min.
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TABLE 7. Variation in cell protein content of 20 culture dishes 
within a single culture of chick embryonic muscle.
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Preparation of human foetal myotube cultures
Limbs were obtained from foetuses of 0 weeks gestation or older. 
Below this age identification of limbs was impossible. Preservation 
of intact limbs was greater with increasing foetal age.
Disaggregation : The disaggregation of human foetal muscle was much
more difficult than that of chick embryo muscle. After 30 min expos­
ure to 0 .1 % (w/v) trypsin large tissue lumps were still present, with 
a low yield of single nucleated cells. Much more complete dissocia­
tion was achieved by a 60 min exposure to the enzyme (Table 8 ). When 
the single cell suspension obtained was plated out into collagen- 
coated 35 ram tissue culture dishes (5 x 10^ cells/dish) the plating 
efficiency (the number of cells present after 24 h in vitro culture, 
expressed as a percentage of the initial plating density) was similar 
whether a 30 or 60 min exposure to trypsin was employed (Table 8 ).
Disaggregation could be achieved by using either 0.1% (w/v) 
trypsin or 0.5% (w/v) collagenase. Cell yields were slightly higher 
with a 1 h exposure to trypsin (Table 9). Plating efficiency was also 
equal, or higher with trypsin (Table 9). For this reason, 0.1% 
trypsin was used routinely in the preparation of single cell suspen­
sions from foetal muscle. Mechanical disaggregation of muscle 
resulted in a much lower cell yield, and plating efficiency (Table 9).
Preplating of muscle cell suspensions: Cell suspensions prepared from
human foetal muscle contained both myoblasts and fibroblasts (see 
Figure 14a). An attempt was made to enrich the cell suspension in 
myoblasts by preferential attachment of the fibroblasts to tissue 
culture flasks, following the method of Yaffe (1968). In this study 
between 10 and 30% of cells attached to the flask during the preplat­
ing procedure. Examination of the attached cells after 24 h incubation
105.
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TABLE 9. Disaggregation of human foetal muscle tissue.
Preparation/ Disaggregation Cell yield Viability Plating
Foetal age method (xlO^/mg tissue) (%) efficiency
(%)
1 Mechanical 0.35 88.5 -
1 1 weeks Collagenase/
DNAse
2.5 1 0 0 -
Trypsin 3.1 1 0 0 -
2 Mechanical 0.35 82 0.25
1 0  weeks Collagenase/
DNAse
2 . 8 . lOO 5.2
Trypsin 3.1 1 0 0 5.2
3 Mechanical 0.64 81.6 0.3
14 weeks Collagenase/
DNAse
1.9 1 0 0 5.2
Trypsin 1.9 1 0 0 1 0 . 6
V i a b i l i t y  and p l a t i n g  e f f i c i e n c y  w e r e  c a l c u l a t e d  as in Ta bl e 8.
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at 37°C showed that all the cells had a fibroblastic morphology. The 
plating efficiency of unattached cells was essentially identical to 
that of the original cell suspension.
Growth and differentiation: After plating, cells settled on to the
collagen substratum. Most cells appeared spherical when viewed by 
phase-contrast microscopy. By 24 h in vitro some of the attached mono­
nuclear cells had processes on either side, so that an elongation of 
the cell took place (bipolar morphology). Mononucleated cells with 
more than two processes were also present in the first days in 
c u l t u r e  ( m u l t i p o l a r  m o r p h o l o g y ) .  The t w o  ty pe s o f  cell are s h o w n  in 
Fi g u r e  14. It was not p o s s i b l e ,  h o w e v e r ,  to d i s t i n g u i s h  u n f u s e d  
m y o b l a s t s  f r o m  f i b r o b l a s t s  on the b a s i s  o f  th ei r m o r p h o l o g y .  By 48 h 
in culture mononucleated cells had increased in size. Limited con­
tact between cells was visible, with cells of both types being 
involved (Figure I5 ). By day 3 in vitro cell contacts were extensive, 
with multiple fusions being common (Figure 16a,b). Long processes 
extending from one cell to another were also observed, with the 
myoblasts aligning end to end. By day 7 multinucleated cells could 
be seen, and myotubes were well developed by day 14 (Figure 17). The 
myotubes contained three or more nuclei arrayed in rows either centr­
ally or laterally under the cell membrane (Figure 18a,b), or in 
closely-packed groups (Figure 18c). Some myotubes were extensively 
branched (Figure 19).
Reduction of fibroblast growth in cultures : When cultures were grown
in medium containing 1 0 % foetal calf serum^ m o n o n u c l e a r  c e l l s  o f t e n  
overgrew the cultures by 10 days (Figure 20a). Preplating alone had 
no effect on tliis overgrowth (Figure 20b). Three different cytotoxic 
drugs were used in an attempt to reduce the overgrowth
FIGURE 14.
H&E Stained preparation showing mononucleated cells of 
varying morphologies in a 24h culture of enzymatically 
dissociated human foetal muscle. Seeded at 5xlO^/35mm dish,
in 199 m e d i u m ,  c o n t a i n i n g  10 %  d o n o r  h o r s e  serum.
B: b i p o l a r  m o r p h o l o g y
M: m u l t i p o l a r  m o r p h o l o g y
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FIGURE 15. Onset of fusion.in a 2-day culture of human foetal 
muscle. Cells of both bipolar and m ultipolar
morphologies are seen to exhibit apparent contact. 
Seeded at 5x10^ cells/ml.
FIGURE 16,
Apparent contact between mononucleated cells in a 3-day culture of 
human foetal muscle. In (a) long processes extending from one cell 
toward another can be seen, with some of the processes actually in 
contact with each other. Multiple cell fusions can be seen, such as 
that running from top right to bottom left of the field involving at 
least 6 cells. At higher power -(b)- it can be seen that cells of all 




FIGURE 17. Appearance of myotubes at day 14 in a culture of
5human foetal muscle. Seeded at 5x10 /ml.
FIGURE 18. Arrangement of nuclei in myotubes of a 14-day culture 








FIGURE 19. An extensively branched myotube in a 14-day culture 
of human foetal muscle.
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of cultures (Table 10). Vincristine caused extensive cell death, 
with most cells "rounding up" and detaching from the substratum.
Both adriamycin and cytosine arabinoside were successful in reducing 
the fibroblast density of cultures when added at day 3 (Figure 20c,d). 
However, due to the relatively long time-scale of myotube formation,
, many myoblasts were also killed, resulting in little enrichment of 
the cultures. When the drugs were added later than day 3 (to allow 
more extensive myoblast fusion) they were ineffective in checking 
fibroblast growth. Because of this cytotoxic drugs were not routine­
ly employed in the preparation of human myotube cultures.
Cultures grown in medium containing 10% donor horse serum had 
much less fibroblastic contamination, and myotube formation was 
extensive (Figure 20e,f).
Effect of media formulation on growth of myotube cultures: The
various media, and supplements used in the cultivation of human foetal 
myotube cultures are detailed in Table 11. Changing the medium had 
little effect on culture growth, and medium 199 was chosen for routine 
preparation of myotube cultures and studies of myolysis. The presence 
of 2.5% chick embryo extract was found to be toxic to human myotube • 
cultures. As has already been stated, the addition of horse serum 
resulted in least fibroblastic contamination of the cultures.
Effect of initial plating density on growth of myotube cultures
4 6The initial plating density ranged from 1 x 10 - 2 x 10
cells/culture dish. At 1 x 10^ cells/dish or less no growth or 
fusion occurred. Myotube formation occurred at all concentrations 
greater than this, with optimal growth and differentiation occurring 
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FIGURE 20.
(a) 10-day culture of human foetal muscle grown in medium containing 
foetal calf serum. The culture is completely overgrown by
' mononuclear cells,
(b) A similar culture to (a) after preplating of the dissociated 
cell suspension according to the procedure of Yaffe (1968), No 
reduction in the mononuclear cell contamination was achieved,
(c) 10-day culture of human foetal muscle after previous exposure to 
adriamycin. The drug has killed both myoblastic and fibroblastic 
cells, resulting in a low density mixed culture. Subsequent 
regrowth resulted in overgrowth as in (a).
(d) 10-day culture of human foetal muscle after previous exposure 
to cytosine arabinoside. Some selective kill of mononuclear
cells has occurred, resulting in a culture enriched in myotubes. 
Remaining mononuclear cells however , regrew and myotubes were 
arrested at an early stage of maturation,
(e) 10-day culture of human foetal muscle grown in medium containing 
horse serum. Selective inhibition of mononuclear cell, growth has 
occurred, resulting in a relatively pure population of myotubes.
(f) The same culture as (e) shown at 14 days. The small 







TABLE 11. Media and medium supplements used in the preparation 








10% foetal calf serum ; 10% horse serum
10% foetal calf serum + 2% chick embryo
extract
10% foetal calf serum 
10% horse serum
120.
Preparation of AChR from Torpedo marmorata
Table 12 shows a typical purification scheme for AChR from 
frozen Torpedo electric organ. The specific activity of the purified 
AChR ranged from 2 - 1 0  nmoles toxin binding sites/mg protein (7 
preparations). The purity and subunit composition of the final AChR 
preparation was assessed by SDS polyacrylamide gel electrophoresis 
under reducing conditions. The gel pattern obtained (Figure 21) was 
similar to those in previous reports of purified Torpedo AChR 
(Barnard et al., 1979; Lindstrom et al., 1979; Raftery et al., 1979), 
with four major bands at 40000, 50000, 57000 and 64000 daltons.
125Preparation and characterisation of I -Ot»BGT
125Figure 22 shows a typical elution profile of I -ok-BGT from
125Sephadex G 25. The ratio of o(-BGT to I in the reaction mixture
125 'was approximately 3 to 1, and incorporation of the total I added 
to the reaction vessel into o(-BGT averaged 91 - 3% (mean - S.D., 
n = 10 determinations). The specific activity of the labelled toxin 
was 7 3 3 - 8  Ci/ mmol (n = 10). The biological activity of the 
labelled o(-BGT was calculated by using the formula
125 125Biological activity = Total I bound - I bound in blank x 100%
125Total I added
125A filter blank which contained buffer and I -Ol-BGT but
without AChR retained 4.6 - 0.9% (n = 4) of the total radioactivity
125added to the assay sample. The biological activity of the I - 
C1-.BGT was 56 - 5% (n = 5) with a range of 41 - 75%. It was found that 
72 - 1% (n = 5) of the total radioactivity in the labelled toxin was 
precipitated by 6% (w/v) trichloroacetic acid.
The iodinated oc-BGT was separated into mono - and di-iodinated
121.
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FIGURE 21. An SDS polyacrylamide electrophoresis gel of purified 








species by the method of Vogel et al. (1972). Figure 23a shows the
elution profile from CM-Sephadex C 50 of a typical, routine preparat- 
125ion of I -d —BGT. The major peak (Peak IV) , containing 69% of the
bound radioactivity, was considered from its elution position to be
mono-iodo o(-BGT (Vogel et al., 1972). Peak III was similarly taken
to contain di-iodo toxin. The molar ratio of mono - to di-iodo
d(-BGT in the preparation was calculated to be approximately 6.4:1,
125Peak II may represent aggregated I -OC-BGT (Jailkhani et al., 1984),
125while peak I consisted of either I non-covalently associated with
125o(-BGT or completely denatured I -d  —BGT (see below). The recovery 
of radioactivity from the ion-exchange column was close to 1 0 0 %.
For preparation of mono - and di-iodo CX-BGT the iodination pro­
cedure was performed with 100 ̂ g of <x-BGT. The elution profile of 
125this I - cX-BGT preparation from CM-Sephadex C 50 is shown in 
Figure 23b. The ratio of mono - to di-iodo toxin was 1.6:1. The 
increased proportion of di-iodo oC-BGT probably resulted from a higher 
concentration of chloramine - T in the scaled up iodination reaction 
(1.67 mg/ml compared with 1 mg/ml in the routine preparation).
Three fractions were collected from the column eluate (Figure 
23b). Fractions 2 and 3 were considered to be di - and mono-iodo 
t/-BGT respectively. The concentration of iodinated toxin in the two 
peaks was calculated by using the parameters shown in Table 13. By 
these means a concentration of 62 praol/ml was calculated for di-iodo 
toxin, and 116 pmol/ml for mono-iodo toxin.
The three fractions were further characterised by binding to 
Torpedo AChR. A maximum of only 10% of fraction 1 was bound to AChR, 
suggesting that it consisted largely of non-covalently associated 
^^^I, or denatured and biologically inactive ^I -(X—BGT. Excess
124.













TABLE 13. Parameters used in calculating the concentration of mono- 
and di-iodo Qkr bungarotoxin eluted from CM-Sephadex C50.
125Specific activity of Na I 2320
(mCi/jjatom I)
D.p.m./^Ci radioactivity 2.2xicf
.*. D.p.m./^iatom I 5.1x10^2
Efficiency of %-counter 60%
Atoms l/molecule of = 2 (di-iodo toxin)
cX- bungarotoxin 1 (mono-iodo toxin)
126 













125FIGURE 23b. Fractionation of I-d- bungarotoxin (lOÔ g) on 
CM - Sephadex C50.
The dashed line shows the probable elution position of unlabelled 














AChR bound a maximum of 6 8 % of fraction 2, and 80% of fraction 3,
125while 53% of an aliquot of the I -OC.--BGT taken prior to fraction­
ation was bound to the receptor.
Co-chromatography of unlabelled ot-BGT and mono-iodo <X.-BGT from
CM-Sephadex has been reported (Blanchard et al., 1979), and therefore
an experiment was designed to determine whether either fraction 2 or
3 also contained unlabelled toxin. This was done by determining the
concentration of a preparation of Torpedo AChR by binding of serial
125dilutions of AChR to unfractionated I - oC-BGT, or mono -, or di- 
iodinated oC-BGT. Table 14 shows the results obtained, basing the 
receptor concentration calculation on the concentration of mono - or 
di-iodo toxin previously calculated. The results show that mono-iodo 
oc-BGT seriously underestimated the AChR concentration, compared with 
both unfractionated and di-iodo toxin, implying the presence of 
unlabelled oc-BGT co-chromatographing with this fraction in an 
approximately equal concentration with the labelled toxin. The prob­
able elution position of unlabelled oC-BGT from the ion-exchange column 
is, therefore, also shown in Figure 23b. To confirm further that the 
di-iodo Ü-BGT fraction was free of unlabelled toxin, the di-iodo toxin 
was mixed with a theoretically equal amount of unlabelled toxin, and 
this mixture was then bound to the receptor. Under these conditions, 
double the amount of AChR was required to bind the same percentage of 
excess Ok-BGT from the toxin mixture than with the pure di-iodo 
fraction, indicating again that the di-iodo toxin contained no 
unlabelled OC-BGT.
The saturation binding of di-iodo oC-BGT to AChR on chick myo-
125tube cultures was also compared with that of unfractionated I - 
oC-BGT. A mean of 93 fmol per culture dish of unfractionated toxin
129.
TABLE 14. Torpedo AChR concentration calculated by binding to 
mono- and di-iodinated Ok- bungarotoxin.
<X- bungarotoxin preparation AChR concentration 
(pmol/ml)





(n = 3 experiments on triplicate cultures) were bound to the myotubes, 
compared with 92 fmol of di-iodo ok-BGT (n = 3) .
125I - o(-BGT binding to AChR
125A typical binding curve of I - OC-BGT binding to purified
Torpedo AChR is shown in Figure 24. AChR concentration was determined
from the linear portion of the binding curve, where toxin was in excess
over receptor. The calculation of AChR concentration assumed total
recovery of o(-BGT from the iodination procedure. No correction for
125the biological activity of the I - ok-BGT has been made in the cal­
culation of AChR concentrations quoted in this thesis.
125The specific binding of I - ck-BGT to chick myotube cultures
is shown in Figure 25. The for the binding was calculated,from the 
125I - ok-BGT concentration giving half maximal binding,to be approxi-
-9 125mately 2.5 x 10 M. For routine determinations of I -ok—BGT bind­
ing capacity of myotube cultures, the toxin was used at a final con­
centration in excess of 10 nM.
125A typical concentration curve for the specific binding of I -
Ok-BGT to human myotubes is shown in Figure 26. The binding at
saturation was much less than that to chick myotube cultures. The
-9was calculated to be 6.5 x 10 M. Of note also was the high con-
-3centration of décaméthonium bromide (10 M) necessary to prevent 
oc-BGT binding, and allow a measure of non-specific toxin binding.
125Inhibition of I -Ok-BGT binding to chick muscle AChR by
Concanavalin A
125Concanavalin A inhibited I - 0 (-BGT binding to chick myotubes 
by a maximum of 63% at concentrations of up to 1 mg/ml (Figure 27).
131.














FIGURE 25. The specific binding of 125I- 01 - bungarotoxin (BGT)
to chick embryonic myotubes.
E a ch p o i n t  r e p r e s e n t s  the m e a n  ± s.e.m. o f  th re e s e p a r a t e  
d e t e r m i n a t i o n s  on t r i p l i c a t e  c u l t u r e s  o f  m y o t u b e s  at 6 - 8 days in 










"^^^ I-oc-B G T  concentra tion  ( nM )
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125.FIGURE 26. The specific binding of I-ûi- bungarotoxin (BGT) 
to human foetal muscle cells in culture.
E a c h  p o i n t  r e p r e s e n t s  the m e a n  o f  t w o  s e p a r a t e  d e t e r m i n a t i o n s  on 
d u p l i c a t e  c u l t u r e s  o f  m y o t u b e s  g r o w n  f o r  14 days in 199 m e d i u m ,  
c o n t a i n i n g  1 0 %  d o n o r  h o r s e  serum.
The a m o u n t  o f  a - B G T  b o u n d  at s a t u r a t i o n  was v e r y  s i m i l a r  to that 
s h o w n  by F r a n k l i n  et al (1 980) for a d u l t  h u m a n  m u s c l e  in c u l t u r e  











FIGURE 27. Inhibition by Concanavalin A of the specific binding







Concanavalin A (m g/m l)
10
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Preparation of Ffab*)^ and Fab fragments
The titre of anti - (Torpedo AChR) antibody in the sheep anti-
serum used in this thesis was approximately 30 (expressed as moles 
125I - o( — BGT binding sites precipitated per litre of serum). The 
antiserum gave a single precipitin line in immunodiffusion and rocket 
electrophoresis with purified AChR from Torpedo marmorata (Barkas ejb 
al., 1978).
F (ab^)̂  were prepared from IgG by peptic digestion, and separated 
from undigested IgG, Fab fragments and smaller peptides by gel fil­
tration on Ultrogel ACA 34. Figure 28 shows a typical elution profile 
of pepsin - digested IgG from ACA 34. The profile was similar for 
non-iramune or immune IgG, with the relative proportions of Ffab^lg 
and Fab varying from preparation to preparation. F(ab^)  ̂was, however, 
always predominant. A relatively pure preparation of F(ab' ) 2 was 
achieved by collecting only the central portion of the F(ab^ ) 2 peeik 
(Figure 28).
The purity of F(ab' ) 2 and Fab fragments was assessed by SDS 
polyacrylamide gel electrophoresis under non-reducing conditions. A 
typical gel profile is shown in Figure 29. Both immune and non-immune 
Fab (slots 1 and 2) showed a single major band at 50000 daltons.
Immune and non-immune F(ab* ) 2 (slots 3 and 4) ran as a single major 
band at lOOOOO daltons.
Affinity purification of F (ab' ) 2 fragments
The affinity column used for purification of anti-AChR F(ab 
fragments consisted of Torpedo AChR bound to o(-BGT, which was itself 
covalently attached to a Sepharose 4 B solid support. This avoided 
any distortion or shielding of antigenic sites on the receptor which
136.














FIGURE 29. An SDS polyacrylamide electrophoresis gel of Fab and
F(ab > 2 fragments from sheep IgG.
Track 1 . Immune Fab
Track 2 . Non-immune Fab
Track 3. Immune FCab^)^






m i g h t  a r i s e  f r o m  c o v a l e n t  c o u p l i n g  o f  the A C h R  to S e p h a r o s e  4 B  ( S c h w a r t z
et a l ., 1979). A f t e r  i n c u b a t i o n  o f  the a f f i n i t y  gel w i t h  i m m u n e
F ( a b ' > 2 , m o s t  o f  the F ( a b ' > 2  p r e p a r a t i o n  was e l u t e d  in the v o i d
v o l u m e  ( n o n - b o u n d  f r a c t i o n ) .  A c o n s i s t e n t  5% o f  the F ( a b ' ) 2  f r a g m e n t s
r e m a i n e d  b o u n d  to the co lu mn. T h e s e  w e r e  c o n s i d e r e d  to be the s p e c i f i c
a n t i - T o r p e d o  A C h R  a n t i b o d y  f r a g m e n t s  w i t h i n  the im mu ne F ( a b ' ) 2
p r e p a r a t i o n ,  an d  a va lu e o f  5 %  o f  the total F ( a b ' ) 2  c o n c e n t r a t i o n  was
c o n s e q u e n t l y  u s e d  in c a l c u l a t i n g  the "free F ( a b ' ) 2 " c o n c e n t r a t i o n  in
the S c a t c h a r d  a n a l y s i s  o f  s p e c i f i c  F ( a b ' ) 2  b i n d i n g  to b o th T o r p e d o  A C h R
and c h i c k  m y o t u b e  A C h R  ( F i g u r e s  38 a n d 42) and the b i n d i n g  a n a l y s i s  o f
the i n h i b i t i o n  o f  a - B G T  b i n d i n g  by F X a b ' ) .  f r a g m e n t s  ( F i g u r e  35). The
1  ̂a f f i n i t y - b o u n d  F(ab F r a g m e n t s  w e r e  e l u t e d  f r o m  the c o l u m n  w i t h  0.2
M a m m o n i u m  h y d r o x i d e ,  f o l l o w i n g  the m e t h o d  o f  M a r t i n e z  et al (1977).
These e l u t i o n  c o n d i t i o n s  w e r e  c h o s e n  in s t e a d  o f  the m o r e  c o n v e n t i o n a l l y
used a c i d i c  c o n d i t i o n s  ( H u d s o n  and Hay, 1976) b e c a u s e  o f  the s e n s i t i v i t y
of T o r p e d o  A C h R  to acid pH ( S a i t o h  et a l ., 1979; W o n n a c o t t  et a l .,
1980a). The a m m o n i u m  h y d r o x i d e - e l u t e d  F ( a b ' ) 2  was q u i c k l y  b r o u g h t  to
neutral pH by gel f i l t r a t i o n  in o r d e r  to p r e v e n t  d é n a t u r a t i o n .
125P r e p a r a t i o n  o f — I - F ( a b ' ) 2  and Fab f r a g m e n t s
E a r l y  a t t e m p t s  to r a d i o - i o d i n a t e  F ( a b ' ) 2  f r a g m e n t s  w e r e  p e r f o r m e d
in 0.1 M Tris bu ffer, pH 8 . 0  c o n t a i n i n g  0 . 1 5  M NaCl, and p r o d u c e d  the
type o f  e l u t i o n  p r o f i l e  f r o m  S e p h a d e x  G 50 sh ow n in F i g u r e  30. The 
125i n c o r p o r a t i o n  o f  I i n to p r o t e i n  a v e r a g e d  o n l y  3 4 %  (n = 2).
In an a t t e m p t  to i n c r e a s e  this i n c o r p o r a t i o n  F ( a b ' ) 2  was
t r a n s f e r r e d  i n to 0.1 M p h o s p h a t e  bu f f e r ,  pH 7. 0  by d i a l y s i s  p r i o r  to the
i o d i n a t i o n  r e a c t i o n .  The e l u t i o n  p r o f i l e s  o f  im m u n e  and n o n - i m m u n e
F ( a b ' ) 2  f r o m  S e p h a d e x  G 50 f o l l o w i n g  i o d i n a t i o n  u n d e r  th e s e  c o n d i t i o n s
are sh o w n  in F i g u r e  31 a and b. Im m u n e  F ( a b ' > 2  was l a b e l l e d  to a
s p e c i f i c  a c t i v i t y  o f  27 ± 0 . 6  C i / m m o l  (n = 10), w i t h  81 ± 2 %  (n = 10)
125i n c o r p o r a t i o n  into p r o t e i n  o f  the total I a d d e d  to the r e a c t i o n
125vessel. N o n - i m m u n e  I - F ( a b ' ) 2  had a s p e c i f i c  a c t i v i t y  o f  28 ±
0.3 C i / m m o l  (n = 10), w i t h  84 ± 0 . 9 %  (n = 10) i n c o r p o r a t i o n  o f  ^^^I 
into p r o t e i n .
T y pical e l u t i o n  p r o f i l e s  f r o m  S e p h a d e x  G 50 for i m m u n e  an d  non-
139.
FIGURE 30. Gel filtration of immune on Sephadex G50





















































immune Fab fragments, iodinated in 0.1 M phosphate buffer, pH 7.0, are
shown in Figure 32 a and b. The protein peak was generally broader
than that obtained with F (ab ̂)2 ' Immune Fab was labelled to a specific
activity of 13.6 - 0.1 Ci/mmol (n = 3), with 81 - 1.2% incorporation 
125of I into protein. Non-immune Fab was labelled to a specific
activity of 14.0 - 0.1 Ci/ mmol (n = 3), with 84 - 0.6% (n = 3)
125incorporation of I into protein.
125 /Inhibition of I - c<-BGT binding to AChR by F (ab ) ̂ and Fab
fragments
125The inhibition of binding of I -o( — BGT to purified Torpedo 
AChR by pre-incubation with immune or non-immune FCab^)^ and Fab
fragments is shown in Figure 33. The corresponding inhibition of
125 fI -o^-BGT binding to chick myotube cultures by F (ab )  ̂and Fab
fragments is shown in Figure 34. The binding of the inhibitory immune
Ftab^ïg and Fab fragments in the two systems was analysed by use of
the Hill equation (Figure 35). The degree of inhibition of toxin
binding was used as a measure of the fractional saturation of the IgG
fragments to AChR, taking Bmax to be the maximum inhibition observed.
/The X  - axis represents log^^ of specific anti - (Torpedo AChR) F(ab )^
or Fab, and was calculated as being 5% of the total F (ab^^ or Fab pre­
incubated with receptor (see affinity purification of F(ab^)  ̂above). 
The values of n and K obtained from this analysis are given in Table 
15.
AChR turnover from chick myotubes in culture
AChR turnover from chick myotubes was measured by loss of speci- 
125fically bound I -Ca(-BGT into the incubation medium, both in the 
presence and absence of immune F (ab )  ̂fragments. Figure 36 shows
143.
125.FIGURE 33. The inhibition of specific I-oC~ bungarotoxin
binding to Torpedo marmorata AChR by Fab and F(ab* > 2  
fragments.
O Non-immune Fab 
® Immune Fab 








125.FIGURE 34. The inhibition of specific I- (X- bungarotoxin









F(ab' >2 or Fab (juM-25
125FIGURE 35. Hill plots for the inhibition of I-OC- bungarotoxin 
binding to AChR by immune Fab and F (ab')̂  fragments.
s h o w n  in F i g u r e s  33 a n d  34.
In each case:
125B = The percentage inhibition of I- bungarotoxin binding
125B = The maximum inhibition of I-M- bungarotoxin binding max
[x] = The concentration of specific anti-Torpedo AChR fragments,
calculated as 5% of the total immune Fab or Ffab'lg preparation
a d d e d  ( x - a x i s  in F i g u r e s  33 and 34), b a s e d  on the p e r c e n t a g e  of 
i m m u n e  F ( a b ' > 2  w h i c h  b o u n d  to an a f f i n i t y  c o l u m n  o f  
t o x i n - c o n j u g a t e d  T o r p e d o  A C h R  ( R e s u l t s  p . 138)
(a) I n h i b i t i o n  o f  toxin b i n d i n g  to T o r p e d o  A C h R  by Fab.
(b) I n h i b i t i o n  o f  toxin b i n d i n g  to T o r p e d o  A C h R  by FX ab')^.
(c) I n h i b i t i o n  o f  toxin b i n d i n g  to c h i c k  e m b r y o n i c  m y o t u b e s  
by F(ab' )̂ .
145.
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TABLE 15. Values of the dissociation constant (K̂ ) and Hill 
coefficient (n) for the oç- bungarotoxin blocking 
population of antibody fragments derived from sheep 
anti-AChR antiserum.
Antibody fragment Antigen 5) n
Fab Purified Torpedo AChR - 81.4x10 M 1
F(ab^ ) 2 Purified Torpedo AChR - 8  3x10 M 0.85
F(ab' > 2 Chick myotube AChR 5xl0”^M 0.9
The v a l u e s  o f  and n w e re c a l c u l a t e d  f r o m  the Hill pl ot s sh o w n
in F i g u r e  35, by use o f  the Hill e q u a t i o n  ( M e t h o d s  p 90)
147.
FIGURE 36. Effects of immune F ( a b 2 on the degradation rate of 
the AChR in cultured chick embryonic myotubes.
■ AChR degradation in the absence of Ffab'ig at 4°C.
O AChR degradation in the presence of FCab')^ at 4°C.
A  AC.hR degradation in the absence of FCab')^ at 37°C.














that at 4 C loss of bound -cX-BGT was negligible, whether
F (ab ) 2 was present or not. AChR loss from the myotubes at 37^C in 
the absence of F(ab' ) 2 was much greater than at 4°C, illustrating the
strict temperature dependence of AChR degradation. The presence of
I 125immune F (ab fragments significantly increased the loss of I -
o(-BGT from the myotubes at 37°C.
125 II - F (ab ) 2 binding to Torpedo AChR
- F(ab' ) 2 binding to Torpedo AChR was measured by a DEAE - 
cellulose filter assay. The binding of non-immune F ( a b g was mini­
mal (Figure 37 a and b) , being always <0.2% of the total added 
radioactivity. Figure 37a shows the binding of - Ftab'jg
fragments to increasing concentrations of Torpedo AChR. The bound 
radioactivity at saturation represented a meein of 5 .6 %  of the total 
added radioactivity, and indicates that all of the anti - (Torpedo 
AChR) antibody fragments in the F(ab' ) 2 preparation (see affinity 
purification of F (ab')2 ) were bound by an excess of AChR. The binding 
of increasing - F(ab' ) 2 to a fixed concentration of receptor
was both specific and saturable (Figure 37b). Scatchard analysis of 
this binding curve (Figure 3 8 )  indicated apparent homogeneity in the 
binding affinity of - F(ab' ) 2 to the purified AChR.
2.5 X  10 M̂.
The value of was calculated to be
The binding of - F(ab' ) 2 to Torpedo AChR was inhibited by
up to 90% following pre-incubation of receptor with the unlabelled 
parent immune F (ab' ) 2 or affinity - purified immune F(ab' ) 2  fragments, 
while both non-immune F(ab' ) 2 fragments, and the non-bound fraction
FIGURE 37. The binding of I-F(ab to Torpedo marmorata AChR.
Immune F(ab*)^
□ Non-immune F (ab' ) 2
A; B i n d i n g  o f  a f i x e d  a m o u n t  o f  ^ ^ ^ I - F ( a b > 2  (25 pmol) to 
i n c r e a s i n g  a m o u n t s  o f  T o r p e d o  AChR.
8: B i n d i n g  o f  a f i x e d  a m o u n t  o f  T o r p e d o  A C h R  (I pm ol) to i n c r e a s i n g
1c o n c e n t r a t i o n s  o f  I - F ( a b ) 2
B i n d i n g  was a s s a y e d  by a D E A E - c e l 1ul o s e  f i l t e r  d i sc a s s a y  as 
d e t a i l e d  in the M e t h o d s  ( p 8 9 ) . S p e c i f i c  b i n d i n g  was taken to be the 
b i n d i n g  o f  im mu ne F X a b ^ g  f r a g m e n t s ,  since the b i n d i n g  o f  
n o n - i m m u n e  f r a g m e n t s  was n e g l i g i b l e .  The r a d i o a c t i v i t y  b o u n d  to 
f i l t e r s  f r o m  b l a n k  s a m p l e s  c o n t a i n i n g  no A C h R  was s u b t r a c t e d  f r o m  
























FIGURE 38. Scatchard analysis of the specific binding of anti-
Torpedo AChR (cib * ) 2 to purified Torpedo
marmorata AChR.
The concentration of free (cib ̂ ) 2 was that of specific anti-
Torpedo AChR F(ab')2 , calculated as 5% of the total concentration
o f  the Immune 25 I - F ( a b  > 2  p r e p a r a t i o n  a d d e d  ( x - a x i s  in
F i g u r e  37b), b a s e d  on the p e r c e n t a g e  o f  im mu ne F ( a b ^ > 2  w h i c h  
b o u n d  to an a f f i n i t y  c o l u m n  o f  t o x i n - c o n j u g a t e d  T o r p e d o  A C h R  





^ ^ ^ l-F (a b *)2 bound (pmol)
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FIGURE 40. Inhibition of the specific binding of ^^^I-F(ab*), 
fragments to Torpedo marmorata AChR by unlabelled 
F(ab*)_ fractions.
Non-immune-’F Cab ) _ fragments
■ Parent immune FCab^ïg fragments
à Nonbound fraction from toxin-AChR affinity column 




Unlabelled F (ab ')g  ( juM )
V5
153.
from the toxin-receptor affinity column were without effect (Figure 40)
125 II - F (ab )  ̂binding to chick myotubes in culture
The binding of immune and non-immune - F(ab* ) 2 fragments to
chick embryo myotubes is shown in Figure 41. The binding of non-immune
F(ab' ) 2 was much greater in this system than that to purified Torpedo
AChR, probably due to non-specific, or low affinity binding to membrane
antigens on the surface of the myotubes, other than AChR. Specific
binding of anti-AChR F(ab* ) 2 was taken to be the difference between
binding of immune and non-immune F (ab 2 . This specific binding was
subjected to Scatchard analysis (Figure 42). Although the number of
data points is small, the plot indicates a relative homogeneity of
-7binding affinity. was calculated to be 1 x 10 M.
125I - Fab binding to chick myotube cultures
125The binding of immune and non-immune I - Fab fragments to
125myotube cultures is shown in Figure 43. The binding of I - Fab to
cultures was much more variable than that of - F (ab^)2 , with
saturable binding not always being achieved. Specific binding of 
125I - Fab was taken to be the difference in binding between immune 
125and non-immune I - Fab.
125 tInhibition of I - F (ab ) 2 binding to AChR by ol-BGT
Figure 45 shows that pre-incubation of purified Torpedo AChR
125 rwith an excess of unlabelled oC-BGT prior to I - F (ab binding 
reduced the specific binding of immune ^^^I - F(ah^)^ by an average 
of only 3.5%,
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FIGURE 41. The binding of to chick embryonic
myotubes.
■ Immune ^^^I-Ffab^jg 
O Non-immune ^^^I-FCab^)^
The dashed line indicates the specific binding of anti-AChR 
^^^I-FCab')^ , calculated as the difference between the binding 















FIGURE 42. Scatchard analysis of the specific binding of anti-
Torpedo AChR ^^^I-FCab'ig to chick embryonic myotubes.
125 IThe concentration of free I-F(ab )  ̂ is that of specific anti­
receptor F (ab' ) 2 r calculated as 5% of the total concentration of
the I m m u n e 125 I - F ( a b / ) 2  a d d e d  ( x - a x i s  in F i g u r e  41), b a s e d  on 
the p e r c e n t a g e  o f  i m m u n e  F ( a b ^ 2  w h i c h  b o u n d  to an a f f i n i t y  






) 2 4 6
125i_F{ab')2 bound (pm ol/m g ce l l  p ro te in )
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125.FIGURE 43. The binding of I-Fab fragments to chick embryonic
myotubes.
Q Non-immune I-Fab
■  -r 125.■ Immune
125.
I-Fab
The dashed line indicates the specific binding of anti-AChR Fab










FIGURE 45. The effect of o*-- bungarotoxin on the specific binding
of ^^^I-FCab'lg to Torpedo marmorata.
■ Binding in the absence of ot- bungarotoxin.












TABLE 16. Inhibition of specific binding to chick
embryonic myotubes byxik” bungarotoxin.
^^^I-F(ab')2
(pmol/dish)








125 JSpecific I - F(ab )̂  binding to AChR on chick myotube cult­
ures was likewise unaffected by pre-incubation of cultures with excess
cX-BGT (Table 16), with essentially no inhibition of binding at either
125subsaturating (1 nM) or saturating (2 nM) concentrations of I - 
F(ah^)^.
125 /Inhibition of I - F(ab )  ̂binding to chick myotube cultures by
Torpedo AChR
125 /Pre-incubation of I - F (ab )  ̂with purified Torpedo AChR
125 /reduced the specific binding of I - F (ab )  ̂to chick myotubes by
125 Iup to approximately 80% (Figure 46). The binding of I - F (ab
after pre-incubation with 10 mM phosphate buffer, pH 7.4 containing
0.1% (v/v) Triton XlOO was also determined. The final concentration
of Triton XlOO in the binding assay was always less than 0.01%, and
125 /this concentration had no significant effect on I - F(ab )  ̂binding 
to the cultures (Figure 46). Microscopic examination of the myotube 
cultures after exposure to 0.01% (v/v) Triton XlOO showed that no 
gross morphological damage to the myotubes had occurred during the 
binding procedure.
Effect of heat - inactivation on ^^^I - F(ab*)^ binding to AChR
The ol-BGT binding capacity of Torpedo AChR was almost totally 
abolished, with only 0.4% of the initial toxin binding capacity re­
maining, after 10 min exposure of the AChR at 60°C. In contrast the
125 /specific binding of I - F (ab )  ̂to purified Torpedo AChR was only 
reduced by approximately 40% after 30 min at 60 C (Figure 47).
The ability of Torpedo AChR exposed to a temperature of 60°C for
125 /30 min to inhibit specific I - F(ab binding to chick myotubes 
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untreated receptor (Figure 47).
125 fEffect of SDS - dénaturation on I - F (ab )  ̂binding to AChR
The specific binding of untreated (control) and SDS - denatured 
125 tTorpedo AChR to I - F(ab )̂  is shown in Figure 48. The SDS -
125 ytreated receptor bound approximately 35% as much immune I - F (ab )^
at saturation as control AChR.
125Pre-incubation of SDS - treated Torpedo AChR with I -
F(ab' ) 2 caused only 11% inhibition of specific F (ab^)  ̂binding to
125chick myotube cultures. Untreated AChR was pre-incubated with I - 
F(ab^ ) 2 in the presence of 0.05% (w/v) SDS (the residual SDS con­
centration in the denatured AChR preparation used) as a control, and 
caused an inhibition of - F(ab* ) 2 binding to the cultures of
67%. Thus the residual antigenic activity of the denatured AChR was 
approximately 16% of that for the untreated receptor.
125 IEffect of periodate - oxidation on AChR binding to I - F (ab ) ̂
125The binding of periodate - treated Torpedo AChR to I - 
F(ab' ) 2 was essentially the same as that of untreated receptor, with 
the specific binding at saturation of the modified AChR being approxi­
mately 94% of the control (Figure 49).
The effect Of periodate - oxidation on the ability of Torpedo
125 /AChR to inhibit specific I - F (ab binding to chick myotube
cultures is shown in Table 17. The treatment increased the ability
of the receptor to inhibit F(ab' ) 2 binding by 20%. The presence of
sodium metaperiodate also slightly increased the specific binding of 
125 II - F (ab ) 2 to the cultures, while the oxidation buffer and poly­
ethylene glycol had no effect on F(ab/ ) 2  binding, or its inhibition
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FIGURE 47. The effect of heat inactivation on the specific binding
of Torpedo marmorata AChR to I-Ffab'jg fragments.
□ Percentage of ^^^I-Ffab'lg binding to Torpedo AChR (0.2pmol)
remaining after heat inactivation of the receptor,
125■ Percentage of I-FCab'lg binding to Torpedo AChR (2pmol)
remaining after heat inactivation of the receptor,
125^ Percentage inhibition of specific I-Ftab'lg binding to
chick embryonic myotube cultures by heat inactivated Torpedo 
AChR.
125 Percentage of I- ok- bungarotoxin binding remaining after








FIGURE 48. Specific binding of SDS-denatured Torpedo marmorata













FIGURE 49. The effect of periodate-oxidation of Torpedo marmorata 
AChR on its specific binding to anti-AChR ( a b ,
■ Untreated AChR











TABLE 17. Effect of periodate oxidation on the ability of Torpedo 
AChR to inhibit the binding of ^^^I-FCab*)^ to chick 
embryonic myotubes.
Incubation Inhibition of specific ^^^I-F(ab* ) 2
binding to myotubes (%)
Unmodified Torpedo AChR 7 0 + 3
Torpedo AChR + periodate 9 0 + 1
(molar ratio *= 1:500)
*Torpedo AChR + buffer alone 73 + 2
^^^I-F(ab') 2 + buffer alone 0 + 1
^^^I-F(ab' ) 2 + periodate -13 + 3
(molar ratio = 1:500)
Controls indicating buffer alone included the addition of ethylene 
glycol to the reaction mixture.
167
by Torpedo AChR.
125 fEffect of glycosidase treatment on AChR binding to I - F (ab )^
Analysis of T. foetus - treated Torpedo AChR by gas liquid 
chromatography indicated a reduction in the carbohydrate content of 
the receptor of at least 50% (A, Clements, unpublished results). The 
binding of concanavalin A to the T. foetus - treated AChR was reduced 
by 70% (Wonnacott et al., 1980a).
Figure 50 shows that T. foetus treatment had little effect on
125 Ithe saturation binding of I - F (ab )  ̂to purified Torpedo AChR.
The binding assay was performed at 4°C to reduce the effect that any 
residual glycosidase activity in the treated receptor preparation 
might have had on F(ab^ ) 2 binding to the AChR.
Table 18 shows that T. foetus - treatment of Torpedo AChR did 
not impair its ability to inhibit specific - F (ab ̂ ) 2 binding to
chick myotubes. The binding assay was performed totally at 4°C to 
reduce the effect that residual glycosidase activity might have had on 
the assay. Table 18 shows that the presence of T. foetus extract at 
this temperature had no significant effect on F (ab^ ) 2 binding to the 
myotube cultures.
3-H  - C a r n i t i n e  u p t a k e  by c h i c k  m y o t u b e s  In c u l t u r e
In an in itial e x p e r i m e n t  10 r e p l i c a t e  7 - d a y  c u l t u r e s  o f  c h i c k  m y o t u b e s  
had t a k e n  up a n d r e t a i n e d  4 . 5 + 0 . 6 %  (mean + sd) o f  the initial - 
c a r n i t i n e  H-C) a d d e d  ( a p p r o x i m a t e l y  3 0 , 0 0 0  cpm) a f t e r  the 18h 
i n c u b a t i o n  e m p l o y e d  in l a b e l l i n g  m y o t u b e s  w i t h  ^H-C. O f  this, 39 + 5 %  
o f  the r e t a i n e d  c o u n t s  w e r e  lost d u r i n g  the f u r t h e r  5h i n c u b a t i o n  
e m p l o y e d  in the m y o l y s i s  as sa y. The m e a n  r e t e n t i o n  o f  ^ H - C  in all 
control c u l t u r e s  at the end o f  the m y o l y s i s  a s s a y  was 16900 c p m  (n = 21 
a s s a y s  o f  t r i p l i c a t e  c u l t u r e s ) .
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by Torpedo AChR.
125 /Effect of glycosidase treatment on AChR binding to I-F(ab )^
Analysis of T. foetus - treated Torpedo AChR by gas liquid 
chromatography indicated a reduction in the carbohydrate content of 
the receptor of at least 50% (A. Clements, unpublished results). The 
binding of concanavalin A to the T. foetus - treated AChR was reduced 
by 70% (Wonnacott et al., 1980a).
Figure 50 shows that T. foetus treatment had little effect on
125 /the saturation binding of I - F(ab )  ̂to purified Torpedo AChR.
The binding assay was performed at 4°C to reduce the effect that any 
residual glycosidase activity in the treated receptor preparation 
might have had on F(ab^)  ̂binding to the AChR.
Table 18 shows that T. foetus - treatment of Torpedo AChR did • 
not impair its ability to inhibit specific - F(ab* ) 2 binding to
chick myotubes. The binding assay was performed totally at 4°C to 
reduce the effect that residual glycosidase activity might have had on 
the assay. Table 18 shows that the presence of T. foetus extract at 
this temperature had no significant effect on F(ab^ 2  binding to the 
myotube cultures.
- H  - C a r n i t i n e  u p t a k e  by c h i c k  m y o t u b e s  In c u l t u r e
In an in itial e x p e r i m e n t  10 r e p l i c a t e  7 - d a y  c u l t u r e s  o f  c h i c k  m y o t u b e s  
had ta k e n  up a n d r e t a i n e d  4.5 + 0 . 6 %  (mean + sd) o f  the initial - 
c a r n i t i n e  (^ H-C) a d d e d  ( a p p r o x i m a t e l y  3 0 , 0 0 0  cpm) a f t e r  the 18h 
i n c u b a t i o n  e m p l o y e d  in l a b e l l i n g  m y o t u b e s  w i t h  ^H-C. O f  this, 39 + 5 %  
o f  the r e t a i n e d  c o u n t s  w e r e  lost d u r i n g  the f u r t h e r  5h i n c u b a t i o n  
e m p l o y e d  in the m y o l y s i s  assay. The m e a n  r e t e n t i o n  o f  ^ H - C  in all 
control c u l t u r e s  at the end o f  the m y o l y s i s  a s s a y  was 16 90 0 c p m  (n = 21 
as s a y s  o f  t r i p l i c a t e  c u l t u r e s ) .
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FIGURE 50. Specific binding of deglycosylated Torpedo marmorata
12 5AChR to anti-Torpedo AChR I-F{ab
Untreated AChR













TABLE 18. Effect of glycosidase treatment on the ability of Torpedo 
AChR to inhibit the binding of binding to
chick embryonic myotubes.
Incubation Inhibition of specific ^^^I-Ffab'lg 
binding to myotubes (%)
Unmodified Torpedo AChR. at 4°C 56 + 3
Unmodified Torpedo AChR at 37*̂ C 67 + 2
Torpedo AChR + T. foetus 57 + 1
extract at 4°C
Torpedo AChR + T. foetus 62 + 5
extract at 37°C
^^^I-F(ab')^ + T. foetus 2 + 8
extract alone
no.
L y s i s  o f  c h i c k  m y o t u b e s  by no rm al a n d  m y a s t h e n i c  s e r a  
Bo th no r m a l  c o n t r o l  and m y a s t h e n i c  s e r a  w e r e  h i g h l y  ly t i c  t o w a r d  c h i c k3m y o t u b e  c u l t u r e s ,  as d e t e r m i n e d  by the loss o f  H-C. Th e  m e a n  lysis 
c a u s e d  by 5 no rmal h u m a n  s e r a  ( 5 %  v/v) not p r e - a b s o r b e d  w i t h  c h i c k e n  
liver h o m o g e n a t e  was 5 8 %  ( r a n g e  = 43 - 79%). Ten m y a s t h e n i c  s e ra s h o w e d  
a m u c h  w i d e r  r a n g e  o f  m y o l y s i s  ( r a n g e  = 0 - 70%) w i t h  a m e a n  o f  3 5 %  ly si s
A b s o r p t i o n  o f  s e r a  w i t h  c h i c k e n  l i v e r  h o m o g e n a t e  
In an a t t e m p t  to r e d u c e  the lytic e f f e c t s  o f  no rm al h u m a n  s e r a  on c h i c k  
m y o t u b e s ,  s e r a  ( 1 - 5 ml) w e r e  a b s o r b e d  a g a i n s t  a c h i c k e n  l i v e r  h o m o g e n a t e  
p r i o r  to use in the m y o l y s i s  a s s a y .  The m y o l y s i s  o f  5 no rm al sera ( 5 %  
v/v) b e f o r e  a n d a f t e r  a b s o r p t i o n  is c o m p a r e d  in T a b l e  19. T h e r e  was a 
s i g n i f i c a n t  r e d u c t i o n  in the ly ti c e f f e c t s  o f  a b s o r b e d  s e r a  for 4 o u t  o f  
the 5 s e r a  t e st ed. The lysis o f  a b s o r b e d  no rm al s e ra at 2 . 5 %  v/v was 
a l w a y s  less than 10%, and this c o n c e n t r a t i o n  w a s t h e r e f o r e  c h o s e n  for 
c o m p a r i n g  the lytic e f f e c t s  o f  a b s o r b e d  normal n u m a n  and m y a s t h e n i c  sera.
Ly s i s  o f  c h i c k  m y o t u b e  c u l t u r e s  by a b s o r b e d  s e r a  
To c o m p a r e  the lysis o f  no rmal and m y a s t h e n i c  s e ra a f t e r  a b s o r p t i o n  w i t h  
c h i c k e n  li ve r h o m o g e n a t e ,  10 no rm al and 14 m y a s t h e n i c  s e r a  w e r e  t e s t e d  at 
2 . 5 %  (v/v). The r e s u l t s  o f  this s t u d y  are s h o w n  in T a b l e  20. Normal 
s e ra g a v e  a r a n g e  o f  m e a n  lysis f r o m  0- 6% , w i t h  an o v e r a l l  m e a n  for the 
co ntrol g r o u p  o f  3%. For the 14 m y a s t h e n i c  s e r a  the r a n g e  was g r e a t e r  
(0 -2 0 % ) ,  w i t h  an o v e r a l l  m e a n  o f  8%. The v a r i a t i o n  in ly si s f r o m  a s s a y  
to a s s a y  u s i n g  the same s e r u m  is i n d i c a t e d  by the s t a n d a r d  d e v i a t i o n  o f  
this m e a n  lysis, an d  was g r e a t e r  for normal s e r a  than f o r m y a s t h e n i c  s e r a  
( a v e r a g e  c o e f f i c i e n t  o f  v a r i a t i o n  (cov) 8 7 %  a n d 4 5 %  o f  the m e a n  
r e s p e c t i v e l y ) .  The v a r i a b i l i t y  in ^ H - C  r e t e n t i o n  w i t h i n  t r i p l i c a t e s  in 
the same a s s a y ,  was a l s o  h i g h e r  f o r  normal s e r a  t h an f o r m y a s t h e n i c  s e r a  
( a v e r a g e  cov 7 5 %  an d  4 5 %  o f  the m e a n  lysis r e s p e c t i v e l y ) .
T h e r e  was a s t a t i s t i c a l l y  s i g n i f i c a n t  d i f f e r e n c e  b e t w e e n  the lytic 
a c t i v i t y  o f  c o nt rol no rmal s e r a  a n d t h a t  o f  m y a s t h e n i c  s e r a  (p<0 .05 ,  
s t u d e n t ' s  test). Six o f  the 14 m y a s t h e n i c  s e r a  g a v e  ly ti c a c t i v i t y  
c l e a r l y  o u t i s d e  o f  the normal r a ng e, s u g g e s t i n g  t h a t  focal lysis o f  the 
m u s c l e  cell m e m b r a n e  m a y  be a s i g n i f i c a n t  c o n t r i b u t o r  in the p a t h o l o g y  o f  
m y a s t h e s i a  gr a v i s .  For the m y a s t h e n i c  sera t e s t e d  th e r e  was no 
c o r r e l a t i o n  b e t w e e n  the a n t i - A C h R  a n t i b o d y  t i t r e  a n d lytic a c t i v i t y  
(T a b l e  20; c o r r e l a t i o n  c o e f f i c i e n t  r = 0.04).
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TABLE 19. Lysis of chick embryonic myotubes by normal human sera 
before and after absorption against chicken liver 
homogenate.
Serum







1 43 67 -56
2 50 30 40
3 60 55 8
4 67 37 45
5 79 51 35
mean 60 48 14
Lysis was d e t e r m i n e d  by the r e t e n t i o n  o f  ^ - c a r n i t i n e  r e l a t i v e  to 
control c u l t u r e s  w i t h o u t  serum, and was c a l c u l a t e d  a c c o r d i n g  to the 
f o r m u l a  shown in the M e t h o d s  (p 95).
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FIGURE 51. Lysis of myotubes by normal human sera.
O Lysis of chick embryonic myotubes by serum absorbed against 
chicken liver homogenate.






Serum (% of incubation vo lum e)
Ly si s wa s  d e t e r m i n e d  by the r e t e n t i o n  o f  - c a r n i t i n e  r e l a t i v e  to 
co ntrol c u l t u r e s  w i t h o u t  serum, and was c a l c u l a t e d  a c c o r d i n g  to the 
f o r m u l a  sh ow n in the M e t h o d s  (p 95).
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TABLE 20. Lysis of chick embryo myotubes by normal and myasthenic 
sera absorbed against chicken liver homogenate.
Patient Diagnosis Anti-AChR antibody Lysis (%)
number -intitre (xlO M) mean ±8 d.
1 Normal control n.d. 0 + 4 ( 6 ) *
2 I I 0 + 2 (6)
3 I I  II 11 1 + 2 (12)
4 I I  I I II 2 + 3 (6)
5 I I  II II 3 + 4 (6)
6 II II II 4 + 3 (5)
7 I I  II II 5 + 2 (6)
8 II  II II 6 + 2 (6)
9 I I  II 11 6 + 2 (6)
10 II 6 + 3 (11)
11 Generalised M.G. 76 0 + 3 (5)
12 186 0 + 1 (2)
13 394 0 + 2 (7)
14 Ocular M.G. 28 2 + 3 (6)
15 Generalised M.G. 4 2 + 1 (2)
16 101 4 + 3 (5)
17 Ocular M.G. 11 4 + 3 (3)
18 2 7 + 4 (6)
19 Generalised M.G. 0 10 + 2 (6)
20 I I  I I 956 12 + 2 (6)
21 I I  1» 34 13 + 3 ( 6 )
22 11 II 31 16 + 4 ( 6 )
23 I I  II 0 18 + 2 (6)
24 11 II 6 20 + 2 (5)
n.d. ; not determined 
M.G. ; myasthenia gravis 
^ Figures in brackets indicate the number of determinations
L y s i s  w a s  d e t e r m i n e d  by i n c u b a t i o n  o f  6-8 d a y  m y o t u b e  c u l t u r e s  w i t h  
2 . 5 %  (v/v) s e r u m  in the ^ H - c a r n i t i n e  r e t e n t i o n  a s s a y  as d e t a i l e d  
in the M e t h o d s  (p 94). L y s i s  was c a l c u l a t e d  a c c o r d i n g  to the 
f o r m u l a  s h o w n  in the M e t h o d s  (p 95).
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E f f e c t s  o f  h e a t  i n a c t i v a t i o n  a n d c o m p l e m e n t  a c t i v i t y  on 
s e r u m - m e d i a t e d  lysis o f  c h i c k  m y o t u b e  c u l t u r e s  
A  s i n g l e  m y a s t h e n i c  s e r u m  ( p a t i e n t  22, T a b l e  20) was h e a t - i n a c t i v a t e d  by 
i n c u b a t i o n  at 5 6 ^ C  fo r  30 min. T o  t e s t  the e f f e c t s  o f  the 
h e a t - t r e a t m e n t  on the lytic a c t i v i t y  o f  the serum, a s a m p l e  of the 
h e a t - i n a c t i v a t e d  s e r u m  was c o m p a r e d  in the m y o l y s i s  a s s a y  (final 
c o n c e n t r a t i o n  2 . 5 %  v/v) with a s a m p l e  o f  the same s e r u m  t a k e n  p r i o r  to 
h e a t - t r e a t m e n t .  The u n t r e a t e d  s e r u m  had a lytic a c t i v i t y  o f  15%, w h i l e3the t r e a t e d  s e r u m  g a v e  no lysis, w i t h  H - C  r e t e n t i o n  e q u i v a l e n t  to t h at 
o f  co nt rol c u l t u r e s  w i t h o u t  serum. C o - i n c u b a t i o n  o f  g u i n e a  pig 
c o m p l e m e n t  ( M il es) at a final c o n c e n t r a t i o n  o f  1 0 %  v/v w i t h  the 
h e a t - i n a c t i v a t e d  serum, in the m y o l y s i s  a s s a y  r e s t o r e d  the m y o l y s i s  o f  
the s e r u m  to 5 %  ( 3 0 %  r e s t o r a t i o n  o f  the o r i g i n a l  a c t i v i t y  o f  the 
u n t r e a t e d  se ru m). S i n c e  normal h u m a n  s e r u m  was no t  s i m i l a r l y  t r e a t e d ,  it 
is not p o s s i b l e  to say w h e t h e r  this r e s t o r a t i o n  o f  ly si s w a s  s i g n i f i c a n t ,
or was d u e to the i n h e r e n t  v a r i a b i l i t y  o f  ^ H - C  r e t e n t i o n  in the
m y o l y s i s  assay.
S e r u m - m e d i a t e d  lysis o f  h u m a n  fo etal m y o t u b e  c u l t u r e s  
In a p r e l i m i n a r y  e x p e r i m e n t  the lytic a c t i v i t y  o f  o n e  no rm al h u m a n  s e r u m  
to w a r d  c h i c k  e m b r y o  m y o t u b e s  and hu m a n  foetal m y o t u b e s  was c o m p a r e d  at 
c o n c e n t r a t i o n s  o f  2. 5  - 10% v/v in the m y o l y s i s  a s s a y  ( F i g u r e  51). In 
c o n t r a s t  to the c o n c e n t r a t i o n  d e p e n d e n t  lysis o f  c h i c k  m y o t u b e s ,  e v en 
af t e r  a b s o r p t i o n  o f  the s e r u m  a g a i n s t  c h i c k e n  liver, the u n a b s o r b e d  s e r u m  
was t o t a l l y  d e v o i d  o f  lytic a c t i v i t y  t o w a r d s  h u m a n  fo et al m u s c l e  c u l t u r e s
The m y o l y s i s  o f  h u m a n  foetal m u s c l e  c u l t u r e s  by 3 no rm al a n d  6 m y a s t h e n i c  
sera ( 1 0 %  v/v) is s h o w n  in T a b l e  21. T h r e e  o f  the 6 m y a s t h e n i c  sera 
sh o w e d  m y o t o x i c i t y  g r e a t e r  than the m a x i m u m  lysis o b t a i n e d  w i t h  normal 
sera. The m e a n  ly s i s  o f  the n o rm al s e r u m  ( p a t i e n t s  1-3) a n d  m y a s t h e n i c
s e r u m  ( p a t i e n t s  4-9) g r o u p s  was 3 %  and 8 %  r e s p e c t i v e l y .  D u e to the small
n u m b e r  o f  s a m p l e s  t e s t e d  the d i f f e r e n c e  in lysis b e t w e e n  the normal 
s e r u m  g r o u p  and the m y a s t h e n i c  s e r u m  g r o u p  was not s t a t i s t i c a l l y  
s i g n i f i c a n t  ( T w o - s a m p l e  ranks test, p> 0.1). The c o e f f i c i e n t  of 
v a r i a t i o n  b e t w e e n  t r i p l i c a t e  c u l t u r e s  w i t h i n  the same a s s a y  was s i m i l a r  
for b o t h  no rmal a n d m y a s t h e n i c  sera, and a v e r a g e d  3 0 %  o v e r  all the 
sa m p l e s  te st ed.
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Diagnosis Anti-AChR antibody 
-10titre (xlO M)
* Lysis (%)
1 Normal control n.d. 0
2 n.d. 4
3 n.d. 5






n.d. ,* not determined.
* E a c h  v a l u e  r e p r e s e n t s  the m e a n  lysis f r o m  a s i n g l e  d e t e r m i n a t i o n  on 
t r i p l i c a t e  c u l t u r e s  o f  m y o t u b e s  at 14-21 d a y s  in v i t r o .
S e r a  w e r e  t e s t e d  f o r  lytic a c t i v i t y  at 10% v/v final c o n c e n t r a t i o n  
in the ^ H - c a r n i t i n e  r e t e n t i o n  assay. Lysis was c a l c u l a t e d  
a c c o r d i n g  to the f o r m u l a  s h o w n  in the M e t h o d s  s e c t i o n  (p 95).
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DISCUSSION
Establishment of muscle - cell cultures
The process of myogenesis (Figure 52) has been described in 
detail. The uninucleate cells that give rise to muscle fibres are 
myoblasts, and have been prepared from explants of embryonic muscle 
(Lewis and Lewis, 1917) or by treatment of embryonic muscle with 
enzymes (Rinaldini, 1959). Myoblasts prepared from adult muscle 
(Pogogeff and Murray, 1946) are probably derived from satellite cells 
(Mauro, 1961; Bischoff, 1975). The myoblast cells subsequently fuse 
to form multinucleated myotubes.
The establishment of myotube cultures from chick embryo skele­
tal muscle is well documented (for review see Haushka, 1972). When 
monodispersed muscle cell preparations are used, collagen coating 
of culture dishes has been found to be essential for good differenti­
ation in culture (Haushka and Konigsberg, 1966; O'Neill and Stockdale, 
1972). It seems likely that collagen does not provide any vital 
nutrients, but rather acts as a superior growth surface for the 
attachment and growth of cells (Cleator and Beswick, 1972). The 
growth medium commonly employed is a chemically "undefined" medium 
which has been found to give optimum growth and differentiation in 
culture (Yasuko et al., 1981). The presence of embryo extract is 
essential for myoblast fusion and myotube formation (De La Haba 
and Amundsen, 1972). A trophic protein (termed "sciatin") isolated 
from chicken sciatic nerve (Markelonis et al., 1980) was demonstrated 
to be the major component in chick embryo extract required for myo­
genesis (Oh and Markelonis, 1980). This trophic factor has now been 
shown to be identical to the serum protein, transferrin (Markelonis 
and Oh, 1983).
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FIGURE 52. A schematic representation of the process of 
myogenesis. (After Witkowski,1977).











Myoblast fusion in the cultures used in this study occurred 
approximately synchronously at about 50 h in vitro. This type of 
rapid burst of fusion has been previously noted by other authors 
(Morris and Cole, 1972; O'Neill and Stockdale, 1972). At fusion myo­
genic cells withdraw from the mitotic cycle, with cells due to enter 
S - phase remaining in G 1 instead, prior to undergoing fusion.
Nuclei in the myotubes formed do not synthesise DNA (Morris and Cole, 
1972) . Thus the rapidly - dividing fibroblasts present in cultures 
Ccin be killed by a cell cycle phase - specific DNA - synthesis 
inhibitor, such as cytosine arabinoside (Fischbach, 1972), with no 
apparent deleterious effect on myotube morphogenesis (Moss et al.,
1978) . Such treatment of the cultures in this study resulted in a 
relatively pure myotube population in culture.
Over the past 40 years a number of attempts have been made to 
grow human muscle cells in culture. Many of these have used adult 
human muscle, from amputation or biopsy, as a tissue source, and have 
mostly involved placing explants of chopped muscle into an environ­
ment containing growth media and growth substrates (for review see 
Witkowski, 1977). Cultures derived from single muscle cells or 
muscle cell pieces obtained by enzymic dissociation of adult muscle 
have also been established (Morgan and Cohen, 1974; Yasin et al., 
1977).
There have been few published reports of cultures derived from 
human foetal muscle (Kakulas et al., 1968; Haushka, 1974a,b; Emery 
and McGregor, 1977; Sevan et al., 1977; Cambridge and Stem, 1981). 
Haushka (1974a,b) used cloning techniques to determine the proportion 
of myogenic cells present in foetuses of different ages. Muscle cells 
were prepared by enzymic dissociation and plated at cloning densities.
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The percentage of clones containing myotubes and the plating efficiency 
both rose with increasing foetal age. Minguetti and Mair (1981) showed 
that human skeletal muscle development in vivo falls into two phases.
In the first phase from about 9 - 1 8  weeks the developing muscle con­
sisted mainly of myoblasts and myotubes. In the second phase from 18 
weeks onward the muscle was almost entirely fully developed muscle 
fibres.
In the present study myotube cultures were established from 
foetal muscle from 8 - 1 5  weeks. As found by Haushka there was an 
increase in plating efficiency with increasing foetal age (Tables 8 
and 9). Conversely, the cell yield was reduced from limbs of older 
foetuses.
Methods used to prepare cells for culture depend principally on 
the age of the donor. In general, explants are preferred for adult • 
tissue, while enzymatic or mechanical dissociation have been used with 
embryonic or neonatal tissue (Witkowski, 1977) . The method of mechani­
cal dissociation used in this study was based on that of Tepperman 
et al. (1975) for chick embryonic muscle. These authors found that 
trypsinisation yielded almost double the number of cells given by 
mechanical dissociation, and gave better cell survival. This finding 
is in broad qualitative agreement with the results of this study.
The much greater reduction in cell yield by mechanical dissociation 
of human foetal muscle in this study reflects the generally increased 
difficulty in disaggregating human tissue. The relatively long period 
of trypsinisation necessary to achieve good dissociation is a further 
confirmation of this fact. Haushka (1972) reviewed enzymic dissocia­
tion of normal embryonic skeletal muscle and showed that only trypsin 
and collagenase had been successfully used. In this study typsinisa- 
tion resulted in an overall greater cell yield and plating efficiency
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thcin treatment of the tissue with collagenase.
Although media for the growth of embryonic animal muscle are 
well established, a great variety have been used for human muscle 
cells (Witkowski et al., 1976). Human muscle cell cultures have been 
grown in medium 199, Eagle's minimum essential medium, Dulbecco's 
minimum essential medium. Ham's F10 and Puck's NCI. Clearly, minor 
variations in composition of the defined medium do not significantly . 
affect muscle cell growth and differentiation (for review see 
Witkowski, 1977), and this finding is confirmed by the present study. 
Human muscle cells do not have an obligatory requirement for chick 
embryo extract, and a number of studies have used media without this 
supplement (for review see Witkowski, 1977). In this study chick 
embryo extract was toxic to human muscle cell cultures, in keeping 
with the findings of Haushka (1972) and Skrbic et al. (1975). Both 
horse and foetal calf serum have been successfully used in media to 
grow human myotubes, although horse serum has been generally preferred 
(for review see Witkowski, 1977). Fibroblastic growth was greatly 
reduced in cultures grown in media containing horse serum in this 
study, although myotubes were generally not as well developed as 
those in cultures grown in media containing foetal calf serum.
Attempts to reduce the fibroblastic contamination of cultures grown in 
the presence of foetal calf serum by either "selective plating" 
according to the method of Yaffe (1968), or by use of cytotoxic drugs 
were unsuccessful, as has been previously found (Robertson, J.G. 
unpublished observation).
Cell cultures prepared from muscle are a heterogeneous populat­
ion of cells, and it may be difficult to distinguish myoblasts from 
fibroblasts (Willraer, 1965). Myogenic cells, however, are character­
ised by their ability to fuse, and the multinucleate myotube cam be
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unequivocably recognised as a muscle cell. Myotubes in this study
\
were defined as possessing at least three morphologically normal 
nuclei, as binucleate cells can arise in cultures of fibroblasts 
(Witkowski, 1977).
125I - oC— BGT as a probe for the AChR
In general, two methods, tritiation and radioiodination, have
been used to radiolabel the ligands used in binding studies. Tritium
labelling results, in most cases, in a labelled ligand which is
biologically indistinguishable from the native ligand. In addition,
the long radiochemical half-life of tritium (over 12 years) permits
extended storage with no loss of sensitivity due to radioactive decay.
However, the specific radioactivities obtained with tritium labelling
are much lower than can be achieved by radioiodination. For example,
one atom of ^^^I provides the same number of disintegrations per unit
131time as 600 atoms of tritium. Of the two isotopes of iodine, I
and ^^^I, ^^^I has a much shorter half-life (8 days compared to 60 
125 125days for I), and I has accordingly been the preferred isotope 
for radiolabelling. When attempts are made to achieve high specific 
activities however certain problems can arise which may lead to the 
labelled ligand exhibiting different behaviour from the parent com­
pound (Hunter, 1978; Schmidt, 1984). For this reason attention has
125been devoted to characterising the I - (X— BGT used in this study.
It has been shown that the native ol - BGT used for radioiodina­
tion was at least 98% pure (Barkas, T. unpublished observation).
The method of iodination used routinely was the chloramine - T
method initially devised by Hunter and Greenwood (1962) to produce a
125radioiodinated product of high specific radioactivity. The I -
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ot-BGT used in this study was labelled to a mean specific radioactivity
of 733 Ci/mmol., and had a mean biological activity of 56%. The
125remaining 44% of radioactivity probably consisted of both I non- 
covalently bound to toxin, and denatured labelled toxin. This fract­
ion was eluted unbound from an ion-exchange column designed to bind 
OC- BGT (Figure 2 3) and did not bind to Torpedo AChR. The ways in 
which proteins can be damaged during radioiodination with chloramine 
- T have been discussed by Hunter (1978). In an attempt to determine
the percentage of radioactivity corresponding to non-covalently 
125associated I, the labelled o(- BGT was precipitated with 6% (w/v)
trichloroacetic acid. However, the radioactivity precipitated from 
N - (propionyl - Ĥ) propionylated ot-BGT, which is 98% biologically 
active, using this method never exceeded more than approximately 70% 
(Stephenson, F.A. unpublished observation), and consequently this 
parameter had limited use in the assessment of non-covalently bound 
in the - (X-BGT preparation.
AChR concentrations determined with the high specific activity
125I - oC-BGT used routinely in this study may have been underestimated 
due to the reduced biological activity of the labelled toxin. ' Thus, 
correction of Torpedo AChR concentrations for 10O% biological activity 
resulted in values in good agreement with those obtained using the 98% 
biologically active N - (propionyl - Ĥ) propionylated oC- BGT 
(Stephenson, F.A. unpublished observation).
125The I - C/-BGT preparation consisted of a mixture of mono -
125and di - iodinated species, with mono-iodo (X-BGT ( - 0(-BGT)
predominating, together with a small fraction which was presumed to 
125be aggregated I - OL-BGT (Figure 23a). Chloramine - T iodination 
has been previously reported to cause aggregation of proteins (Krohn
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et al., 1972; Sherman et al., 1974) including c<-BGT (Jailkhani et al.,
1984). Further evidence for the presence of aggregated toxin is the
increased size of the peak attributed to it at a higher Chloramine - T
125concentration (Figure 23b). BGT and diiodo -oC-BGT
125( -oC-BGT) have been reported to differ in both the kinetics and
affinity of their binding to soluble and membrane-bound AChR (Vogel 
et al., 1972; Lukasiewicz et al., 1978; Blanchard et al., 1979; James
et al., 1980). For this reason, an attempt was made to prepare
125 125- and - CK-BGT, and to compare their binding to AChR.
125 - OC-BGT v/as found to partially co-chromatograph with unlabelled 
o(-BGT (see Results), as has been previously reported (Blanchard et al.,
1979; James et al., 1980). In this study there was no significant
difference in the binding at saturation, or of the concentration of
toxin necessary to achieve saturable binding,to chick muscle AChR,
between ^^^Ig - 0(-BGT and the unfractionated ^^^I - toxin preparation,
125although the rate of binding was not determined. I^ - 0(-BGT has
been shown to bind to Torpedo AChR with the same rate constant as
native toxin (James et al., 1980) indicating that monosubstitution 
125with I does not alter the binding properties of o(- BGT.
125Binding of I - Ol-BGT to myotube cultures
When muscle cultures from chick embryo are grown, oC- BGT 
binding activity remains at a very low level until some 55 - 60% of 
myoblasts have undergone fusion. AChR elaboration does not, however, 
depend on fusion per se, since postmitotic, fusion-arrested myoblasts 
also increase in o(-BGT binding activity (Patersen and Prives, 1973). 
Sytkowski et al. (1974) found that, in normal muscle cultures, toxin 
binding reached a plateau at 6 - 7 days after plating, and remained con­
stant at this level for at least 10 days in culture. These authors
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also found that, at day 5 in culture, AChR's were evenly distributed 
at a low density over the whole myotube surface. By day 7 discrete 
clusters of AChR were present on 1% of the myotubes, and by day 11 
more than 80% of the myotubes had one or more receptor clusters. On 
the basis of these findings, chick myotube cultures of 6 - 8 days in 
vitro were used in all the experiments reported in this thesis, in 
an attempt to have a relatively homogeneous population of AChR for 
study.
Chick myotubes in culture respond to agonists that normally 
activate nicotinic cholinergic receptors at the neuromuscular junction, 
but not to agonists that do not normally act on skeletal muscle. All 
of the nicotinic AChR stimulant drugs tested to date have produced a 
response. This includes décaméthonium, succinylcholine and pilocarpine 
(Harvey and Dryden, 1974. ). The response of cultured muscle to 
acetylcholine is blocked by the nicotinic antagonist, d - tubocurarine, 
at low concentrations, but by atropine only at concentrations of 100 - 
lOOO times the effective tubocurarine concentration (Dryden,1970).
Elson (1979) has noted that the pharmacological properties of early 
(10 day) embryonic chick AChR have not been fully characterised.
125In initial work to determine I -o(-BGT binding to chick myo­
tubes in this study, non-specific binding was measured in the presence
-4of d - tubocurarine (10 M final concentration). The maximum pro­
tection of toxin binding obtained was 75%. Décaméthonium bromide 
(10  ̂M final concentration) inhibited ^^^I - cx-BGT binding by an 
average of 87%, and was consequently used in preference to tubocura­
rine. The greater protection afforded by décaméthonium over 
tubocurarine has been previously reported in this system (Vogel et al., 
1972; Paterson and Prives, 1973).
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125After binding of I -Cd-BGT to myotube cultures, the labelled
cell monolayer has been suspended by mechanical methods (Patrick et
al., 1972), or by solubilisation with trypsin (Vogel et al., 1972;
Paterson and Prives, 1973) or NaOH (Elson, 1979). In this study the
most consistent results were obtained with NaOH suspension of the
125cells. A 60 min incubation with I - o(-BGT was performed to allow 
maximum binding of the toxin. A number of reports have shown that 
maximum binding is obtained in about 20 - 30 min (Vogel et al.,
1972; Patrick et al., 1972; Paterson and Prives, 1973), and a 60 min 
incubation time has been routinely used (Vogel et al., 1972; Sytkowski 
et al., 1974).
125The maximum specific binding of I - ol-BGT in this report was
relatively consistent from culture to culture (0.36 - 0.06 pmol/mg
cell protein; n = 10). The binding curve obtained was very similar to
that of Vogel et al. (1972) who used chick embryo muscle cultures at
12512 days in vitro. The of I - ot-BGT binding to chick myotubes
-9was calculated to be 2.5 x 10 M. This is of the same order as that
-9calculated from the study of Vogel et al. (1972) (1 - 2 x 10 M) and
-9the of high affinity sites (7.2 x 10 M) determined by Elson 
(1979).
Human myotube cultures have been shown to respond to ionto-
phoretic application of acetylcholine, but not to the muscarine
stimulant, acetyl - - methylcholine (Robertson, J.G. unpublished
observation). However,few reports of Ck- BGT binding to human muscle
125in culture have appeared. In this study the binding of I -Ot—BGT 
to human myotubes was much less, and of reduced affinity, compared to 
chick myotubes (Figures 25 and 48). In addition, the protection 
offered by décaméthonium was also considerably lower than- in the case
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of chick embryo muscle cultures (a 100 - fold excess concentration
125was necessary to block I - Ol — BGT binding significantly). Previous 
studies of human muscle in tissue culture have not obtained very 
mature fibres. For example, the frequency of occurrence of cross- 
striations eind spontaneous contractions, where reported, has not been 
high (Witkowski et al., 1976; Crain et al., 1970; Yasin et al., 1977). 
Cross-striations only appeared in adult human myotubes after a long 
period in culture (Pogogeff and Murray, 1946). In the dissociated 
cell cultures reported here, maintenance for more than 2 - 3  weeks 
was difficult because of three major problems: (1) Fibroblastic over­
growth of cultures, (2) Fungal contamination and (3) Autolysis of 
myotubes, so that the myotubes did not have sufficient time for 
extensive maturation. The low level of <X- BGT binding to the cult­
ures is therefore probably a reflection of the limited development of 
the myotubes in culture.
F (ab )  ̂and Fab binding to AChR
F(ab* ) 2 and Fab fragments of IgG were prepared from the sera of
both normal sheep (non-immune fragments), and of sheep immunised with
Torpedo AChR and exhibiting symptoms of EAMG (immune fragments).
Both immune and non-immune F(ab^ ) 2 and Fab chromatographed as single
molecular weight species in SDS - polyacrylamide gel electrophoresis,
indicating their purity through the separation procedure. The immune
F(ab' ) 2 fragments retained the ability of the original antiserum to
recognise and bind AChR. This was confirmed by their total inhibition
125of precipitation of I - labelled Torpedo AChR by rabbit antiserum 
to Torpedo receptor, while non-immune F (ab )  ̂fragments were without 
effect (Wonnacott et al., 1980a).
Both intact IgG and F (ab )  ̂fragments from anti-AChR antisera
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have been shown to cause increased degradation of AChR from the mem­
branes of cultured muscle cells (Heinemann et al., 1977; Prives et 
al., 1979; Patrick eind Berman, 1980). This phenomenon is known as 
"antigenic modulation". Immune F (ab S 2 fragments caused antigenic 
modulation of chick myotube cultures at 37°C (Figure 36), which was 
very similar to that described by Prives et al. (1979) for rabbit 
anti-AChR F{ab'ĵ  fragments. This further confirmed that the 
fragments were not functionally impaired by the purification 
procedure.
To study the direct binding of F(ab )  ̂and Fab fragments to
125unmodified AChR, the fragments were labelled with I by the method
of McConahey and Dixon (1966) , which was designed to cause minimum
functional damage to the protein labelled. Early attempts to
iodinate F (ab ̂ ^ fragments were performed in Tris/HCl buffer, pH 8.0,
125and resulted in a poor incorporation of I into tlie protein. This 
was probably because the pH in the iodination reaction rose above 8, 
where the efficiency of labelling falls off rapidly (Hunter, 1978).
Reduction of the pH by use of a phosphate buffer resulted in a much
125 /greater incorporation of I into the F(ab ) ^.
Immune ^^^I - F (ab^)  ̂fragments bound saturably to purified
125 ITorpedo AChR (Figure 37b) while non-immune I - F (ab )  ̂showed 
little binding above tliat of controls from which AChR was excluded. 
Excess of Torpedo AChR bound approximately 5% of the total immune 
^^^I - F(ab ̂ ) 2 added., corresponding to the fraction of the F(ab^ ) 2 
preparation representing specific anti-AChR antibody frag­
ments, as determined by affinity purification. This indicated no
impairment of function of the F(ab ) 2 fragments after labelling with
125 125 II. The specificity of immune I - F (ab binding to the
188.
receptor was confirmed by the almost complete inhibition of the bind­
ing given by unlabelled immune or affinity - purified Ffab^ig 
fragments. In contrast non-immune F{ab^)^ or the unbound fraction 
from the affinity column were without effect. The affinity purified 
Ffab'ig fragments maximally inhibited the binding of ^^^I - F ( a b g 
fragments to AChR at considerably lower protein concentrations than 
required for the parent fragments to achieve the same effect, and 
represented an approximately 6 - fold purification of the immuno- 
specific F(ab^)^ fragments. It is not clear why a higher purification 
was not obtained. One possibility is that some inactivation occurred
in the presence of 0.2 M NH^OH during elution from the affinity
125 (column. A Scatchard plot of I - F(ab binding to purified 
Torpedo AChR
-8gave an average intrinsic dissociation constant of 2.5 x 10 M, which 
is of the same order as tlie K^'s reported by Lindstrom et al. (1981) 
for mAb binding to isolated Torpedo AChR.
125 /In the present study immune I - F (ab )  ̂and Fab bound 
specifically to chick myotubes in culture. Non-specific, or non­
receptor binding to the myotubes was determined from the binding of 
125non-immune I - fragments. This was the only practical measure of
non-specific binding possible, because of the large concentration of 
125 /I - F(ab )̂  needed to achieve saturable binding, and the relatively 
long incubation time employed in the binding assay. Aarli (1970) 
reported that muscle-binding )(- globulins from normal human sera 
bound to the tissue only by the Fc portion of the molecule, and this 
was part of the rationale for using F(ab^ ) 2 fragments to determine
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binding to the AChR on chick myotubes. Nevertheless the binding of . 
125 /non-immune I - F(ab ) ̂ and Fab to the myotubes was considerable, 
although it was non-saturable.
A cross reactivity between the foreign immunizing AChR (from fish 
electric organ) and self muscle receptor is required for the induction 
of the autoimmune process in EAMG. It is thus important to study those 
antibodies that cross-react with muscle AChR (Souroujon et al., 1983). 
As expected, the cross reactivity between the anti - (Torpedo AChR) 
F(ab^ 2  fragments and chick myotube AChR was quite low. This is shown
by the stoichiometry of the reactants (amount of AChR; amount of
/ 125specific anti-AChR F (ab )̂ ) at saturation of the receptor with I -
F(ab')2 , which was approximately 2:1 for binding to purified Torpedo 
AChR but 1:100 for binding to myotube AChR, giving a cross reactivity 
of 0.5%, in keeping with the low levels of cross-reactivity reported 
previously (Lindstrom et al., 1978, 1979b; Vincent, 1980; Tzartos e^ 
al., 1981). This suggests substantial differences in the immunogenic 
properties of the two receptors. Differences in the antigenic deter­
minants between solubilised and membrane-bound AChR (Martinez-Carrion
et al., 1981) may also contribute to the lack of cross-reactivity.
125 tA Scatchard plot of specific I - F (ab binding to myotube cult-
-7ures showed a single class of binding sites with a of 1 x 10 M. 
This is again consistent with a limited cross-reactivity between anti­
body binding to Torpedo and chick muscle AChR, and is in keeping with 
the findings of Tzartos and Lindstrom (1981) and Tzartos et al. (1981) 
who found that most of a panel of mAbs to Torpedo AChR which were 
capable of cross reacting with AChRs from other species were directed 
at the "main immunogenic region" on the receptor.
In an attempt to develop a binding - inhibition assay which 
could be used in conjunction with AChR modification to probe the
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nature of the cross-reacting antigenic sites on chick myotube AChR,
125 tpurified Torpedo AChR was preincubated with I - F(ab )̂  fragments
prior to assaying binding of the F (ab )  ̂to chick myotube cultures.
Under these conditions binding was inhibited by a maximum of approxi-
125 #mately 80% and indicated clearly that I - F (ab )  ̂binding to the
myotubes was specifically directed at the AChR. One possible
explanation for the lack of complete inhibition is that a percentage
of the F(ab )  ̂molecules bound to the Torpedo AChR by one arm only,
leaving the other arm of the divalent molecule free to interact with
the myotube receptor. The 20% remaining F(ab^ 2  binding to myotube
cultures would then be a purely statistical function based on a random 
/binding of F (ab )  ̂to the available sites on the Torpedo receptor.
125I - Fab fragments bound much more variably and with a lower
125 taffinity to chick myotubes than I - F (ab )  ̂.
This is not surprising since the binding
affinity of Fab fragments to antigen is known to be generally signifi­
cantly lower than that of the parent immunoglobulin (Eisen, 1974).
The variability of binding may indicate a variable degree of damage 
to the protein during the purification and iodination procedure.
Interrelationship of the antigenic cind toxin binding sites of the AChR 
The interaction of an enzyme with a specific antibody usually 
leads to a reduction in enzyme activity (for review see Arnon, 1973).
This has its counterpart for the AChR in the direct blockade of 
cholinergic ligand binding to the receptor by anti-AChR antibodies. 
Such a blockade could be an important factor in the pathogenesis of 
myasthenia gravis, and would explain the curare-like neuromuscular 
block evident early in the course of the disease,before any structural
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damage at the synapse can be demonstrated. Changes in the levels of 
antibodies specific for the cholinergic binding site may also account 
for the rapidly occurring clinical exacerbations and remissions seen 
in myasthenia, and for the immediate improvement that occasionally 
follows a single plasmapheresis treatment.
Myasthenic sera have been shown to contain antibodies which 
inhibit ol - BGT binding to both solubilised and membrane-bound AChR 
(for review see Vincent, 1980). The percentage of myasthenic patients 
possessing such antibodies has been reported to range from O (Harvey 
et al., 1978) to 65% (Bradley et al., 1979). In a study of 12 
myasthenic sera, Whiting et al. (1983) found that anti - Ol-BGT site 
antibodies varied from o “ 33% of the total anti-AChR antibody popu­
lation, while Dwyer et al. (1979) reported 4 patients in which anti­
toxin site antibodies represented 51 - 100% of the total population. 
The presence of antibodies capable of blocking OL- BGT binding to the 
receptor in myasthenic patients has been shown to correlate with 
disease severity (Lefvert et al., 1981; Drachman et al., 1982).
Lefvert et al. (1981) showed that most patients exhibiting anti-toxin 
site antibody activity had disease in later stages (II B, III or IV) 
of the Osserman classification. These authors also found that anti-., 
bodies to the ligand binding site were mostly found in subclasses 1 
and 3. More recently, however Whiting et al. (1983) found that such 
antibodies were restricted to subclass 3 in only 2 of 12 patients.
The ability of anti-AChR antibodies in EAMG to inhibit toxin 
binding to the receptor has varied from O - 100% for membrane boqnd 
AChR (Lindstrom, 1977; Zum and Fulpius, 1977; Karlin et al., 1978; 
Eldefrawi, 1978) and from 25 - 100% for solubilised receptor (Zurn and 
Fulpius, 1977; Harvey et al., 1978; Claudio and Raftery, 1980; Penn 
et al., 1976; Aharonov, 1977; Wonnacott et al., 1980b).
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Most studies have shown an incomplete inhibition of toxin b i n d ­
ing to the AChR even in extreme antibody excess. T h i s  i s  a  c h a r a c t e r ­
istic feature of antibody - enzyme interactions (Cinader, 1953).
125Incomplete inhibition of I - 01-BGT binding to both purified 
Torpedo AChR and chick myotube AChR was also found in this study. The 
incomplete inhibition of toxin binding by anti-receptor antibodies has 
led some authors to postulate the existence of heterogeneity in the 
AChR population with respect to antigenic specificity (Mittag et al., 
1981a) but may also be explained as a simple statistical function 
resulting from random binding of a heterogeneous population of anti- 
AChR antibodies to the receptor. Thus the binding of one antibody 
molecule might sterically hinder or prevent the binding of a second 
antibody molecule overlying the toxin binding site (Figure 53).
Such a mechanism has also been proposed by James et al. (1983).
There are three mechanisms by which anti-AChR antibodies could 
inhibit toxin binding to the AChR. Firstly antibody molecules could 
directly compete with CX- BGT for the same site. Secondly, the anti­
body might bind at a site close to the toxin binding site and steric*- 
ally hinder the binding of the toxin molecule. Thirdly, antibody 
might bind at a site remote from the toxin binding site but alter the 
conformation of the receptor in such a way as to modify its toxin 
binding capacity,
125In this study I  - &-BGT binding to chick myotube AC hR  in situ 
could be inhibited by anti-AChR F (ab ̂) ̂ fragments but not by Fab frag­
ments. The lack of inhibition of toxin binding to membrane-bound AC hR  
by Fab fragments was also found by Claudio and Raftery (1980) and 
Martinez-Carrion et al. (1981), but is not due to an inability of Fab 
to bind to the AChR (Martinez-Carrion et al., 1981 and Figure 33).
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FIGURE 53. A schematic model for the steric inhibition of
cX- bungarotoxin binding to AChR by anti-receptor 
antibody.
OC - bungarotoxin 
anti-"toxin site" antibody
anti-AChR antibody directed at other antigenic sites. 
In ̂  the binding of toxin is blocked by the anti-"toxin site" 
antibody, while in B_ the anti-site antibody is prevented from 
binding by a second antibody directed away from the toxin- 






The inhibition of c(- BGT binding by F(ab^)̂  fragments was not due to
antigenic modulation of the AChR, since no increase in receptor
degradation in the presence of immune F (ab^^ was observed under the 
conditions of the inhibition assay (Figure 36) . This is not surpris­
ing since the assay was performed at 4°C (F(ab  ̂binding),followed 
by 25°C (toxin binding) for only a short time, and the process of 
modulation has a strict temperature dependence (Baumann and Doyle, 
1980) and is not significant for AChR at 23°C or below (Heinemann et 
al., 1977; Appel et al., 1977). The results obtained in this study 
are consistent with a steric block of oC~ BGT binding by the anti-AChR 
antibodies, rather than a direct competition for the same combining
site on the receptor. This is further confirmed by the fact that
125preincubation of chick myotubes with cX- BGT had no effect on I -
F(ab* ) 2 binding. This finding is similar to the small (5 - 15%)
125inhibition of I - labelled anti-AChR antibody binding to Torpedo
marmorata membrane fragments by cX- BGT reported by Zum and Fulpius
(1977). The fact that F(ab )  ̂but not Fab fragments inhibited toxin 
binding in this system indicates that the sterically hindering anti­
genic site is not in very close proximity to the ot- BGT binding site. 
As the surface diameter of the AChR is about 8.5 nm (Kistler et al., 
1932) and the maximum distance between the two arms of an IgG molecule 
is of the order of 12 nm (Edelraan cind Gall, 1969) it is theoretically 
possible for an antibody bound at any given receptor determinant to 
cover any other region of the receptor surface.
Both immune F(ab^ 2  and Fab fragments inhibited binding of
125I - cX-BGT to purified Torpedo AChR. For Fab fragments this is in 
agreement with the findings of Claudio and Raftery (1980), who demon­
strated a 26 - 70% inhibition of c<- BGT binding to Torpedo AChR by
Fab fragments from anti - (Torpedo AChR) antisera raised in both
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rabbits and rats. In contrast Mihovilovic and Martinez-Carrion (1979)
demonstrated no inhibition of toxin binding by high affinity anti-AChR
Fab fragments, although the time dependence of toxin binding was
changed suggesting some overlap between the Fab and toxin combining
sites. As in the case of chick myotubes, preincubation of Torpedo
125 #AChR with CX- BGT did not inhibit the binding of I - F(ab ) ̂ to
the receptor. The inhibition of toxin binding in this system, there­
fore, again appears to be by steric hindrance of the oC- BGT binding 
site by antibody bound at an adjacent antigenic site.
The curves for inhibition of binding of ^^^I -CX-BGT by F(ab' ) 2  
and Fab fragments when analysed by a Hill plot all gave Hill 
coefficients close to unity , indicating one molecule of antibody
bound per toxin binding site. Using a similar analysis, Mittag et al. 
(1981a) found two antibody molecules bound per toxin site in myasthenic 
sera containing anti-toxin site antibodies.
The conformational state of the AChR is important for the 
inhibition of toxin binding by anti-receptor antibodies. (Bartfield 
and Fuchs, 1979; Claudio and Raftery, 1980). In this study the lack 
of inhibition of toxin binding to chick myotube AChR by Fab fragments, 
in contrast to the 80% inhibition to purified Torpedo AChR suggests 
that the membrane-bound and solubilised AChR are antigenically 
different. Differences in the binding of high affinity anti-AChR 
Fab fragments and mAb's to solubilised and membrane-bound receptor 
have been previously reported (Martinez-Carrion et al., 1981;
Souroujon et al., 1983), and could result from the exposure of hidden 
antigenic determinants by the solubilisation procedure.
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Interrelationship of carbohydrate and antigenic sites on AChR
Membrane-bound carbohydrate is known to contribute to cell sur­
face specificity in a wide range of systems (Harrison and Lunt, 1980), 
Impairment of AChR glycosylation in cultured muscle has been shown to 
hinder accumulation of the receptor in the cell membrane by both pre­
venting the assembly of subunits into a functional macromolecule 
(Merlie et al. , 1982), and increasing the susceptibility of the AChR 
to degradation by cellular proteases (Prives and Olden, 1980). The 
interrelationship between carbohydrate and the ck - toxin binding site 
on the AChR has been studied by a number of investigators. Concanava- 
lin A, a ligand specific for carbohydrate moieties, binds to the AChR 
at multiple, cooperative binding sites (Mittag et al., 1981a) and 
causes inhibition of CX- toxin binding to both solubilised and 
membrane-bound receptor (Wonnacott et al., 1980b; Mittag et al., 1981;
Boulter and Patrick, 1979). In these studies the inhibition was
incomplete, ranging from 25 - 90%, and was postulated to be due to 
steric hindrance rather than direct involvement of carbohydrate 
residues in the CX- toxin recognition site (Wonnacott et al., 1980b). 
This was confirmed by the finding that the equilibrium and kinetic 
properties of AChR - toxin complex formation were not modified by 
treatments which caused the destruction or removal of carbohydrate 
residues from the receptor (Wonnacott et al., 1980b; Criado and
Barrantes, 1982). In the present study, Concanavalin A caused a
125maximum 60% inhibition of I -Ot-BGT binding to chick myotubes, 
indicating a similar juxtaposition of carbohydrate to the toxin 
binding site in this system as in those previously reported.
The contribution of carbohydrate to the antigenicity of the 
AChR has also been examined. Mittag et al. (1976, 1981b) reported 
that 65% of myasthenic patients possessed anti-AChR antibodies which
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interfered with the binding of labelled AChR to Concanavalin A
coupled to beaded agarose gel. Similarly Wonnacott et al. (1980a)
125showed that the binding of Concanavalin A to I - labelled Torpedo 
AChR was specifically inhibited to a maximum of 25% by anti - (Torpedo 
AChR) F (ab )  ̂and Fab fragments. Dwyer et al. (1981a) and Hall et al. 
(1983) both found that some myasthenic sera inhibited the binding of 
d- BGT to extrajunctional rat AChR to a greater extent than to 
junctional receptor, and that this difference was reduced or abolished 
by glycosidase treatment of the receptor. Taken together, these find­
ings indicate that carbohydrate may be one of many antigenic sites on 
the AChR. To clarify further the role of carbohydrate in the antigen­
icity of the AChR, the direct effects of removing carbohydrate groups
125 ffrom the receptor,on I - F (ab )  ̂binding to purified Torpedo AChR,
and to chick myotube AChR in situ was studied. Neither periodate
oxidation, nor glycosidase treatment of Torpedo AChR reduced its
fability to bind directly to labelled anti-AChR F (ab )  ̂fragments, or 
to inhibit the binding of the fragments to chick embryo muscle in 
culture. The efficacy of the treatments was, however, evidenced by a 
45 and 70% reduction in binding of the receptor to Concanavalin A by 
periodate and glycosidase treatments respectively. These findings 
are in good agreement with those previously reported using AChR 
labelled with either -o(-BGT, or directly with ^^^I,as antigen
(Weinberg and Hall, 1979; Wonnacott et al., 1980a; Dwyer et al.,
1981a). These results, therefore, show little evidence of a role for 
the carbohydrate component of the AChR as a major antigenic determinant, 
and indicate that the antibodies to Torpedo AChR used in this study 
are primarily directed at sites other than the carbohydrate itself.
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The effect of AChR - dénaturation on antigenicity
Atassi (1975, 1978) demonstrated that the antigenic determinants 
of a protein are generally formed by six or seven amino acid residues. 
If these residues are adjacent the determinant is termed "continuous". 
If the amino acids forming the determinant are from different parts of 
the primary sequence, and the determinant is formed by folding back of 
the polypeptide chain or by residues from adjacent chains, the deter- 
mincint is termed "discontinuous". Antibodies directed against 
continuous determinants would be expected to bind
to the denatured protein, whereas antibodies to discontinuous 
determincints, which are conformationally dependent, would bind only to 
the intact, native protein.
To determine whether the immune ^^^I - F (ab^)^ fragments used in 
this study were directed primarily at continuous or non-continuous 
determinants, the effect of AChR dénaturation on the binding of 
F(ab^ ) 2 fragments to the receptor was studied.
SDS - treatment of Torpedo AChR resulted in a 65% decrease in 
125 /the maximum amount of I - F(ab Xg directly bound to the receptor, 
while heat-inactivation at 60°C for 30 min caused only a 35% loss of 
F (ab^ ) 2 binding. In contrast, the toxin binding capacity of the 
receptor was almost completely abolished by a lO min exposure at 
this temperature, as has been previously reported (Saitoh et al.,
1979). The loss of antigenicity on dénaturation is in keeping with 
the findings of Bartfield and Fuchs (1977), who analysed the anti­
genic specificities of untreated and reduced, carboxymethylated 
Torpedo AChR, and found that some antigenic determinants were 
abolished by the dénaturation procedure. These determinants may be 
functionally important, since denatured AChR does not induce any
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symptoms of EAMG in inoculated animals (Valderrama et al., 1976; 
Lindstrom et al., 1976c; Bartfield and Fuchs, 1977; Claudio and 
Raftery, 1980).
The ability of Torpedo AChR denatured by SDS - treatment, or 
exposure at 60°C to inhibit the binding of - F(ab')̂  to chick
myotubes was decreased to a greater extent than its ability to direct­
ly bind the F (ab ̂ ^ fragments (to 16 and 30% of the inhibition caused 
by intact receptor for the two treatments respectively). This accords 
with Lindstrom et al. (1979b) who found that most interspecies cross­
reaction occurred at conformationally dependent determinants, and 
suggests that the interactions of the anti - (Torpedo AChR) antibody 
fragments used in this study with the receptor in situ in chick myo­
tubes are primarily directed at conformational sites on the receptor. 
Such sites are significantly immunogenic and hence may be of particular 
relevance to tlie pathogenesis of myasthenia gravis.
Lysis of muscle cells in culture by myasthenic sera
Anti-AChR antibody is present in over 85% of myasthenia gravis 
patients and is thought to be responsible for the reduction in end- 
plate AChR which underlies the basic defect in neuromuscular trans­
mission. Anti-receptor antibodies may reduce the number of available 
receptors by three main mechanisms.
1) By direct blockade of AChR function, resulting from antibody
binding to the acetylcholine binding site, the ion-channel or to some 
important conformational determinant.
2) By increasing the rate of AChR degradation (antigenic modulation),
3) By antibody - mediated damage of the AChR and lysis of the post-
synaptic region, possibly in conjunction with complement or cellular 
elements.
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The evidence available suggests that all three mechanisms may 
be involved in the pathogenesis of myasthenia gravis. The contribution 
of direct blockade of AChR function, and of antigenic modulation to 
AChR loss have been extensively documented, but are both insufficient, 
by themselves, to account for the development of muscle weakness in 
myasthenia gravis and EAMG (Berman and Heinemann, 1984; Lindstrom,
1979). By contrast the contribution of antibody - mediated lysis of 
the postsynaptic membrane has been relatively little studied, despite 
the proposal that this may be the most important mechanism operating 
in both acute EAMG and myasthenia gravis (Lindstrom and Engel, 1981; 
Drachman, 1981). For this reason the lysis of muscle cells in culture 
by myasthenic sera has been studied.
The identification of specific myotube damage in inflammatory 
muscle diseases and myasthenia gravis has been attempted by direct 
light microscopic assessment (Currie, 1970; Liveson et al., 1976) or 
by studies of chromium - 51 release from labelled muscle cultures 
(Dawkins and Mastaglia, 1973). However, damage to fibroblasts, which 
generally contaminate myotube cultures, Ccinnot be distinguished from 
myotube damage by these methods, leading to inaccuracies in the 
determination of muscle - specific lysis. An alternative approach 
would be to employ a compound selectively taken up by myotubes and 
likely to be released rapidly following myotube damage. Carnitine 
( - amino - ^ - hydroxy butyric acid 3 - methyl - betaine) , though
found in a number of cell types, occurs in particularly high concen­
tration in muscle cells (Greville and Tubbs, 1968). Both cardiac and 
skeletal muscle cells take up carnitine by means of a membrane - 
associated active transport system (Rebouche, 1977). The uptake of 
tritiated (̂ H) - carnitine into human foetal muscle cells in culture 
has been studied (Cambridge and Stem, 1981) . Uptake into myotubes
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was approximately 5 - times higher than that into fibroblast 
cultures, and was much more efficient, with a 7 - fold higher Km/Vmax 
ratio. Specific - carnitine loss from myotubes following incu­
bation with lymphocytes from patients with inflammatory muscle disease 
was also demonstrated by these authors. The metliod was considerably 
more sensitive than either visual assessment of cell lysis, or loss of 
chromium - 51,since only myotubes were labelled to any significant 
extent, and loss of membrane integrity not gross enough to be micro­
scopically visible could be detected. The loss of - carnitine 
from myotube cultures was accordingly used to determine antibody - 
mediated myotoxicity in this study.
Both normal human and myasthenic sera caused myolysis of chick 
embryo muscle cultures. Lysis of chick myotubes by normal sera was 
also observed by Harvey et al. (1978), and suggests the widespread 
occurrence of natural anti-chick antibodies. Absorption of the 
normal sera with chicken liver homogenate considerably reduced their 
myolytic activity, in keeping with the findings of Harvey et al.
(1978).
In a study of the lytic effects of myasthenic sera on mouse 
somite cultures containing mature cross-striated muscle fibres 
Liveson et al. (1975) found 3 of 17 sera which caused partial
destruction of the cross-striated fibres observable by light micro­
scopy. Cytolysis of the muscle cells in excised frog nerve-muscle 
preparations by 2 of 22 myasthenic sera was also observed by Nastuk 
et al. (1959). In the present study, 5 of 14 myasthenic sera prev­
iously absorbed against ckicken liver possessed lytic activity which 
was clearly outside of the normal range. The greater percentage of 
positive sera than shown in the two previous reports cited is prob­
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ably a reflection of the increased sensitivity of the - carnitine 
release assay as a measure of cytotoxicity in muscle cultures. The 
myolysis observed was not related to anti-AChR antibody titre of the 
myasthenic serum, with two of the lytic sera having no detectable 
titre. This suggests that myolysis may be caused by antibodies to 
muscle components other than the AChR, which are present in up to 70% 
of myasthenic sera (Mehl and Lang, 1984). An alternative possibility 
is that lysis is mediated by antibodies directed at the toxin binding 
site of the AChR. These antibodies are not detected by the immuno­
précipitation assay commonly used to determine anti-AChR antibody 
titre in myasthenic sera, as the antigen used is a receptor-toxin 
complex.
Complement may play a role in antibody - mediated damage to 
muscle cells. Research on complement - deficient mice, rcibbits and 
guinea pigs indicates that complement plays an important role in EAMG. 
Acute EAMG is prevented in rats depleted of C3 by treatment with cobra 
venom factor (Lennon et al., 1978). Similarly guinea pigs that were 
C4 - deficient developed normal titres of antibody against Torpedo 
AChR, but did not exhibit clinical symptoms (Eldefrawi, 1978). In 
myasthenia gravis focal lysis of the postsynaptic membrane Ccin be 
observed ultrastructurally, with fragments containing AChR, antibody 
and C3 being shed from the membrane into the synaptic cleft (Engel 
et al., 1977). In this study heat-inactivation of myasthenic sera 
totally abolished their myolytic activity, and this was only partially 
restored by the addition of guinea pig complement. Liveson et al. 
(1976) also found that the addition of complement did not restore the 
myolytic activity of heat-inactivated sera. In contrast to this 
Harvey et al. (1978) found that fresh-diluted guinea-pig serum 
restored the lytic activity of sera heat-inactivated at 56°C for
203.
60 min, and recent results indicate that high levels of complement 
will restore the myolytic activity of heat-inactivated myasthenic sera 
against rat myotubes (Childs, L., Harrison, R. and Lunt, G.G. (1985)
J. Neuroimmunol. in the press).
In view of the relatively limited cross-reactivity between 
myasthenic anti-AChR antibodies and chick myotube cultures (Fulpius 
et al., 1980), the high percentage of myasthenic sera giving lysis 
suggests that antibody - mediated myolysis may be an important mechan­
ism in the pathogenesis of myasthenia gravis. To further explore the 
significance of this mechanism, and to try to eliminate the problems 
of normal serum toxicity in the myolysis assay,an attempt was made to 
develop human foetal myotubes in culture, and limited differentiation 
and development of multinucleated muscle cells was obtained. Normal 
human sera were essentially non-toxic to the human foetal muscle 
cultures, while 3 of 6 myasthenic sera gave significant myolysis.
The limited nature of myotube development may have caused the extent 
of myolysis in this system to be underestimated, but again the high 
percentage of myolytic sera indicates the important contribution that 
muscle-specific membrane damage may have in the loss of available AChR 
observed in myasthenia gravis.
Suggestions for further study
In spite of the fact that some 90% of myasthenic patients have 
detectable anti-AChR antibody titres in their sera, the exact relation­
ship of antibody to disease state is not clear. Although there is cin 
overall statistical correlation when titre and clinical status are 
compared in sufficiently large groups of patients, the correlation is 
poor when individual patients are compared (Lefvert et al., 1978; 
Barkas et al., 1979). In myasthenia there is clearly a heterogeneous
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population of antibodies (Mittag et al., 1981a,b) but not all of them 
are pathogenic, because high concentrations are known to occur in some 
patients in complete remission (Lefvert et al., 1978) and in healthy 
newborns to myasthenic mothers (Lefvert, 1978). Disease state may be 
more closely related to subpopulations of anti-receptor cintibodies 
directed against particular determinants on the AChR. For this reason 
it is important to determine the antigenic specificities of anti-AClÙl 
antibodies in both myasthenia gravis and EAMG.
Antibodies are normally formed preferentially against the most 
exposed portions of the surface structure of an antigen (Crumpton 
1974). When AChR is detergent-solubilised, the conformation of the 
molecule will be significantly altered from that of the membrane- 
bound receptor, and antigenic determinants normally hidden within the 
postsynaptic membrane may become exposed. Conversely, normally exposed 
sites may become masked. A number of reports have identified such 
differences in both ligand binding to the AChR (Boulter and Patrick,
1979) and in anti-receptor antibody reactivity (Martinez-Carrion et 
al., 1981; Souroujon et al., 1983; Neumann et al., 1984). The reaction 
of antibody with membrane-bound AChR should, therefore, be further 
studied in order to determine the antibody subpopulations which may 
directly affect muscle AChR function in myasthenia gravis and EAMG.
In this respect the cross-reactive binding of antibodies raised 
against Torpedo AChR with chick muscle AChR in culture may represent 
a good model. A cross-reactivity between the foreign immunising AChR 
(from fish electric organ) and self muscle receptor is required for the 
induction of the autoimmune process in EAMG. It is thus important to 
study those antibodies that cross-react with muscle receptor. In view 
of the limited cross-reactivity between AChR from fish and skeletal 
muscle it is reasonable to suppose that cross-reactive antibodies will
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be directed at highly conserved sites on the receptor. In so far as 
it is reasonable to assume that the conserved sites are relatively 
important in the functioning of the receptor molecule, then anti­
bodies directed towards those sites could represent subclasses with 
particular relevance to the disease state in myasthenia gravis.
Thus antibodies directed against the highly- conserved Qk- toxin 
binding site were found to be present predominantly in severely-ill 
myasthenic patients (Lefvert et al., 1981), and Lindstrom et al.
(1981) found a homologous region on fish AChR and muscle AChR from a 
variety of sources which was highly immunogenic. The apparent homo­
geneity of binding of anti - (Torpedo AChR) antibody to chick myotubes 
found in this study (see preceding discussion) may also reflect well 
the situation in myasthenia gravis and EAMG. Pressman (1970)
showed that in many cases the antibody population of an antiserum is 
composed of a limited number of antibody types with different 
affinities. Tzartos and Lindstrom (1980) detected a "main immuno­
genic region" on the extracellular surface of the CX- subunit of AChRs 
from a number of species to which most of the antibodies in the sera 
of an animal immunised with intact AChR were directed, and Bray and 
Drachman (1982) found that Scatchard plots of myasthenic sera binding 
to human AChR were linear, indicating a dominant antibody type in the 
sera. Vincent and Newsom-Davis (1982) also demonstrated a population 
of high avidity antibody in each of 35 sera from myasthenic patients 
with ocular or generalised disease. Thus the specificity of binding 
to skeletal muscle in culture of both monoclonal and polyclonal anti­
bodies raised against purified AChR should be extensively studied.
In this study antibody - mediated muscle cell lysis has been 
demonstrated to be a function of many myasthenic sera. The nature of 
the antibodies producing this lytic activity, and the role of
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complement in producing myolysis need much further investigation. In 
particular the relationship of myolysis to the IgG subclass distribu­
tion in individual patients should be studied, in view of the wide 
variation in such distributions already demonstrated (Vincent cuid 
Bilkhu, 1982) and the known differences of the subclasses in their 
ability to fix complement (Natvig and Kunkel, 1973). The ability of 
myasthenic sera to activate complement irrespective of subclass 
distribution may also prove to be of significance, in light of the 
recent report of Adler et al. (1984) that autoantibodies to thyro- 
globulin inexplicably did not activate complement. The characteristics 
of anti-skeletal muscle antibodies other than anti-AChR which are 
present in many myasthenic sera (Gilhus et al., 1983), and their con­
tribution to myolysis should also receive further study. The use of 
human muscle in culture may prove extremely useful in estimating the ' 
size of the contribution played by myolysis to the aetiology of 
myasthenia gravis. The development of mature cultures of relatively 
pure myotubes from human foetal material is therefore an important 
goal of future research. The use of serum-free defined media, and 
muscle - specific growth factors in achieving this aim are obvious 
areas for further study. Fambrough et al. (1982) have reported pro­
ducing myotube cultures in which greater than 97% of nuclei were in 
multinucleated structures,lysing fibroblasts and myoblasts with a mAb 
specific for these cells, in conjunction with guinea pig complement.
The use of such specific cytolytic agents should therefore also be 
further developed.
Myasthenia gravis still eludes a simplistic explanation, with a 
number of mechanisms contributing to the antibody-induced loss of 
functional AChR. As most patients have antibodies capable of inducing 
these pathological mechanisms in large excess over their AChR content.
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endogenous factors must also be important in determining a patient's 
response to the immune assault. Attempts to understand, treat and 
cure the disease have led to significant advances in our knowledge of 
the AChR and of the underlying mechanisms of autoimmune diseases.
This trend seems likely to continue.
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REFERENCES
AARLI, J.A. (1970) Clin. Exp. Immunol. 1_, 23-30.
ABDOU, N.I.,LISAK, R.P. and ZWEIMAN, B. (1974) New Engl, J. Med. 
291, 1271-1275.
ADLER, T.R., BEALL, G.N., CURD, J.G., HEINER, D.C. and SABHARWAL, 
U.K. (1984) Clin. Exp. Immunol. 383-389.
AHARONOV, TARRAB-HAZDAI, R., ABRANSKY, O. and FUCHS, S. (1975)
Proc. Natl. Acad. Soi. USA 72, 1456-1459.
AHARONOV, A., TARRAB-HAZDAI, R., SILMAN, I. and FUCHS, S. (1977) 
Immunochem. 14, 129-137.
ALAJOUANINE, T., SCHERRER, J. and BOURGUIGNON, A. (1959) Revue 
Neurologique 100, 238-241.
ALMON, R.R. and APPEL, S.H. (1975) J. Neurochem. TL» 1513-1519. 
ALI-ION, R.R., ANDREW, C.G. and APPEL, S.H. (1974) Science 186,
55-57
ANDERSON, D.J. and BLOBEL, G. (1981) Proc. Natl. Acad. Sci. USA 
78, 5598-5602.
ANDERSON, D.J. and BLOBEL, G. (1983) Cold Spring Harbor Symp. 
Quant. Biol. 48, 125-134.
ANDREASON, J.J., DOERGE, D.R. and McNAMEE, M.G. (1979) Arch. 
Biochem. Biophys. 194, 468-480.
ANHOLT, R. (1981) Trends in Biochem. Sci. j5, 288-291.
ANHOLT, R., FREDKIN, D.R., DEERINCK, T., ELLISMAN, M., MONTAL,
M. and LINDSTROM, J. (1982) J. Biol. Chem. 257, 7122-7134.
APPEL, S.H., ALMON, R.R. and LEVY, N. (1975) New Engl. J. Med.
293, 760-761.
209.
APPEL, S.H., ANWYL, R., McADAMS, M.W. and ELIAS, S. (1977) Proc. 
Natl. Acad. Sci. USA , 2130-2134.
ARGOV, Z., NICHOLSON, L., FAWCETT, P.R.W., MASTAGLIA, F.L. and 
HALL, M. (1980) Lancet 1, 203.
ARNON, R. (1973) in The Antigens (SELA, M. ed. ) Vol.l, p.87, 
Academic Press, New York.
ATASSI, M.Z. (1975) Immunochem. 423-438.
ATASSI, M.Z. (1978) Immunochem. 1̂ , 909-936.
AXELROD, D., RAVDIN, P., KOPPEL, D.E., SCHLESSINGER, J., WEBB,
W.W., ELSON, E.L. and PODLESKI, T.R. (1976) Proc. Natl. Acad.
Sci. USA 21/ 4594-4598.
BALLIVET, M., PATRICK, J., LEE, J. and HEINEMANN, S. (1982) Proc. 
Natl. Acad. Sci. USA 79, 4466-4470.
BARKAS, T., HARRISON, R., LUNT, G.G. and WATSON, C.M.J. (1978) 
Biochem. Soc. Trans. _6/ 636-638.
BARKAS, T., HARRISON, R., LUNT, G.G., STEPHENSON, F.A., BEHAN,
P.O. and SIMPSON, J.A. (1979) in Progress in Neurological Research 
( BEHAN, P.O. and CLIFFORD ROSE F. eds. ) pp.169-174, Pitman 
Medical Press, Tunbridge Wells.
BARNARD, E.A., DOLLY, J.O., LO, M. and MANTLE, T. (1978) Biochem. 
Soc. Trans, 649-651.
BARNARD, E.A., DOLLY, J.O., LANG, B., LO, M. and SHORR, R.G. (1979) 
in Advances in Cytopharmacology ( Ceccarelli, B. and Clementi, F. 
eds. ) Vol.3, pp.409-436, Raven Press, New York.
BARNSTAPLE, C., JESSELL, T., SANES, J., STEVENS, C. and 
ROBERTSON, M. (1983) Nature 306, 14-16.
BARRANTES, F.J., NEUGEBAUER, D.-CH. and ZINGSHEIM, H.P. (1980)
FEBS Lett. 112, 73-78.
BARTFIELD, D., and FUCHS, S. (1977) FEBS Lett. 77, 214-218.
210.
BARTFIELD, D. and FUCHS, S. (1979) Biochem. Biophys. Res. Commun.
89, 512-519.
BAUMANN, H. and DOYLE, D. (1980) Cell 097-907.
BENDER, A.N., ENGEL, W.K., RINGEL, S.P., DANIELS, M.P. and VOGEL,
Z. (1975) Lancet 1, 607-608.
BERANEK, R. and VYSKOCIL, F. (1967) J. Physiol. 188, 53-66.
BERG, D.K., KELLY, R.B., SARGENT, P.B., WILLIAMSON, P. and HALL,
Z.W. (1972) Proc. Natl. Acad. Sci. USA 147-151.
BERGSTROM, K., LEFVERT, A.K., MATELL, G. and PIRKANEN, R. (1978) 
in The Biochemistry of Myasthenia Gravis and Muscular Dystrophy 
( LUNT, G.G. and MARCHBANKS, R.M. eds. ) pp.177-178, Academic 
Press, London and New York.
BERMAN, P.W. and HEINEMAIJN, S.F. (1984) J. Immunol. 132, 711-717. 
BERMAN, P;'W., PATRICK, J., HEINEMANN, S., KLIER, F.G. and STEIUBACH, 
J.H. (1981) Ann. N.Y. Acad. Sci. 377, 237-256.
BERSINGER, N.A., VELAZCO, M.-I., JAMES, R.W. and FULPIUS, B.W.
(1983) Neurochem. Int. 5, 459-462.
BEUTNER, E.N., WITEBSKY, E., RICKEN, D. and ADLER, R.H. (1962)
J. Am. Med. Assoc. 182, 46-58.
BEVAN, S. and STEINBACH, J.H. (1977) J. Physiol. (London) 267, 
195-213.
BEVAN, S., KULLBERG, R.W. and HEINEMANN, S.F. (1977) Nature 267, 
263-265.
BEVAN, S., KULLBERG, R.W. and RICE, J. (1978) Nature 2 7 3 , 4 6 9 - 4 7 1 .  
BIESECKER, G. (1973) Biochem. JL2_/ 4 4 0 3 - 4 4 0 9 .
BISCHOFF, R. (1975) The Anatomical Record 182, 215-236.
BLANCHARD, S.G., QUAST, U., REED, K., LEE, T., SCHIMERLIK, I., 
VANDLEN, R., CLAUDIO, T., STRADER, C.D., MOORE, H-P.H. and RAFTERY, 
M.A. (1979) Biochem. 18, 1875-1883.
211.
BLOCH, R.J. (1979) J. Cell. Biol. 626-643.
BLOCH, R.J. and GEIGER, B. (1980) Cell 21 / 25-35.
BLUMCKE, S. and NIEDORF, H.R. (1965) Virchow's Archiv. fur Patholo-
gisch. Anatomie und Physiologie 340, 93-104.
BOULTER, J. and PATRICK, J. (1979) J. Biol. Chem. 254, 5652-5657.
BRADLEY, R.J., DWYER, D., MORLEY, B.J., ROBINSON, G., KEMP, G.E. 
and OH, S.J. (1979) Prog. Brain Res. 49, 441-448.
BRAY, J.J. and DRACHMAN, D.B. (1982) J. Immunol. 128, 105-110. 
BROCKES, J.P. and HALL, Z.W. (1975) Biochem. l̂ , 2092-2099.
BURDEN, S. (1977) Dev. Biol. 6JL, 79-85.
BURSZTAJN, S. and FISHBACH, G.D. (1984) J.. Cell Biol. 98, 498-506.
CAMBRIDGE, G. and STERN, C.M.M. (1981) Clin. Exp. Immunol. 43, 
211-219.
CARTER, B., HARRISON, R., LUNT, G.G., BEHAN, P.O. and SIMPSON, J.A. 
(1980) J. Neurol. Neurosurg. Psychiat. £3, 397-402.
CARTER, B., HARRISON, R., LUNT, G.G., MORRIS, H., SAVAGE-MARENGO,
T. and STEPHENSON, F.A. (1981) Ann. Clin. Biochem. 18, 146-152. 
CASTLEMAN, B. (1966) Ann. N.Y. Acad. Sci. 135, 496-505.
CHABNER, B.A. (1981) in Cancer and Chemotherapy Vol. Ill ( CROOKE,
S.T. and PRESTAYKO, A.W. eds. ) pp.3-24, Academic Press, London. 
CHANG, H.W. and BOCK, E. (1979) Biochem. 172-179.
CHANGEUX, J.P. (1975) in Handbook of Psychopharmacology ( IVERSON, 
L.L. ed. ) Vol.6, pp.235-301, Plenum Press, New York.
CHANGEUX, J.P. (1981) in The Harvey Lectures, Series 75, pp.85-254, 
Academic Press, New York.
CHANGEUX, J.P. and DANCHIN, A. (1976) Nature 264, 705-712.
CHANGEUX, J.P., GAUTRON, J., ISRAEL, M. and PODLESKI, T. (1969)
Comp. Rend. Acad. Sci. Paris 269, 1788-1791.
CHANGEUX, J.P., KASAI, M. and LEE, C.Y. (1970) Proc. Natl. Acad.
Sci. USA 67, 1241-1247.
212,
CHANGEUX, J.P., MEUNIER, J.C. and HUCHET, M. (1971) Mol. Pharmacol. 
_5y 538-553.
CINADER, B. (1963) Ann. N.Y. Acad. Sci. 103, 495.
CLAUDIO, T.R. and RAFTERY, M.A. (1900) J. Immunol. 124, 1130. 
CLEATOR, G.M. and BESWICK, T.S.L. (1972) Cytobios 5, 231-239.
COERS, C. and WOOLF, A.L. (1959) The Innervation of Muscle: A 
Biopsy study. Blackwell Scientific Publications, Oxford.
COHEN, E.P. and LIANG, W. (1976) in Membranes and Neoplasia: New
Approaches and Strategies (MARCHESI, V.T. ed. ) pp.89-98, Liss,
New York.
COHEN, J.B., BOYD, N.D., YENG, A.Y., MEDYNSKI, D.C., NEUBIG, R.R,
St. JOHN, P. and SHERA, N.S. (1980) in Psychopharmacology and 
Biochemistry of Neurotransmitter Receptors ( YAMAMURA, H., OLSEN,
R. and USDIN, eds. ) pp.47-62, Elsevier/North Holland, Amsterdam. 
COLQUHOUN, D. (1979) in The Receptors. A Comprehensive Treatise 
( O'BRIEN, R.D. ed.) Vol.l, pp.93-142, Plenum Press, New York, 
COMPSTON, D.A.S., VINCENT, A., NEWSOM-DAVIS, J. and BATCHELOR,
J.R. (1980) Brain 103, 579-601.
CONTI-TRONCONI, B.M. and RAFTERY, M.A. (1982) Ann. Rev. Biochem.
51, 491-530.
CONTI-TRONCONI, B.M., DUNN, S.M.J. and RAFTERY, M.A. (1982) Biochem. 
21, 893-899.
COOPER, D. and REICH, E. (1972) J. Biol. Chem. 247, 3008-3013. 
CRAIN, J.M., ALFEI, L. and PETERSON, E.R. (1970) J. Neurobiol. 
_1/ 471-489.
CRIADO, M. AND BARRANTES, F.J. (1982) Neurochem. Int. _4_» 289-302. 
CRIADO, M., EIBL, H. and BARRANTES, F.J. (1984) J. Biol. Chem.
259, 9188-9198.
CRUMPTON, (1974) in The Antigens ( SELA, M. ed. ) Vol.2, p.173, 
Academic Press, New York.
213.
CULL-CANDY, S.G., MILEDI, R., TRAUTMANN, A. and UCHITEL, O.D. (1980) 
J. Physiol. 299, 621-638.
CURRIE, S. (1970) Acta Neuropathol. (Berlin) 11.
DALE, H.H. (1914) J. Pharmacol. Exp. Ther. 147-190.
DALE, H.H., FELDBERG, W. and VOGT, M. (1936) J. Physiol. (London) 
353-380.
DALY, J.W., KARLE, I., MYERS, C.W., TOKUYAMA, T., WATERS, J.A. 
and WITKOP, B. (1971) Proc. Natl Acad Sci. USA 6£, 1870.
DALZIEL, A.W., ROLLINS, E.S. and McNAMEE, M.G. (1980) FEBS Lett.
122, 193-196.
DAWKINS, R.L. and MASTAGLIA, F.L. (1973) New Engl. J. Med. 288, 
434-438.
DE LA HABA, G. and AMUNDSEN, R. (1972) Proc. Natl. Acad. Sci. USA 
1131-1135.
DEL CASTILLO, J. and KATZ, B. (1955) J. Physiol. 128, 157-181.
DE ROBERTIS, E., FISZER, S. and SOTO, E.F. (1967) Science 158, 928. 
DESMEDT, J.E. (1966) Ann. N.Y. Acad. Sci. 209-246.
DESOUKI, A., ELDEFRAWI, A.T. and ELDEFRAWI, M.E. (1981) Exp. Neurol. 
73, 440-450.
DEVILLERS-THIERY, A., CHANGEUX, J.P., PAROUTAUD, P. and STRASBERG,
A.D. (1979) FEBS Lett. 104, 99-105.
DEVILLERS-THIERY, A., GIRAUDAT, J., BENTABOULET, M. and CHANGEUX, 
J.P. (1983) Proc. Natl. Acad. Sci. USA 80, 2067-2071.
DEVREOTES, P.N. and FAMBROUGH, D.M. (1975) J. Cell Biol. _6i» 335. 
DEVREOTES, P.N. and FAMBROUGH, D.M. (1976) Cold Spring Harbor 
Symp Quant. Biol. 40, 237.
DIXON, W.E. (1906) Brit. Med. J. _2_/ 1807.
DOLLY, J.O. (1979) in Physiological and Pharmacological Biochemistry 
( TIPTON, K. ed. ) Vol.26, pp.257-309, University Park Press, 
Baltimore.
214.
DOLLY, J.O. and BARNARD, E.A. (1974) FEBS Lett, 145-149.
DOLLY, J.O. and BARNARD, E.A. (1977) Biochem. _!§./ 5053-5060.
DOWNES, J.M., GREENWOOD, B.M. and WRAY, S.H. (1966) Quarterly J. 
Med. 2Ë./ 85-105.
DRACHI4A1\I, D.B. (1981) Ann. Rev. Neurosci. j4/ 195-225.
DRACHI4AN, D.B., ANGUS, C., ADAMS, R., MICHELSON, J. and HOFFMAN,
G. (1978) New Engl. J. Med. _298, 1116-1122.
DRACHMAN, D.B., ADAI4S, R.V., JOSIFEK, L.F. and SELF, S.G. (1982)
Nev/ Engl. J. Med. 307, 769-775.
DRYDEN, W.F. (1970) Experientia _28, 984-986.
DU BOIS RAYMOND (1877) in Gessammelte Abhandlungen zur allgemeinen 
Muskel-und Nervenphysik Vol.2, Veit, Leipzig.
DU VERNAY, V.H. (1981) in Cancer and Chemotherapy VolJII ( CROOKE, 
S.T. and PRESTAYKO, A.W. eds. ) pp.234-271, Academic Press, London. 
DWYER, D.S., BRADLEY, R.J., OH, S.J. and KEMP, G.E. (1979) Clin. 
Exp. Immunol. 22» 448-451.
DWYER, D.S., BRADLEY, R.J., FURNER, R.L. and KEMP, G.E. (1981a) 
Brain Res. 217, 23-40.
DWYER, D.S., KEARNEY, J.F., BRADLEY, R.J., KEMP, G.E. and OH, S.J. 
(1981b) Ann. N.Y. Acad. Sci. 377, 143-155.
EDELMAN, G.M. and GALL, W.E. (1969) Ann. Rev. Biochem. _3§./ 415-466. 
EHRMANN, R.L. and GEY, G.O. (1956) J. Natl. Cancer Inst. 16.' 1375- 
1403
EINARSON, B., GULLICK, W., CONTI-TRONCONI, B., ELLISMAN, M. and 
LINDSTROM, J. (1982) Biochem. 21, 5295-5302.
EISEN, H. (1974) Immunology pp.373-403, Harper and Row, Hagerstown, 
Maryland.
EKSTEDT, J. and STALBERG, E. (1967) Opuscula Medica 73-76. 
ELDEFRAWI, M.E. (1978) Fed. Proc. 37, 2823-2827.
215.
ELDEFRAWI, M.E. and ELDEFRAWI, A.T. (1973a) Biochem. Pharmacol.
22, 3145-3150.
ELDEFRAWI, M.E. and Eldefrawi, A.T. (1973b) Arch. Biochem. Biophys. 
159, 362-373.
ELDEFRAWI, M.E., ELDEFRAWI, A.T., SEIFERT, S. and O'BRIEN, R.D. 
(1972) Arch. Biochem. Biophys. 150, 210- 218.
ELLENA, J.F., BLAZING, M.A. and McNAMEE, M.G. (1983) Biochem.
22, 5523-5535.
ELMQVIST, D., HOFMANN, W.W., KUGELBERG, J. and QUASTEL, D.M.J.
(1964) J. Physiol. _174, 417-434.
ELSON, H.F. (1979) J. Supraraol. Struc. 10, 39-50.
EMERY, A.E.H. and McGREGOR, L. (1977) Clin. Genetics JL2, 183-187. 
ENGEL, A.G., TSUJIHATA, M., LAMBERT, E., LINDSTROM, J. and LENNON, 
V.A. (1976a) J. Neuropath. Exp. Neurol. 35, 569-587.
ENGEL, A.G., TSUJIHATA, M., LINDSTROM, J. and LENNON, V.A. (1976b) 
Ann. N.Y. Acad. Sci. 274, 60-79.
ENGEL, A.G., LINDSTROM, J.M., LAMBERT, E.H. and LENNON, V.A.
(1977) Neurol. 27, 307-315.
ENGEL, A.G., SAKAKIBARA, H., SAHASHI, K., LINDSTROM, J., LAMBERT, E. 
and LENNON, V. (197 9) Neurol. 29, 179.
ENGEL, A.G., SAHASHI, K. and FUMAGALLI, G. (1981) Ann. N.Y. Acad. 
Sci. 377, 158-173.
EPSTEIN, M. and RACKER, E. (1978) J. Biol. Chem. 253, 6660-6662. 
FAMBROUGH, D.M. (1979) Physiol. Rev. _59, 165-227.
FAMBROUGH, D.M. (1981) in Receptors and Recognition Series B
( LEFKOWITZ, R.J. ed. ) Vol.13, pp.125-142.
FAMBROUGH, D.M. (1984) in Neuromuscular Diseases ( SERRATRICE, G. 
et al., eds. ) pp.465-470, Raven Press, New York.
FAMBROUGH, D.M. and RASH, J.E. (1971) Dev. Biol. _28# 55-63.
FAMBROUGH, D.M. and DEVREOTES, P.N. (1978) J. Cell Biol. 76, 237-244.
216.
FAMBROUGH, D.M., BAYNE, E.K., GARDNER, J.M., ANDERSON, M.J., 
WAKSHULL, E. and ROTUNDO, R.L. (1982) in Neuroimmunology ( BROCKES^ 
J. ed. ) pp.49-90, Plenum Press, New York.
FATT, P. and KATZ, B. (1951) J. Physiol. 320-370.
FELTKAMP, T.W., VAN DEN BERG-LOONEN, P.M., NIJENHUIS, L.E., 
ENGELFRIET, C.P., VAN ROSSUM, A.L., VAN LOGHEM, J.J. and OOSTERHUIS,
H.J.G.H. (1974) Br. Med. J. 2., 131-133.
FISCHBACH, G.D. (1972) Dev. Biol. 28./ 407.
FISCHBACH, G.D. and COHEN, S.A. (1973) Dev. Biol. 31, 147-162. 
FROEHNER, S.C., REINESS, C.G. and HALL, Z.W. (1977a) J. Biol.
Chem. 252, 8589-8596.
FROEHNER, S.C., KARLIN, A. and HALL, Z.W. (1977b) Proc. Natl.
Acad. Sci. USA 74, 4685-4688.
FUCHS, S., BARTFIELD, D., MOCHLY-ROSEN, D., SOUROUJON, M. and 
FEINGOLD, C. (1981) Ann. N.Y. Acad. Sci. 377, 110-123.
FULPIUS, B.W. (1976) in Motor Innervation of Muscle ( THESLEFF,
S. ed. ) pp.1-29, Academic Press, London and New York.
FULPIUS, B.W., ALLIOD, C., BERSINGER, N.A., GUENOUD, S., JAMES, R.W. 
and ZURN, A.D. (1978) Muscle and Nerve 2/ 336.
FULPIUS, B.W., MISKIN, R. and REICH, E. (1980) Proc. Natl. Acad.
Sci. USA 77, 4326-4330.
GILHUS, N.E., AARLI, J.A. and MATRE, R. (1983) J. Neuroimmunol.
_5/ 239-249.
GOLDSTEIN, G. and MANGANARO, A. (1971) Ann. N.Y. Acad. Sci. 183, 
230-240.
GOLDSTEIN, G. and WHITTINGHAM, S. (1966) Lancet ii, 315-318. 
GOLDSTEIN, A.L., THURMAN, G.B., COHEN, G.H. and ROSS10, J.L. (1976) 
Ann. N.Y. Acad. Sci. 274, 390-401.
GOMEZ, C.M. and RICPMAN, D.P. (1983) Proc. Natl. Acad. Sci. USA 
F R A N K L I N ,  G I, Y A S I N ,  R, H U G H E S ,  B P and T H O M P S O N ,  EJ (1980) J 
Neurol Sci 43, 3 1 7- 327 .
217.
30, 4089-4093.
GOMEZ, C.M., RICHMAN, D.P., BERMATJ, P.W., BURRES, S.A., ARNASON, 
B.G.W. and FITCH, F.W. (1979) Biochem. Biophys. Res. Commun. 88, 
575-582.
GORDON, A.S., MILFAY, D. and DIAMOND, I. (1983) Proc. Natl. Acad. 
Sci. USA 80, 5862-5866.
GOTTI, C., CONTI-TRONCONI, B.M. and RAFTERY, M.A. (1982) Biochem. 
_21, 3148-3154.
GOTTI, C., CASADEI, G.L. and CLEMENTI, F. (1983) Neurosci. Lett.
_35, 143-148.
GREVILLE, G.D. and TUBBS, P.K. (1968) Essays in Biochem. 4_/ 155. 
GULLICK, W.J. and LINDSTROM, J.M. (1982) J. Cell Biochem. 19, 
223-230.
GULLICK, W., TZARTOS, S. and LINDSTROM, J. (1981) Biochem. 20, 
2173-2180.
HALL, J.E. (1981) Biophys. J. 33, 373-381.
HALL, Z.W., ROISIN, M.P., GORIN, P. and GU, Y. (1983) Proc.of Int. 
Union of Physiol. Sci. 15, 383 ( Abstract ).
HANLEY, M.R. (1978) Biochem. Biophys. Res. Commun. 82, 392-401. 
HARRISON, R. and LUNT, G.G. (1980) Biological Membranes :Their 
Structure and Function, pp.131-165, Blackie, Glasgow.
HARRISON, R. , LUNT, G.G., MORRIS, H. and SAVAGE-I-IARENGO, T. (1981) 
Ann. N.Y. Acad. Sci. 377, 332-341.
HARVEY, A.L. and DRYDEN, W.F. (1974) Eur. J. Pharmacol. 22' 5-13. 
HARVEY, A.L., BARKAS, T., HARRISON, R. and LUNT, G.G. (1978) in The 
Biochemistry of Myasthenia Gravis and Muscular Dystrophy ( LUNT,
G.G. and MARCHBANKS, R.M. eds. ) pp.167-175, Academic Press, London. 
HARVEY, A.L., ROBERTSON, J.G., BARKAS, T., HARRISON, R., LUNT, G.G., 
STEPHENSON, F.A., CAMPBELL, M.J. and TEAGUE, R.H. (1978) Clin.
Exp. Immunol. 34, 411-416.
218,
HASSON-VOLOCH, A. (1958) Nature 218, 330-333.
HAUSHKA, S.D. (1972) in Growth, Nutrition and Metabolism of Cells 
in Culture Vol. 2 ( ROTHBLAT, G.H. and CRISTOFALO, V.J. eds. ) 
pp.68-130, Academic Press, New York.
HAUSHKA, S.D. (1974a) Dev. Biol. _3Z' 329-344.
HAUSHKA, S.D. (1974b) Dev. Biol. T?/ 345-368.
HAUSHKA, S.D. and KONIGSBERG, I.R. (1966) Proc. Natl. Acad. Sci.
USA _55, 119 .
HEIDMANN, T. and CHANGEUX, J.P. (1978) Ann. Rev. Biochem. 47, 
317-357.
HEIDMANN, T., SOBEL, A. and CHANGEUX, J.P. (1980) Biochem. Biophys. 
Res. Commun. 93, 127-133.
HEILBRONN, E., MATTSON, C. and ELFMAN, L. (1974) Proc.9th FEBS 
meeting 37, 29-37.
HEINEMANN, S., BEVAN, S., KULLBERG, R., LINDSTROM, J. and RICE, J. 
(1977) Proc. Natl. Acad. Sci. USA 74, 3090-3094.
HEINEMANN, S., MERLIE, J.P. and LINDSTROM, J. (1978) Nature 
( London ) 274, 65-67.
HUANG, L. (1979) FEBS Lett. 102, 9-12.
HUCHO, F. (1981) Trends in Biochem. Sci. 242-245.
HUDSON, L. and HAY, F.C. (1976) Practical Immunology, Blackwell 
Scientific Publications, Oxford.
HUNTER, W.M. (1978) in Handbook of Experimental Immunology ( WEIR,
D.M. ed. ) pp.14.1-14.40, Blackwell, Oxford.
HUNTER, W.M. and GREENWOOD, F.C. (1962) Nature ( London ) 194, 
495-496.
ITO, Y., MILEDI, R., MOLENAAR, P.C., VINCENT, A., POLAK, R.L., VAN 
GELDER, M. and DAVIS, J.N. (1976) Proc. Roy. Soc. 192, 475-480.
ITO, Y., MILEDI, R., VINCENT, A. and NEWSOM-DAVIS, J. (1978) Brain 
101, 345-368.
219.
JAILKHANI, B.L., ASTHANA, D., JAFFERY, N.F. and SUBBALAXMI, B.
(1984) J. Neuroimmunol. 6, 337-345.
JAMES> R.W., BERSINGER, N.A., SCHWENDIMANN, B. and FULPIUS, B.W. 
(1980) Hoppe-Seyler's Z. Physiol. Chem. 361, 1517-1524.
JAMES, R.W., ALLIOD, C. and FULPIUS, B.W. (1983) Mol. Immunol. 20, 
1363-1368.
JOHNS, T.R., CROWLEY, W.J., MILLER, J.Q. and CAMPA, J.F. (1971)
Ann. N.Y. Acad. Sci. 183, 64-71.
JOHNSON, I.S. (1982) in Cancer Medicine ( HOLLAND, J.F. and FREI,
E. eds. ) pp.910-920, Lea and Febiger, Philadelphia.
JOHNSON, A.G. and WOOLF, A.L. (1965) Acta Neuropathalogica 4, 
436-441.
JOLLY, F. (1895) Berliner Klinische Wochenschrift 32, 1-7.
KAKULAS, B.A., PAPADIMITRIOU, J.M., KNIGHT, J.O. and MASTAGLIA, F.L. 
(1968) Proc. Aust. Assoc. Neurol. _5_/ 79-85.
KAO, I. and DRACHMAN, D.B. (1977) Science 195, 74-75.
KARLIN, A. (1974) Life Sci. jL4_' 138 5 -1 4 1 5 .
KARLIN, A. (1980) in The Cell Surface and Neuronal Function ( POSTE,
G., NICOLSON, G. and COTMAN, C. eds. ) pp.191-260, Elsevier-North 
Holland Biomedical Press, New York.
KARLIN, A., PRIVES, J., DEAL, W. and WINNIK, M. (1971) J. Mol.
Biol. 175-188.
KARLIN, A., H0LTZÎ4AN, E., VALDERRAMA, R., DAMLE, V., HSU, K. and 
REYES, F. (1978) J. Cell Biol. 1^ 577-592.
KARLIN, A., DAMLE, V., HAI4ILT0N, S., McLAUGHLIN, M., VALDERRAMA, P. 
and WISE, D. (1979) in Advances in Cytopharmacology ( CECCARELLI,
B. and CLEMENTI, F. eds. ) Vol.3, pp.183-188, Raven Press, New York. 
KARLSSON, E., HEILBRONN, E. and WIDLUND, L. (1972) FEBS Lett.
28, 107-111.
220.
KATZ, B. and MILEDI, R. (1965) Proc. Roy. Soc. (London) Series B. 
161, 453-495.
KATZ, B. and MILEDI, R. (1972) J. Physiol. 224, 665-669.
KEESEY, J.C., TOURTELLOTE, W.W., HERMANN, C., ANDREWS, J.M. and 
LINDSTROM, J. (1978) Lancet 777.
KEMP, G., MORLEY, B., DWYER, D. and BRADLEY, R.J. (1980) Membrane 
Biochem. _3_/ 229-257.
KISTLER, J., STROUD, R.M., KLYMKOWSKY, M.W., LALANCETTE, R.A. and 
FAIRCLOUGH, R.H. (1982) Biophys. J. _37_' 371-383.
KLETT, R.P., FULPIUS, B.W., COOPER, D., SMITH, M., REICH, E. and 
POSSANI, L.D. (1973) J. Biol. Chem. 248, 6841-6853.
KOETHE, S.M., COOK, A., McQUILLEN, D.P. and McQUILLEN, M.P. (1981) 
Ann, N.Y. Acad. Sci. 377, 447-453.
KOTT, E. and RULE, A.H. (1973) Neurology (Minneap.) 23, 745-765. 
KROHN, K., SHERMAN, L. and WELCH, M. (1972) Biochim. BiophysI Acta 
285, 404-413.
LANGLEY, J.N. (1907) J. Physiol. (London) 36, 347-384.
LAYNE, E. (1957) Methods in Enzymology 3, 450-451.
LEE, C.Y. (1972) Ann. Rev. Pharmacol. _12_' 265-286.
LEE, C.Y. and CHANG, C.C. (1966) Mem. Inst. Butantan. Internac.
33, 555-572.
LEFVERT, A.K. (1978) Clin. Exp. Immunol. _3£' 111-117.
LEFVERT, A.K. (1981) Ann. N.Y. Acad. Sci. 377, 125-141.
LEFVERT, A.K. (1982) J. Neurol. Neurosurg. Psychiatry _45/ 70-73.
LEFVERT, A.K. and BERGSTROM, K. (1977) Eur. J. Clin. Invest. Ij
115-119.
LEFVERT, A.K., BERGSTROM, K., MATELL, G., OSTERMAN, P.O. and 
PIRSKANEN, R. (1978) J. Neurol. Neurosurg. Psychiatry jll'
LEFVERT, A.K., CUENOUD, S. and FULPIUS, B.W. (1981) J. Neuroimmunol 
1, 125-135.
221.
LENNON, V.A. (1976) Immunol. Commun. 5, 323-344.
LENNON, V.A. and LAMBERT, E.H. (1980) Nature 285, 238-240.
LENNON, V.A. and LAMBERT, E.H. (1981) Ann. N.Y. Acad. Sci. 377, 
77-95.
LENNON, V.A., LINDSTROM, J.M. and SEYBOLD, M.E. (1975) J.Exp. Med. 
141, 1365-1375.
LENNON, V.A., SEYBOLD, M.E., LINDSTROM, J., COCHRANE, C. and 
YULEVITCH, R. (1978)J. Exp. Med. 147, 973-983.
LESTER, H. (1977) Sci. Amer. 236, 106-118.
LEVINE, G.D. and RICE, D.F. (1977) Lab. Invest. 36, 345.
LEWIS, M.R. and LEWIS, W.H. (1917) Am. J. Anat. 169-194.
LINDSTROM, J. (1977) J. Clin. Immunol. Immunopathol. 7, 36-73. 
LINDSTROM, J. (1978) Fed. Proc. 37/ 2828-2830.
LINDSTROM, J. (1979) Adv. Immunol. 27, 1-49.
LINDSTROM, J. and EINARSON, B. (1979) Muscle and Nerve 2./ 173-179. 
LINDSTROM, J.M. and ENGEL, A. (1981) in Receptors and Recognition
Series B ( CUATRECASAS, P. and GREAVES, M. eds. ) pp.161-214,
Chapman and Hall.
LINDSTROM, J. and LAMBERT, E. (1978) Neurol. 25./ 130-138.
LINDSTROM, J. and PATRICK, J. (1974) in Synaptic Transmission and
Neuronal Interaction ( BENNET, M.V.L. ed. ) pp.191-216, Raven Press,
New York.
LINDSTROM, J., EINARSON, B., LENNON, V.A. and SEYBOLD, M.E. (1976a) 
J. Exp. Med. 144, 726-738.
LINDSTROM, J., ENGEL, A.G., SEYBOLD, M.E., LEIWON, V.A. and LAMBERT, 
E.H. (1976b) J. Exp. Med. 144, 739-753.
LINDSTROM, J.M., LENNON, V., SEYBOLD, M.E. and WHITTINGHAM, S. 
(1976c) Ann. N.Y. Acad. Sci. 274, 254-274.
LINDSTROM, J.M., SEYBOLD, M.E., LENNON, V.A., WHITTINGHAM, S. and 
DUANE, D.D. (1976d) Neurol. 26, 1054-1059.
222.
LINDSTROM, J., EINARSON, B. and FRANCY, M. (1977) in Cellular
Neurobiology ( HALL, Z. and KELLEY, R. eds. ) pp.119-130, Liss,
New York.
LINDSTROM, J., EINARSON, B. and MERLIE, J. (1978) Proc. Natl.
Acad. Sci. USA 75, 769-773.
LINDSTROM, J., MERLIE, J. and YOGEESWARAN, G. (1979a) Biochem. 18,
4465—4470.
LINDSTROM, J., WALTER, B. and EINARSON, B. (1979b) Biochem. 18, 
4470-4480.
LINDSTROM, J., GULLICK, W., CONTI-TRONÇONI, B. and ELLISMAN, M.
(1980) Biochem. _19' 4791-4795.
LINDSTROM, J., TZARTOS, S. and GULLICK, W. (1981) Ann. N.Y. Acad. 
Sci. 377, 1-19.
LIVESON, J.A., GODMAN, G., KORNFIELD, P. and BORNSTEIN, M.B. (1976) 
Exp. Neurol. 50, 620-627.
LO, M.M.S., GARLAND, P.B., LAMPRECHT, J. and BARNARD, E.A. (1980) 
FEBS Lett. Ill, 407-412.
LOEWI, O. (1921) Pfugers Arch. ges Physiol. 189, 239-242.
LOTWICK, H., HARRISON, R., LUNT, G. and BEHAN, P. (1983) J. 
Neuroimmunol. 4, 167-174.
LOWRY, O.H., ROSEBROUGH, N.J., FARR, A.L. and RANDALL, R.J. (1951) 
J. Biol. Chem. 193, 265-275.
LUKASIEWICZ, R.J., HANLEY, M.R. and BENNETT, E.L. (1978) Biochem. 
17, 2308-2313.
LYDDIAT, A., SUMIKAWA, K., WOLOSIN, J.M., DOLLY, J.O. and BARNARD,
E.A. (1979) FEBS Lett. 108, 20-24.
MacDERMOTT, V. (1960) Brain 83, 24-36.
MARCH, S.C., PARIKH, I. and CUATRECASAS, P. (1974) Analyt. Biochem. 
60, 145-152.
223.
MARKELONIS, G.J. and OH, T.H. (1983) J. Neurochem. 4 (Suppl.) S108B. 
MARKELONIS, G.J., KEMERER, V.F. and OH, T.H. (1980) J. Biol. Chem.
255, 8967-8970.
MARSH, D., WATTS, A. and BARRANTES, F.J. (1981) Biochim. Biophys. 
Acta 645, 97-101.
MARTINEZ, R.D., TARRAB-HAZDAI, R., AHARONOV, A. and FUCHS, S.
(1977) J. Immunol. 118, 17-20.
MARTINEZ-CARRION, M., FARACH, M. and MIHOVILOVIC, M. (1981) Ann.
N.Y. Acad. Sci. 377, 846-847.
MATTSON, C. and HEILBRONN, E. (1975) J. Neurochem. 899-901.
MAURO, A. (1961) J. Biophys. Biochem. Cytol. _9_/ 493-495.
McCONAHEY, P.J. and DIXON, F.J. (1966) Int. Arch. Allergy 29,
185-189.
McNAMEE, M.G. and OCHOA, E.L.M. (1982) Neurosci. 2305-2319. 
McNAMEE, M.G., WEILL, C.L. and KARLIN, A. (1975) Ann. N.Y. Acad.
Sci. 264, 175-181.
MEHL, V.S. and LANG, R.W. (1984) J. Neuroimmunol. J6/ 347-360.
MERLIE, J.P. and SEBBANE, R. (1981) J. Biol. Chem. 256, 3605-3608. 
MERLIE, J.P., SOBEL, A., CHANGEUX, J.P. and GROS, F. (1975) Proc. 
Natl. Acad. Sci. USA 22, 4028-4032.
MERLIE, J.P., HEINEMANN, S., EINARSON, B. and LINDSTROM, J. (1979)
J. Biol. Chem. 254, 6328-6332.
MERLIE, J.P., HOFFLER, J. and SEBBANE, R. (1981) J. Biol. Chem.
256, 6995.
MERLIE, J.P., SEBBANE, R., TZARTOS, S. and LINDSTROM, J. (1982) J. 
Biol. Chem. 257, 2694-2701.
MERLIE, J.P., SEBBANE, R., GARDNER, S., OLSON, E. and LINDSTROM, J. 
(1983) Cold Spring Harbor Symp. Quant. Biol. 48, 135-146.
224.
MEUNIER, J.C., OLSEN, R.W., MENEZ, A., MORGAT, J.L., FROMAGEOT»
P., RONSERAY, A.M., BOQUET, P. and CHANGEUX, J.P. (1971) Comp. Rend. 
Acad. Sci. Paris 273, 595-598.
MEUNIER, J.C., OLSEN, R.W., MENEZ, A., FROMAGEOT, P., BOQUET, P. and 
CHANGEUX, J.P. (1972a) Biochem. 1̂ / 1200-1210.
MEUNIER, J.C., OLSEN, R.W. and CHANGEUX, J.P. (1972b) FEBS Lett.
24, 63-68.
MEUNIER, J.C., SEALOCK, R., OLSEN, R.W. and CHANGEUX, J.P. (1974)
Eur. J. Biochem. 45, 371-394.
MIHOVILOVIC, M. and MARTINEZ-CARRION, M. (1979) Biochem. 25.' 4522- 
4528.
MILEDI, R., MOLINOFF, P. and POTTER, L.T. (1971) Nature 229, 554-557. 
MINGUETTI, G. and MAIR, W.G.P. (1981) Biol. Neonate 40, 276-294. 
MITTAG, T.W., KORNFIELD, P., TORMAY, A. and WOO, C. (1976) New Engl. 
J. Med. 224, 691-694.
MITTAG, T.W., TORMAY, A. and MASSA, A. (1978) Mol. Pharmacol. 14, 
60—68.
MITTAG, T., MASSA, T., KORNFIELD, P., PAPATESTAS, A., BENDER, A. 
and GENKINS, G. (1981a) Ann. N.Y. Acad. Sci. 377, 342-357.
MITTAG, T., MASSA, T., KORNFIELD, P., PAPATESTAS, A., BENDER, A. 
and GENKINS, G. (1981b) Muscle and Nerve 4, 16-25.
MOCHLY-ROSEN, D., FUCHS, S. and ESHHAR, Z. (1979) FEBS Lett.106, 
389-392.
MOMOI, M.Y. and LENNON, V.A. (1982) J. Biol. Chem. 257, 12757-12764. 
MONNIER, V.M. and FULPIUS, B.W. (1977) Clin. Exp. Immunol. 22' 16-22. 
MORGAI>I, J. and COHEN, L. (1974) In Vitro jD/ 188-195.
MORRIS, G.E. and COLE, R.J. (1972) Exp. Cell Res. T̂ , 191-199.
MOSS, M., NORRIS, J.S., PECK, E.J. and SCHWARTZ, R.J. (1978) Exp.
Cell Res. 113, 445-450.
225.
NACHMANSON, D. (1959) in Chemical and Molecular Basis of Nerve
Activity, Academic Press, New York.
NASTUK, W.C., STRAUSS, A.J.L. and OSSERMAN, K.E. (1959) Am. J. Med. 
26, 394-409.
NASTUK, W.L., PLESCIA, O.J. and OSSERMAN, K.E. (I960) Proc. Soc.
Exp. Biol. Med. 105, 177-184.
NATHANSON, N.M. and HALL, Z.W. (1979) Biochem. 25' 3392-3401.
NATVIG, J.B. and KUNKEL, H.G. (1973) Adv. Immunol. 16_, 1-54.
NEHER, E. and SAKMANN, B. (1976) J. Physiol. 258, 705-729.
NEUMANN, D., FRIDKIN, M. and FUCHS, S. (1984) Biochem. Biophys.
Res. Commun. 121, 673-679.
NEWSOM-DAVIS, J. and VINCENT, A. (1982) Immunol. Today 3, 149-151. 
NEWSOM-DAVIS, J., WILLCOX, N., SCADDING, G., CALDER, L. and VINCENT, 
A. (1981) Ann. N.Y. Acad. Sci. 377, 393-401.
NODA, M., TAKAHASHI, H., TANABE, T., TOYOSATO, M., FURUTANI, Y., 
HIROSE, T., ASAI, M., INAYAMA, S., MIYATA, T. and NUMA, S. (1982) 
Nature 222' 793-797.
NODA, M., TAKAHASHI, H., TANABE, T., TOYOSATO, M., KIKYOTANI, S.,
HIROSE, T., ASAI, M., TAKASHIMA, H., INAYAMAS, S., MIYATA, T. and
NUMA, S. (1983a) Nature 301, 251-255.
NODA, M., TAKAHASHI, H., TANABE, T., TOYOSATO, S., KIKYOTANI, S.,
FURUTANI, Y., HIROSE, T., TAKASHIMA, H., INAYAMA, S., MIYATA, T. and
NUMA, S. (1983b) Nature 302, 528-532.
NODA, M., FURUTANI, Y., TAKAHASHI, H., TOYOSATO, M., TANABE, T., 
SHIMIZU, S., KIKYOTANI, S., KAYANO, T., HIROSE, T., INAYAMA, S. and 
NUMA, S. (1983c) Nature 305, 818-823.
O'BRIEN, R.D., ELDEFRAWI, M.E. and ELDEFRAWI, A.T. (1972) Ann. Rev. 
Pharmacol. 12, 19.
OCHOA, E.L.M., DALZIEL, A.W. and McNAMEE, M.G. (1983) Biochim.
226.
Biophys. Acta 727, 151-162.
OH, T.H. and MARKELONIS, G.J. (1980) Proc. Natl. Acad. Sci USA 77, 
6922-6925.
OLD, L.J., STOCKERT, E., BOYSE, E.A. and KIM, J.H. (1968) J. Exp. 
Med. 227' 523-539.
OLSEN, R.W., MEUNIER, J.C. and CHANGEUX, J.P. (1972) FEBS Lett. 28, 
96-100.
O'NEILL, M.C. and STOCKDALE, F.E. (1972) J. Cell Biol. 52, 52-65. 
OOSTERHUIS, H.J.G.H., BETHLEM, J. and FELTKAMP, T.E.W. (1968) J. 
Neurol. Neurosurg. Psychiatry 31, 460.
OSSERMAN, K.E. and GENKINS, G. (1971) Mt. Sinai J. Med. 38, 497. 
PAPATESTAS, A.E., ALPERT, L.I., OSSERMAN, K.E. and KARK, A.E. (1971) 
Am. J. Med. 25./ 465-474.
PARKES, J.D. and McKINNA, J.A. (1966) Lancet i, 388-391.
PATERSON, B. and PRIVES, J. (1973) J. Cell. Biol. 22' 241-245. 
PATRICK, J. and LINDSTROM, J. (1973) Science 180, 871-872.
PATRICK, J. and BERMAN, P.W. (1980) in The Cell Surface and Neuronal 
Function ( COTMAN, C.W., POSTE, G. and NICOLSON, G.L. eds. ) pp. 
157-190, Elsevier/North Holland Biomedical Press.
PATRICK, J., HEINEMANN, F., LINDSTROM, J., SCHUBERT, D. and 
STEINBACH, J.H. (1972) Proc. Natl. Acad. Sci USA 22' 2762-2766. 
PATRICK, J., LINDSTROM, J., CULP, B. and McMILLAN, J. (1973) Proc. 
Natl. Acad. Sci. USA 25' 3334-3338.
PENN, A., CHANG, H., LOVELACE, R., NIEMI, W. and MIRANDA, A. (1976) 
Ann. N.Y. Acad. Sci. 274, 354-376.
PHILLIPS, H.J. (1973) in Tissue Culture; Methods and Applications 
( KRUSE, P.F. and PATTERSON, M.K. eds. ) pp.406-408, Academic 
Press, New York and London.
POGOGEFF, I.A. and MURRAY, M.R. (1946) Anat. Rec. 95, 321-335.
227.
PRESSMAN, D. (1970) Immunochem. 870.
PRIVES, J.M. and OLDEN, K. (1980) Proc. Natl. Acad. Sci. USA 77,
5253-5267.
PRIVES, J., SILMAN, I. and AMSTERDAM, A. (1976) Cell 7_/ 543-550. 
PRIVES, J., HOFFMAN, L., TARRAB-HAZDAI, R., FUCHS, S. and 
AMSTERDAM, A. (1979) Life Sci. 7̂ , 1713-1718.
PUMPLIN, D.W. and FAMBROUGH, D.M. (1982) Ann. Rev. Physiol. 44,
319-335.
RAFTERY, M.A., SCHMIDT, J., CLARK, D.G. and WOLCOTT, R.G. (1971)
Biochem. Biophys. Res. Commun. 45, 1622-1629.
RAFTERY, M., VANDLEN, R., REED, K. and LEE, T. (1976) Cold Spring
Harbor Symp. Quant. Biol. 40, 193-202.
RAFTERY, M.A., BLANCHARD, S., ELLIOT, J., HARTIG, P., MOORE, H.P., 
QUASTEL, U., SCHMERLIK, M., WITZEMANN, V. and WU, W. (1979) in 
Advances in Cytopharmacology ( CECCARELLI, B. and CLEMENTI, F. 
eds. ) Vol.3, pp.159-189, Raven Press, New York.
RASH, J.E., ALBUQUERQUE, E.X., HUDSON, O.S., MAYER, R.F. and 
SATTERFIELD, J.R. (1976) Proc. Natl. Acad. Sci. USA J73, 4584-4588. 
RASH, J.E., HUDSON, C.S., GRAHAM, W.F., MAYER, R.F., WARNICK, J.E. 
and ALBUQUERQUE, E.X. (1981) Lab. Invest. _44/ 519-530.
REBOUCHE, C.J.(1977) Biochim. Biophys. Acta 471, 145-155. 
REINHARD, R., WALTERS, D. and MAELICKE, A. (1981) Eur. J. Biochem. 
119, 215-224.
RESKE-NIELSON, E., DALBY, A. and DALBY, M. (1965) Acta Neurologica 
Scandinavica 41 Suppl. 13, 289-296.
RINALDINI, L.M. (1959) Exp. Cell Res. 477-505.
ROSS, M.J., KLYMKOWSKY, M.W., AGARD, D.A. and STROUD, R.M. (1977) 
J. Mol. Biol. 116, 635-659.
RUSSELL, D (1953) J. Path. Bact. 65, 279-289.
228.
SAFWENBERG, J.L., HAMMARSTROM, L., LINDBLOM, J.B., MATELL, G., 
MOLLER, E., OSTERMANN, P.O. and SMITH, S.I.E. (1978) Tissue Antigens 
12, 136-142.
SAHASHI, K., ENGEL, A.G., LINDSTROM, J., LAMBERT, E.H. and LENNON, V.
(1978) J. Neuropathol. Exp. Neurol. 37, 212-223.
SAITOH, T., V7ENNOGLE, L. and CHANGEUX, J.P. (1979) FEBS Lett. 108, 
489-494.
SAITOH, T., OSWALD, R., WENNOGLE, L.P. and CHANGEUX, J.P. (1980)
FEBS Lett. 116, 30-36.
SANTA, T., ENGEL, A.G. and LAMBERT, E.H. (1972) Neurology 22, 71-82.
SARGENT, P.B., HEDGES, B.E., TSAVALER, L., CLEMMONS, L., TZARTOS,
S. and LINDSTROM, J.M. (1984) J.Cell Biol. 98, 609-618.
SCHMIDT, J. (1984) J. Biol. Chem. 259, 14033-14037.
SCHMIDT, J. and RAFTERY, M.A. (1973) Analyt. Biochem. _52_/ 349-354. 
SCHUBERT, D., TARIKAS, H., HUMPHREYS, S., HEINEMANN, S. and PATRICK, 
J. (1973) Dev. Biol. 18-37.
SCHUETZE, S.M., FRANK, E.F. and FISCHBACH, G.D. (1978) Proc.Natl.
Acad. Sci USA 1̂ , 520-523.
SEYBOLD, M.E. (1983) JAMA 250, 2516-2521.
SHERMAN, L.A., HARWIG, S. and HAYNE, O.A. (1974) Int. J. Appl. 
Radiation Isotopes 25, 81-85.
SHORR, R.G., DOLLY, J.O. and BARNARD, E.A. (1978) Nature 274, 283-284 
SHORR, R.G., LYDDIATT, A., LO, M.M.S., DOLLY, J.O. and BARNARD, E.A.
(1981) Eur. J. Biochem. 116, 143-153.
SILMAN, I. and KARLIN, A. (1967) Proc. Natl. Acad. Sci. USA 58, 
1664-1668.
SIMPSON, J.A. (1958) Brain 81, 112-144.
SIMPSON, J.A. (1960) Scott. Med. J._5' 419-436.
SIMPSON, J.A. (1974) in Disorders of Voluntary Muscle ( WALTON, J.N.
229.
ed. ) pp.653-692, Churchill Livingstone, London.
SIMPSON, J.A. (1978a) Muscle and Nerve 1, 45-56.
SIMPSON, J.A. (1978b) Muscle and Nerve _1_, 151-156.
SKRBIC, T.R., YASIN, R., van BEERS, G., BULIEN, D. and THOMPSON, E.J.
(1975) Biochem. Soc. Trans. _3' 496-497.
SOBEL, A., HEIDMANN, T., HOFLER, J. and CHANGEUX, J.P. (1978) Proc.
Natl. Acad. Sci. USA 1̂ , 510-514.
SOKOLOVSKY, M., RIORDAN, J.F. and VALLEE, B.L. (1966) Biochem. _5/ 
3582-3589.
SOUROUJON, M.C., MOCHLY-ROSEN, D., GORDON, A.S. and FUCHS, S.
(1983) Muscle and Nerve 6, 303-311.
STEPHENSON, F.A., HARRISON, R. and LUNT, G.G. (1981) Eur. J. Biochem, 
115, 91-97.
STEVENSON, C.T. and DORRINGTON, K.J. (1970) Biochem. J. 118, 703-712. 
STRAUSS, A.J.L., SEEGAL, B.C., HSU, K.C., BURKHOLDER, P.M., NASTUK, 
W.L. and OSSERMAN, K.E. (1960) Proc. Soc. Exp. Biol. Med. 105, 
184-191.
SUGIYAMA, H., BENDA, P., MEUNIER, J. and CHANGEUX, J.P. (1973)
FEBS Lett. _32' 124-128.
SUMIKAWA, K., HOUGHTON, M., SMITH, J.C., BELL, L., RICHARDS, B.M. 
and BARNARD, E.A. (1982) Nucleic Acids Res. _10, 5809-5822.
SYTKOWSKI, A.J., VOGEL, Z. and NIRENBERG, M. W. (1973) Proc. Natl. 
Acad. Sci. USA 20, 270-274.
TARRAB-HAZDAI, R., GEIGER, B., FUCHS, S. and AMSTERDAM, A. (1978) 
Proc. Natl. Acad. Sci. USA 75, 2497-2501.
TARRAB-HAZDAI, R., SCHMIDT-SOLE, Y., MOCHLY-ROSEN, D. and FUCHS, S. 
(1980) FEBS Lett. 118, 35-33.
TENG, N.N.H. and FISZfiAN, M.Y. (1976) J. Supramol. Struct. 4,
230.
381-387.
TEPPERMAN, K., MORRIS, G., ESSIEN, F. and HEYWOOD, S.M. (1975) J. 
Cell Physiol. 35, 561-566.
TINDALL, R.S.A. (1981) Ann. N.Y. Acad. Sci. 377, 316-331.
TOYKA, K.V., DRACHMAN, D.B., PESTRONK, A. and KAO, I. (1975) Science 
190, 397-399.
TURNBULL, G.M., HARRISON, R. and LUNT, G.G. (1985) Int. J. Dev. 
Neurosci. _3y 123.
TZARTOS, S.J. and LINDSTROM, J.M. (1980) Proc. Natl. Acad. Sci. USA 
77, 755-759.
TZARTOS, S. and LINDSTROM, J. (1981) in Monoclonal Antibodies in 
Endocrine Research ( FELLOWS, R. and EISANBARTH, G. eds. ) pp.69-86, 
Raven Press.
TZARTOS, S.J., RAND, D.E., EINARSON, B.L. and LINDSTROM, J.M. (1981) 
J. Biol. Chem. 256, 8635-8645.
TZARTOS, S., SEYBOLD, M.E. and LINDSTROM, J. (1982) Proc. Natl.
Acad. Sci. USA 79_, 188-192.
UENO, S., KANG, J., TAKEUCHI, H. , TAKAHASHI, M. and TARUI, S..
(1980) Clin. Exp. Immunol. 41, 13-18.
URBANIAK, S.J., PENHALE, W.J. and IRVINE, W.J. (1973) Clin. Exp. 
Immunol. 15, 345-354.
VALDERRAMA, R., WEILL, C.L., McNAMEE, M.G. and KARLIN, A. (1976)
Ann. N.Y. Acad. Sci. 274, 108-115.
VAN der GELD, H., FELTKAMP, T.E.W., van LOGHEM, J.J., OOSTERHUIS,
H.J.G.H. and BIEMOND, A. (1963) Lancet ii, 373-375.
VANDLEN, R., WILSON, C., EISENBACH, J. and RAFTERY, M. (1979)
Biochem. 18, 1845-1854.
VINCENT, A. (1980) Physiol. Rev. _60./ 756-824.
VINCENT, A. and BILKHUS, M. (1982) J. Immunol. Methods 51, 359-369.
231.
VINCENT, A. and NEWSOM-DAVIS, J. (1979) in Advances in
Cytopharmacology ( CECCARELLI, B. and CLEMENTI, F. eds. ) Vol.3,
pp.269-279, Raven Press, New York.
VINCENT, A. and NEWSOM-DAVIS, J. (1982) Clin. Exp. Immunol. 49, 
257-265.
VINCENT, A., NEWSOM-DAVIS, J. and MARTIN, V. (1978) Lancet _i_, 1254. 
VOGEL, Z., SYTKOWSKI, A.J. and NIRENBERG, M.W. (1972) Proc. Natl. 
Acad. Sci. USA 22/ 3180-3184.
WALDMANN, T.A., BLAESE, R.M., BRODER, S. and KRAKAUER, R.S. (1978) 
Ann. Int. Med. 88, 226-238.
WALKER, M.B. (1934) Lancet 226, 1200-1201.
WALLIS, I., KOENIG, E. and ROSE, S. (1980) Biochim. Biophys. Acta 
599, 505-517.
WATKINS, W.M. (1966) Methods in Enzymol. _8_/ 700-711.
WEBER, K. and OSBORN, M. (1969) J. Biol. Chem. 244, 4406-4112. 
WEINBERG, C.B. and HALL, Z.W. (1979) Proc. Natl. Acad. Sci. USA 
76, 504-508.
WENNOGLE, L.P. and CHANGEUX, J.P. (1980) Eur. J. Biochem. 106, 
381-393.
WENNOGLE, L.P., OSWALD, R.E., SAITOH, T. and CHANGEUX, J.P. (1981) 
Biochem. 20, 2492-2497.
WERMAN, R. (1966) Comp. Biochem. Physiol. 18, 745.
WERNECK, L.C. (1982) Arq. Neuro-Psiquiatr. 40, 67-76.
WESTWOOD, J.H., THOMAS, P., EDWARDS, R.G. and MÜNRO NEVILLE, A. 
(1975) Protides Biol. Fluids Proc. Colloq. Bruges 24, 413-418. 
WHITING, P.J., VINCENT, A. and NEWSOM-DAVIS (1983) J. Neuroimmunol. 
_5, 1-9.
WILLMER, E.N. (1965) in Cells and Tissues in Culture, Vol.l 
( WILLMER, E.N. ed. ) pp.143-176, Academic Press, New York.
232.
WILSON, A. and STONER, H.B. (1944) Quart. J. Med. 1-18.
WISE, D.S., WALL, J. and KARLIN, A. (1981) J. Biol. Chem. 256, 
12624-12627.
WITKOWSKI, J.A. (1977) Biol. Rev. 431-476.
WITKOWSKI, J.A., DURBRIDGE, M. and DUBOWITZ, V. (1976) In vitro 
12, 98-106.
WONNACOTT, S., HARRISON, R., LUNT, G.G. and BARKAS, T. (1980a)
Eur. J. Biochem. 108, 621-629.
WONNACOTT, S., HARRISON, R. and LUNT, G.G. (1980b) Life Sci. 27, 
1769-1775.
YAFFE, D. (1968) Proc. Natl. Acad. Sci. USA 61, 477-483.
YASIN, R., van BEERS, G., NURSE, K.C.E., AL-ANI, S., LONDON, D.N. 
and THOMPSON, E.J. (1977) J. Neurol. Sci. 32̂, 347-360.
YASUKO, H., ICHIRO, K. and OZAWA, E. (1981) Dev. Growth Differ.
23, 249-254.
YOSHIDA, T., TSUCHIYA, M., ONO, A., YOSHIMATSU, H., SATOYOSHI, E. 
and TSUJI, K. (1977) J. Neurol. Sci. 195-201.
YUNIS, E.J., STUIMAN, 0. and GOOD, R.A. (1971) Ann. N.Y. Acad. Sci. 
183, 205-220.
ZACKS, S.I., BAUER, W.C. and BLUMBERG, J.J. (1961) Nature 190, 
280-281.
ZINGSHEIM, H.P., BARRANTES, F.J., FRANK, J., HANICKE, W. and 
NEUGEBAUER, D.C. (1982) Nature 299, 81-83.
ZURN, A.D. and FULPIUS, B.W. (1977) Eur. J. Immunol. 8, 529-532.
